Clarithromycin is a macrolide antibiotic used to treat a variety of bacterial infections, including respiratory infections, skin infections, and sexually transmitted infections. It was first synthesized in 1980 by researchers at Abbott Laboratories. Clarithromycin works by inhibiting protein synthesis in bacteria, which is essential for their survival. It is effective against a wide range of bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumoniae. Clarithromycin is generally well-tolerated, but it can cause side effects such as nausea, vomiting, diarrhea, and abdominal pain. It is also known to interact with certain medications, so it is important to talk to your doctor about any medications you are currently taking before starting clarithromycin. Clarithromycin is an important antibiotic because it is effective against a wide range of bacteria, including some that are resistant to other antibiotics. It is also relatively safe and well-tolerated. This makes it a valuable tool for treating bacterial infections. Clarithromycin is still studied today because researchers are looking for ways to improve its effectiveness and reduce its side effects. They are also investigating its potential use in treating other conditions, such as cancer and inflammatory bowel disease.'
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 84029 |
| CHEMBL ID | 1741 |
| CHEBI ID | 3732 |
| SCHEMBL ID | 38125 |
| MeSH ID | M0026249 |
| Synonym |
|---|
| BIDD:GT0200 |
| AB00053394-13 |
| AB00053394-12 |
| lactoferrin h & clarithromycin |
| lactoferrin b & clarithromycin |
| DIVK1C_006655 |
| biaxin xl |
| klaricid |
| macladin |
| abbott-56268 |
| veclam |
| clarith |
| cyllind |
| te-031 |
| sdp-015 |
| klacid |
| anx-015 |
| naxy |
| klaricid xl |
| 6-o-methylerythromycin a |
| SPECTRUM_000089 |
| SPECTRUM5_001729 |
| a56268 |
| clm & il-12 |
| clarithromycin & interleukin-12 |
| biaxin |
| te031 |
| 6-o-methylerythromycin |
| a-56268 |
| (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacy |
| BSPBIO_003453 |
| CTY , |
| MLS001424066 |
| astromen |
| clarithromycinum [inn-latin] |
| klarid |
| mavid |
| clacine |
| klaricid pediatric |
| klarin |
| biaxin filmtab |
| zeclar |
| claritromicina [inn-spanish] |
| helas |
| heliclar |
| maclar |
| claricide |
| adel |
| cyllid |
| clathromycin |
| claribid |
| clarithromycine [inn-french] |
| biaxin xl filmtab |
| abbotic |
| kofron |
| mabicrol |
| klaciped |
| bicrolid |
| biaxin hp |
| klax |
| erythromycin, 6-o-methyl- |
| drg-0099 |
| clambiotic |
| C06912 |
| clarithromycin |
| 81103-11-9 |
| MLS000759516 |
| smr000466382 |
| 6-o-methyl erythromycin |
| DB01211 |
| cpd000466382 |
| biaxin (tn) |
| clarithromycin (jp17/usp/inn) |
| D00276 |
| KBIO2_003077 |
| KBIO2_000509 |
| KBIO1_001599 |
| KBIO2_005645 |
| KBIO3_002673 |
| KBIOSS_000509 |
| KBIOGR_001218 |
| SPECTRUM4_000629 |
| SPBIO_001855 |
| SPECTRUM3_001667 |
| SPECPLUS_000559 |
| SPECTRUM2_001668 |
| SPECTRUM1504231 |
| NCGC00178054-01 |
| MLS001201751 |
| LMPK04000014 |
| HMS2094M05 |
| HMS2051G18 |
| HMS2090O11 |
| C2220 |
| clarithromycinum |
| clarithromycina |
| clarithromycine |
| CHEBI:3732 , |
| o(6)-methylerythromycin |
| clarithromycin identity |
| nsc-758704 |
| CHEMBL1741 |
| clarithromycin extended release |
| HMS1922H09 |
| (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dion |
| A840042 |
| (3r,4s,5r,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4r,6r)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacy |
| (14r)-14-hydroxyclarithromycin |
| h1250jik0a , |
| hsdb 8055 |
| nsc 758704 |
| ccris 8833 |
| unii-h1250jik0a |
| clarithromycin [usan:usp:inn:ban:jan] |
| klaricid h.p. |
| tox21_202903 |
| NCGC00260449-01 |
| pharmakon1600-01504231 |
| nsc758704 |
| cas-81103-11-9 |
| dtxcid40820062 |
| dtxsid3022829 , |
| tox21_111429 |
| claritromicina |
| HMS2231A08 |
| CCG-39086 |
| clacid |
| crixan |
| fromilid |
| klabax |
| clarem |
| clacee |
| claridar |
| claripen |
| bdbm50404044 |
| AKOS015894242 |
| S2555 |
| clarithromycin [inn] |
| clarithromycin [usp impurity] |
| clarithromycin [mi] |
| clarithromycin component of prevpac |
| clarosip |
| clarithromycin [orange book] |
| prevpac component clarithromycin |
| clarithromycin [vandf] |
| clarithromycin [ep monograph] |
| clarithromycin [usp-rs] |
| clarithromycin [usp monograph] |
| clarithromycin [mart.] |
| clarithromycin [who-dd] |
| clarithromycin [jan] |
| clarithromycin identity [usp-rs] |
| AB00053394-10 |
| CS-2576 |
| HY-17508 |
| NC00140 |
| SCHEMBL38125 |
| 6-0-methylerythromycin a |
| AGOYDEPGAOXOCK-KCBOHYOISA-N |
| Q-200870 |
| AB00053394_15 |
| AB00053394_14 |
| clarithromycin, >=98% (hplc) |
| clarithromycin, >=95% (hplc) |
| clarithromycin, united states pharmacopeia (usp) reference standard |
| clarithromycin identity, united states pharmacopeia (usp) reference standard |
| sr-05000001992 |
| SR-05000001992-1 |
| SR-05000001992-2 |
| clarithromycin, european pharmacopoeia (ep) reference standard |
| clarithromycin for peak identification, european pharmacopoeia (ep) reference standard |
| clarithromycin, pharmaceutical secondary standard; certified reference material |
| SBI-0206716.P001 |
| HMS3715J17 |
| (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-{[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yl]oxy}-14-ethyl-12,13-dihydroxy-4-{[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame |
| F14975 |
| clarithromycin (biaxin, klacid) |
| (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-(((2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-14-ethyl-12,13-dihydroxy-4-(((2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl)oxy)-7-methoxy-3,5,7,9,11,13-hexame |
| clarithromycin,(s) |
| clarithromycin 100 microg/ml in acetonitrile |
| Q118551 |
| BRD-K49668410-001-07-1 |
| (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-((2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yloxy)-14-ethyl-12,13-dihydroxy-4-((2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yloxy)-7-methoxy-3,5,7,9,11,13-hexamethyl |
| BRD-K49668410-001-18-8 |
| NCGC00178054-06 |
| gtpl10903 |
| (3r,4s,5s,6r,7r,9r,11s, 12r,13s,14s)-6-{[(2s,3r,4s,6r)- 4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-12,13-dihydroxy- 4-{[(2r,4s,5s,6s)-5-hydroxy-4-methoxy-4,6- dimethyloxan-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexamethyl-1- oxacyclotetradecane- |
| Z1515385076 |
| claritromicina (inn-spanish) |
| clarithromycin (mart.) |
| clarithromycin500 mg |
| clarithromycin (usp impurity) |
| clarithromycin (ep monograph) |
| j01fa09 |
| (2r,3s,4s,5r,6r,8r,10r,11r,12s,13r)-5-(3,4,6-trideoxy-3-dimethylamino-beta-d-xylo-hexopyranosyloxy)-3-(2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyloxy)-11,12-dihydroxy-6-methoxy-2,4,6,8,10,12-hexamethyl-9-oxopentadecan-13-olide |
| clarithromycin (usan:usp:inn:ban:jan) |
| clarithromycin (usp monograph) |
| clarithromycin (usp-rs) |
| clarithromycinum (inn-latin) |
| clarithromycin identity (usp-rs) |
| clarithromycine (inn-french) |
Clarithromycin is a 14-member lactone ring macrolide with potent activity against Haemophilus influenzae, including ampicillin-resistant strains. It is an antibiotic commonly used to treat Helicobacter pylori infections.
Clarithromycin has a wide spectrum of activity against many gram-positive and gram-negative organisms, intracellular pathogens, and opportunistic pathogens. It has a bronchial anti-inflammatory effect associated with decreased eosinophilic infiltration. It is more frequently associated with clinically significant drug interactions.
Clarithromycin (CLA) has been widely used in the treatment of bacterial infection. It has been shown to prevent biofilm formation by Staphylococcus aureus.
Clarithromycin increased all-cause mortality and cerebrovascular disease during 10years. It may be a cause of fulminant liver failure either alone or by inhibiting the metabolism of other drugs.
Clarithromycin both treats and prevents MAC disease in beige mice. N-oxide treatment resulted in the increase in hydroxylation of testosterone not only at the 2 beta- and 6 beta-positions (430 and 190%, respectively)
Clarithromycin is a relatively new antibiotic of the macrolide family heralded for an improved side effect profile, dosing schedule, and microbiological activity. This case highlights medication errors that resulted in rare debilitating neurological adverse effects of ranolazine in an elderly due to drug interaction.
In this article, we review the results of 3 studies of the steady-state pharmacokine. Based on serum concentrations, clarithromycin achieved its pharmacodynamic target in 76% of patients.
The activities of clarithromycin or roxithromicin used in combination with other antimicrobial drugs were tested in human macrophages experimentally infected with 23 strains of Mycobacterium avium. Long term use of low dosage oral macrolide Clarithromycus combined with nasal steroid on CRS was efficacy. Synergy was generally demonstrated for claritromycin in combinationwith aminoglycosides, fluoroquinolones or ceftazidime.
The study has shown that the creatinine-based niosomes developed in our laboratory were biocompatible, safe and increased the oral bioavailability of the model hydrophobic Clarithromycin. There was approximately 20% increase in mean absorption rate constant.
Pulsatile dosing showed similar reductions in bacterial density for amoxicillin and clarithromycin when either drug was given alone compared with traditional dosing regimens against all three bacterial isolates. Twice-daily dosage of proton-pump inhibitor (PPI) and clarityromycin was more effective for eradication than once- daily dosage for resistant strains.
| Role | Description |
|---|---|
| antibacterial drug | A drug used to treat or prevent bacterial infections. |
| protein synthesis inhibitor | A compound, usually an anti-bacterial agent or a toxin, which inhibits the synthesis of a protein. |
| environmental contaminant | Any minor or unwanted substance introduced into the environment that can have undesired effects. |
| xenobiotic | A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| macrolide antibiotic | A macrocyclic lactone with a ring of twelve or more members which exhibits antibiotic activity. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Clarithromycin Action Pathway | 1 | 4 |
| Drug induction of bile acid pathway | 0 | 25 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 13.7968 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 10.6840 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 24.5346 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 44.0206 | 0.0002 | 29.3054 | 16,493.5996 | AID743075 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 13.3332 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 0.5174 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 3.9811 | 0.0398 | 16.7842 | 39.8107 | AID1454 |
| snurportin-1 | Homo sapiens (human) | Potency | 0.5174 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 0.5174 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 5.6234 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 5.6234 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 5.6234 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| geminin | Homo sapiens (human) | Potency | 11.5821 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.6315 | 4.4531 | 9.3000 | AID1473740 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.2000 | 5.6774 | 10.0000 | AID1473741 |
| Bile salt export pump | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.1100 | 7.1903 | 10.0000 | AID1473738 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | IC50 (µMol) | 34.7000 | 0.0002 | 2.3185 | 10.0000 | AID681126; AID681127; AID681131; AID681579; AID681580; AID681581; AID681582 |
| Cytochrome P450 3A4 | Homo sapiens (human) | Ki | 5.4900 | 0.0001 | 1.4162 | 9.9000 | AID589114 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 (µMol) | 51.1533 | 0.0009 | 1.9014 | 10.0000 | AID161281; AID161282; AID240820; AID243151; AID408340 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 2.4100 | 6.3433 | 10.0000 | AID1473739 |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | IC50 (µMol) | 3.3113 | 0.1047 | 2.7195 | 7.0795 | AID977603 |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | IC50 (µMol) | 3.0903 | 0.0500 | 2.3797 | 9.7000 | AID977600 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| streptokinase A precursor | Streptococcus pyogenes M1 GAS | EC50 (µMol) | 0.0600 | 0.0600 | 8.9128 | 130.5170 | AID1902 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID206555 | In vivo antibacterial activity of NCTC-10649 strain of Gram positive bacteria Staphylococcus aureus (95% confidence interval) | 1998 | Journal of medicinal chemistry, May-07, Volume: 41, Issue:10 | Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues. |
| AID161282 | Inhibition of K+ channel activity in mammalian cells expressing HERG Kv11.1 | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16 | Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. |
| AID1677798 | Bactericidal activity against penicillin-resistant Staphylococcus aureus assessed as reduction in number of colony forming units incubated for 24 hrs followed by re-plating and reincubation on tryptic soy agar plate for 24 hrs | 2020 | Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21 | Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus. |
| AID523010 | Activity at macrolide 2'-phosphotransferase 1 by PK/LDH-coupled assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Nucleotide selectivity of antibiotic kinases. |
| AID440644 | Antibacterial activity against multidrug-susceptible Haemophilus influenzae 1325 by NCCLS method | 2009 | Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23 | Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. |
| AID588210 | Human drug-induced liver injury (DILI) modelling dataset from Ekins et al | 2010 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12 | A predictive ligand-based Bayesian model for human drug-induced liver injury. |
| AID554518 | Antimicrobial activity against Mycobacterium abscessus isolate MC879-2 at day 7 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID261465 | Antibacterial activity against Streptococcus pneumoniae Mef 5654 | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Synthesis and antibacterial activity of novel C12 vinyl ketolides. |
| AID67074 | Antibacterial activity was evaluated against Enterococcus faecalis (0115) | 1998 | Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14 | Discovery of a novel benzyloxyisoquinoline derivative with potent anti-Helicobacter pylori activity. |
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID1549365 | Bactericidal activity against erythromycin-susceptible Streptococcus pneumoniae ATCC49619 pretreated followed by subculture in absence of compound measured after 24 hrs | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID529896 | Antimicrobial activity against Leptospira interrogans serovar Pomona isolate 4 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID270433 | Antibacterial activity against Streptococcus pneumoniae 280-962 by broth microdilution method | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and antibacterial activity of C12 des-methyl ketolides. |
| AID560510 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b5k3529 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID1539179 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID1473740 | Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID309089 | Antibacterial activity against Streptococcus pyogenes M | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18 | A novel ketolide class: Synthesis and antibacterial activity of a lead compound. |
| AID270436 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae mef S 3427 by broth microdilution method | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and antibacterial activity of C12 des-methyl ketolides. |
| AID730743 | Antibacterial activity against macrolides, lincosamides, streptogramin B and methicillin-resistant Staphylococcus aureus 1609-09 harboring cfr gene assessed as growth inhibition | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6 | Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates. |
| AID1444606 | Antibacterial activity against constitutively macrolides/lincosamides/streptogramines-resistant Staphylococcus aureus ND048910 expressing erm gene by broth microdilution method | 2017 | Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8 | Synthesis of clarithromycin ketolides chemically modified at the unreactive C10-methyl group. |
| AID322983 | Antimicrobial activity against macrolide-susceptible Mycoplasma pneumoniae Mac | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. |
| AID572845 | Antimicrobial activity against Helicobacter pylori TS1776 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. |
| AID558602 | Antimicrobial activity against Streptococcus pneumoniae isolate 33 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID508470 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2011 harboring mef(A) gene after 35 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID671448 | Antimycobacterial activity against Mycobacterium avium ATCC 25291 assessed as inhibition of microbial growth at 2 ug/ml incubated for 6 days by MABA method | 2012 | Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13 | Discovery of novel 5-(ethyl or hydroxymethyl) analogs of 2'-'up' fluoro (or hydroxyl) pyrimidine nucleosides as a new class of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium inhibitors. |
| AID508391 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 1077 after 43 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID533862 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium wolinskyi after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID318666 | Antibacterial activity against Mycoplasma pneumoniae FH Liu by broth microdilution method | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7 | Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens. |
| AID425603 | Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate HM580 in mouse J774A1 cells isolated from colonic mucosal biopsies of patient with Crohn's disease assessed as intracellular killing of bacteria at 10% compound Cmax a | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID520870 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU47 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID543829 | Antimicrobial activity against Borrelia spielmanii isolate TIsar3 after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID402031 | Antimicrobial activity against Helicobacter pylori Sa-3 isolate after 4 days by twofold plate dilution method | 2005 | Journal of natural products, Jun, Volume: 68, Issue:6 | Anti-Helicobacter pylori compounds from Santalum album. |
| AID582686 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 infected in human THP1 cells assessed as concentration required to no apparent bacterial growth after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID535637 | Antimicrobial activity against Group B streptococcus serotype Ib R3 harboring Q557E, A400V mutations in PBP 2X and T567I, G539E mutations in PBP 2B by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility. |
| AID528849 | Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID545932 | Antimicrobial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 2 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID87950 | Minimum inhibitory concentration against Helicobacter pylori (Helicobacter pylori) ARHp strain 115 | 2002 | Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19 | Novel structures derived from 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 2. |
| AID558614 | Antimicrobial activity against Streptococcus pneumoniae isolate 2688 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID368780 | Cmax in fasting human plasma at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID1536966 | Inhibition of LPS-induced delay of apoptosis in human neutrophils assessed as early apoptotic cells at 2.5 uM preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb | 2019 | Journal of natural products, 02-22, Volume: 82, Issue:2 | Eupatoriopicrin Inhibits Pro-inflammatory Functions of Neutrophils via Suppression of IL-8 and TNF-alpha Production and p38 and ERK 1/2 MAP Kinases. |
| AID368787 | Tmax in fasting human interstitial-space fluid of skeletal muscle at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID535633 | Antimicrobial activity against Group B streptococcus serotype Ia R7 harboring T77I, F395V and S353F in PBP 2X; V80A and G613R in PBP 2B; and L45P, N163K, N723S and Y470F in PBP 1A by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility. |
| AID730746 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 2111-10-USA300 harboring cfr gene assessed as growth inhibition | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6 | Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates. |
| AID261461 | Antibacterial activity against Streptococcus pneumoniae 49619 | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Synthesis and antibacterial activity of novel C12 vinyl ketolides. |
| AID508372 | Antibacterial activity against Streptococcus pneumoniae harboring erm(B) and mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID557894 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 at day 7 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID208476 | The compound was tested in vitro for antibacterial activity against constitutively erythromycin resistant Streptococcus pneumoniae 030SJ1 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID372987 | Antimycobacterial activity against Mycobacterium avium JATA51-01 infected C57BL/6J mouse assessed as lung bacterial count at 200 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID1868042 | Antibacterial activity against Streptococcus pyogenes 12-206 by microbroth dilution method | 2022 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 68 | Design and synthesis of novel macrolones bridged with linkers from 11,12-positions of macrolides. |
| AID422670 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID572486 | Antimicrobial activity against Streptococcus pneumoniae ATCC 6303 infected in po dosed NMRI mouse administered thrice daily for 4 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. |
| AID502776 | Antibacterial activity against Helicobacter pylori ATCC 700392 at 0.05 ug/ml by disk agar diffusion method | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Identification of 3',4',5'-trimethoxychalcone analogues as potent inhibitors of Helicobacter pylori-induced inflammation in human gastric epithelial cells. |
| AID1754228 | Antibacterial activity against penicillin-resistant Staphylococcus aureus ATCC 31007 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. |
| AID577486 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315 assessed as inhibition of bacterial biofilm formation by CLSI broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. |
| AID1439726 | Bactericidal activity against Streptococcus pyogenes 12-207 expressing mef incubated for 20 to 24 hrs followed by sub-culturing for 24 hrs in absence of compound | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID525100 | Bacteriostatic activity against Mycobacterium abscessus 390V infected in human monocyte-derived macrophage assessed as inhibition of planktonic cell growth at 4 ug/ml treated 24 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID567798 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes 07U086 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID510853 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 29213 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activities of 6-O-methylerythromycin A 9-O-(3-aryl-2-propenyl) oxime ketolide, 2,3-enol ether, and alkylide analogues. |
| AID565820 | Antimicrobial activity against Chlamydia trachomatis isolates | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. |
| AID574696 | Enhancement of biofilm formation Staphylococcus epidermidis SW104 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID279559 | Antimicrobial activity against Haemophilus influenzae strains causing clinical infections | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea. |
| AID279207 | Antibacterial activity against Streptococcus pneumoniae 3676 by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID112355 | In Vivo evaluation for its effective dose against Haemophilus influenzae (351RD7 AmpR beta (+)) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID87939 | In vitro minimum inhibitory concentration against growth of Helicobacter pylori ATCC 43504. | 1998 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16 | Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents. |
| AID509008 | Antimicrobial activity against Streptococcus pyogenes | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. |
| AID557661 | Antimicrobial activity against Mycobacterium abscessus isolate MC723 at day 9 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID559859 | Antimicrobial activity against Streptococcus agalactiae clinical isolates by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections. |
| AID554544 | Antimicrobial activity against Mycobacterium smegmatis transformed with erm allele Mycobacterium abscessus isolate MC720 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID285161 | Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. |
| AID524825 | Antibacterial activity against erythromycin susceptible Campylobacter sp. by agar plate dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. |
| AID496388 | Antiinflammatory activity against nontypeable beta-lactamase-negative ampicillin-resistant Haemophilus influenzae 4437 infected in mouse ddY assessed as decrease in neutrophil count in bronchoalveolar lavage fluid at 100 mg/kg, po bid for 3 days relative | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. |
| AID422658 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 49 passages with clindamycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID1498149 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 after 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID369651 | Antibacterial activity against Campylobacter jejuni UA709 cmeB::kanamycin-resistant mutant by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni. |
| AID554525 | Antimicrobial activity against Mycobacterium abscessus isolate MC1448 at day 3 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID557907 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 at day 14 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID557793 | Antimicrobial activity against Streptococcus pyogenes clinical isolate expressing mef(A) gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Characterization of macrolide efflux pump mef subclasses detected in clinical isolates of Streptococcus pyogenes isolated between 1999 and 2005. |
| AID208796 | In vitro antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae IID553 strain | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Synthesis and antibacterial activity of acylides (3-O-acyl-erythromycin derivatives): a novel class of macrolide antibiotics. |
| AID717676 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 09E427 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides. |
| AID1427915 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 expressing mefA gene by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID558605 | Antimicrobial activity against Streptococcus pneumoniae isolate 1146 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID558625 | Antimicrobial activity against Streptococcus pneumoniae isolate 3458 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1439739 | Ratio of MBC to MIC against erythromycin-susceptible Moraxella catarrhalis 11B366 | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID201403 | In vitro minimum inhibitory concentration for antibacterial activity against Staphylococcus aureus SR138 (constitutively MLSb-resistant strain encoded by the erm(A) gene) | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID132634 | The compound was tested in vivo for antibacterial activity against inducibly erythromycin resistant Staphylococcus aureus 011GO3 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID565319 | Antibacterial activity against Mycoplasma genitalium M2321 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID558190 | Antimicrobial activity against Mycobacterium abscessus isolate MAB30 at day 14 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1427916 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing ermB/mefA genes by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID675201 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes 1104 expressing ermB ribosomal methylase by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17 | Synthesis and antibacterial activity of 6-O-(heteroaryl-isoxazolyl)propynyl 2-fluoro ketolides. |
| AID416846 | Antimycobacterial activity against Mycobacterium ulcerans isolate CU001 infected in BALB/c mouse left hind foot-pad assessed as incidence of bacterial infection at 100 mg/kg, po administered for 5 days per week measured after 8 weeks | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. |
| AID66411 | In vitro inhibitory activity against enterococci EryRi (19) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID86131 | In vitro minimum inhibitory concentration against Haemophilus influenzae DILL using standard agar dilution method | 2000 | Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8 | Synthesis and antibacterial activity of novel 6-O-substituted erythromycin A derivatives. |
| AID470195 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 by standard dilution assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin. |
| AID270435 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae mef 5654 by broth microdilution method | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and antibacterial activity of C12 des-methyl ketolides. |
| AID422688 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3413 after 50 passages by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID571661 | Ratio of the MIC for Acinetobacter baumannii in the absence of NAB7071 to MIC for Acinetobacter baumannii in the presence of 4 ug/ml of NAB7071 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID221223 | The compound has been evaluated for the in vivo efficacy that protect 50% of mice from lethal infection by Streptococcus Pneumonia EryS 032UC1 strain after oral administration | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID495324 | Antimicrobial activity against Beta-lactamase-positive, ampicillin-cluvulanate-resistant Haemophilus influenzae by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance. |
| AID724498 | Antibacterial activity against Salmonella typhimurium TA98 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID425979 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 49 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID87966 | Minimum inhibitory concentration required to inhibit macroscopic colonial growth of Helicobacter pylori | 2002 | Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1 | Anti-Helicobacter pylori agents. 5. 2-(Substituted guanidino)-4-arylthiazoles and aryloxazole analogues. |
| AID207374 | In vivo antibacterial activity of NCTC-10649 strain of Gram positive bacteria Staphylococcus aureus | 1998 | Journal of medicinal chemistry, May-07, Volume: 41, Issue:10 | Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues. |
| AID279563 | Antimicrobial activity against Haemophilus influenzae BLNAR strains | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea. |
| AID565324 | Antibacterial activity against Mycoplasma genitalium M6286 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID502780 | Antibacterial activity against multidrug-resistant Helicobacter pylori v1254 | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Identification of 3',4',5'-trimethoxychalcone analogues as potent inhibitors of Helicobacter pylori-induced inflammation in human gastric epithelial cells. |
| AID66554 | In vitro inhibitory activity against enterococci EryRc (23); ND=not determined | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID422646 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 44 passages by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID557397 | Antimicrobial activity against Helicobacter pylori clinical isolate by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. |
| AID285325 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci. |
| AID203437 | The compound was tested in vitro for antibacterial activity against 66 strains of inducibly erythromycin resistant Staphylococci; Value is 40/40 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID368800 | AUC (0 to 24 hrs) in human interstitial-space fluid of subcutaneous adipose tissue at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID502374 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by the broth microdilution method | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | A new series of macrolide derivatives with 4''-O-saccharide substituents. |
| AID502520 | Inhibition of Helicobacter pylori invasion into human AGS cells at 2.5 uM after 6 hrs | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Identification of 3',4',5'-trimethoxychalcone analogues as potent inhibitors of Helicobacter pylori-induced inflammation in human gastric epithelial cells. |
| AID496385 | Antiinflammatory activity against nontypeable beta-lactamase-negative ampicillin-resistant Haemophilus influenzae 4437 infected in mouse ddY assessed as decrease in total cell count in bronchoalveolar lavage fluid at 40 mg/kg, po bid for 3 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. |
| AID1221964 | Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979 | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2 | Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. |
| AID574695 | Enhancement of biofilm formation Staphylococcus epidermidis SW098 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID569035 | Antimicrobial activity against penicillin-susceptible Staphylococcus aureus P1 by broth microdilution method | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains. |
| AID508386 | Antibacterial activity against macrolide-resistant Streptococcus pyogenes harboring erm(B) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID440640 | Antibacterial activity against multidrug-susceptible Streptococcus pneumoniae 1016 by NCCLS method | 2009 | Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23 | Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. |
| AID207075 | In vitro inhibitory activity against Staphylococcus aureus (011UC4) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID368982 | Tmax in human interstitial-space fluid of skeletal muscle at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID508440 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 3665 harboring mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID554546 | Antimicrobial activity against Mycobacterium smegmatis transformed with erm allele Mycobacterium abscessus isolate MC958 preincubated with 2 ug/ml erythromycin for 20 to 24 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID577487 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus SH1000 assessed as inhibition of bacterial biofilm formation by CLSI broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. |
| AID369653 | Antibacterial activity against Campylobacter jejuni 001B-40 cmeB::kanamycin-resistant mutant by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni. |
| AID1221958 | Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2 | Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. |
| AID588215 | FDA HLAED, alkaline phosphatase increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID309084 | Antibacterial activity against erythromycin-sensitive Streptococcus pneumoniae | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18 | A novel ketolide class: Synthesis and antibacterial activity of a lead compound. |
| AID1549371 | Selectivity ratio of MBC to MIC for penicillin-susceptible Streptococcus pneumoniae PU 09 expressing mef gene | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID658058 | Antibacterial activity against Moraxella catarrhalis ATCC 23246 after 24 hrs at 37 degC by CLSI protocol based microdilution method | 2012 | Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10 | Novel desosamine-modified 14- and 15-membered macrolides without antibacterial activity. |
| AID508368 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID425980 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 14 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID261459 | Antibacterial activity against Enterococcus faecalis bc11148-2 | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Synthesis and antibacterial activity of novel C12 vinyl ketolides. |
| AID85943 | The compound was tested in vitro for antibacterial activity against 39 strains of Haemophilus influenza AmpR; Value is 2.5/10 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID559369 | Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1536965 | Inhibition of LPS-induced delay of apoptosis in human neutrophils assessed as viable cells at 2.5 uM preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 75.4 + | 2019 | Journal of natural products, 02-22, Volume: 82, Issue:2 | Eupatoriopicrin Inhibits Pro-inflammatory Functions of Neutrophils via Suppression of IL-8 and TNF-alpha Production and p38 and ERK 1/2 MAP Kinases. |
| AID508404 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 3665 harboring mef(A) gene after 26 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID425974 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 after 50 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID508383 | Antibacterial activity against Streptococcus pyogenes harboring mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID508373 | Antibacterial activity against Streptococcus pneumoniae harboring mutation in L4 ribosomal protein after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID368777 | AUC (0 to 24 hrs) in fasting human interstitial-space fluid of skeletal muscle at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID557930 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 at day 9 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID381670 | Antibacterial activity against standard Moraxella catarrhalis after 20 hrs by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13-hydroxy analogues. |
| AID571645 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 4 ug/ml NAB7070 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID567472 | Antimicrobial activity against gBLNAR Haemophilus influenzae by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae. |
| AID422654 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 26 passages by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID528976 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient urine assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID440647 | Metabolic stability in human liver cytosol assessed as compound turnover at 1 uM in presence of aldehyde oxidase inhibitor raloxifene | 2009 | Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23 | Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. |
| AID571765 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID699539 | Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. |
| AID558181 | Antimicrobial activity against Mycobacterium abscessus isolate MAB30 at day 5 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID547657 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 673 by broth microdilution method | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | Synthesis and antibacterial activity of C-12 pyrazolinyl spiro ketolides. |
| AID725374 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 29213 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID725380 | Antibacterial activity against penicillin-resistant, constitutive MLS-resistant Streptococcus pneumoniae PU 11 expressing erm and mef genes by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID208125 | In vitro inhibitory activity against Streptococcus pneumoniae (032UC1) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID528850 | Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient wound assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID283856 | Growth inhibition of Mycobacterium avium 2447 | 2007 | European journal of medicinal chemistry, Jan, Volume: 42, Issue:1 | Design, synthesis, biochemical evaluation and antimycobacterial action of phosphonate inhibitors of antigen 85C, a crucial enzyme involved in biosynthesis of the mycobacterial cell wall. |
| AID203434 | The compound was tested in vitro for antibacterial activity against 23 strains of constitutively erythromycin resistant Staphylococci; Not determined | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID534344 | Antimicrobial activity against Burkholderia pseudomallei Bp174 harboring mini-Tn7T-bpeR+ after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID88102 | The compound was evaluated in vitro for the minimum inhibitory concentration against Helicobacter pylori (13001). | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative. |
| AID279266 | Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 3243 with L22 insertion 93SFRPRA94 mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID571212 | Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of 1 ug/ml NAB739 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID296278 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 03-436 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID567807 | Antibacterial activity against erythromycin-susceptible Haemophilus influenzae 07O394 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID1417286 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 expressing mefA gene after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID535632 | Antimicrobial activity against Group B streptococcus R8 harboring T77I, S353F and A514V in PBP 2X; V80A and G613R in PBP 2B; and L45P, N163K, N723S and G527V in PBP 1A by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility. |
| AID781252 | Antibacterial activity against erythromycin-sensitive Streptococcus pneumoniae 12-8 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. |
| AID574699 | Enhancement of biofilm formation Staphylococcus epidermidis SW021 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID571767 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-M626I mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID728909 | Antibacterial activity against levofloxacin-intermediate and levofloxacin-resistant Streptococcus pneumoniae after 18 hrs by microbroth dilution method | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5 | Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens. |
| AID1691427 | Antibacterial activity against azithromycin-susceptible Haemophilus influenzae ATCC 49247 assessed as reduction in microbial growth relative to ciprofloxacin | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID440650 | Antibacterial activity against multidrug-resistant Streptococcus pneumoniae 1095 harboring ermB infected in po dosed mouse respiratory tract model assessed as survival administered 18 hrs postinfection BID for 2 days measured on day 10 postinfection | 2009 | Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23 | Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. |
| AID1647110 | Antibacterial activity against erythromycin resistant Streptococcus pyogenes R1 by standard broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID206484 | The compound was tested in vitro for antibacterial activity against erythromycin susceptible Staphylococcus aureus 011UC4 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID572850 | Antimicrobial activity against Helicobacter pylori TF2 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. |
| AID508426 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 7127 harboring S20N mutation in L4 ribosomal protein and A105V mutation in L22 ribosomal protein after 16 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID553819 | Antibacterial activity against Escherichia coli ATCC 25922 by CLSI method in presence of 2 mg/L tachyplesin 3 | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis. |
| AID640480 | Antimycobacterial activity against Mycobacterium avium ATCC 25291 assessed as growth inhibition at 2 ug/ml by microplate alamar blue assay | 2012 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2 | Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs. |
| AID574698 | Enhancement of biofilm formation Staphylococcus epidermidis SW015 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID508419 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 24 harboring erm(B) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID26629 | Dissociation constant (pKa) | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID557654 | Antimicrobial activity against Mycobacterium abscessus isolate MC720 at day 7 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID545918 | Antimicrobial activity against in Escherichia coli ATCC 25922 in presence of NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID571641 | Antibacterial activity against Klebsiella oxytoca CCUG51683 by Etest method in presence of 4 ug/ml NAB7066 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID588213 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID368775 | Free AUC (0 to 24 hrs) in fasting human plasma at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID1778127 | Antimicrobial activity against Staphylococcus aureus assessed as microbial growth inhibition by CLSI-protocol based broth microdilution assay | 2021 | Journal of natural products, 04-23, Volume: 84, Issue:4 | Opportunities and Limitations for Assigning Relative Configurations of Antibacterial Bislactones using GIAO NMR Shift Calculations. |
| AID565309 | Antibacterial activity against Mycoplasma genitalium by quantitative TaqMan PCR method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID208282 | Minimum against Streptococcus pneumoniae 6303 (erythromycin susceptible strain) | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. |
| AID1677807 | Antibacterial activity against Staphylococcus aureus ATCC25923 incubated for 24 hrs by CLSI-based broth microdilution method | 2020 | Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21 | Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus. |
| AID554550 | Antimicrobial activity against Mycobacterium smegmatis transformed with erm allele Mycobacterium abscessus isolate MC879-2 preincubated with 2 ug/ml erythromycin for 20 to 24 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID203431 | In vitro inhibitory activity against Streptococci EryRi (98) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID574693 | Enhancement of biofilm formation Staphylococcus epidermidis SW067 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID571929 | Ratio of MIC for Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-M626I mutant gene to MIC for Escherichia coli K-12 3-AG300 | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID781254 | Antibacterial activity against erythromycin-sensitive Streptococcus pneumoniae 12-1 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. |
| AID1691422 | Antibacterial activity against MLSB-resistant Streptococcus pyogenes 12-206 harboring ermA gene assessed as reduction in microbial growth | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID243422 | log (1/Km) value for human liver microsome cytochrome P450 3A4 | 2005 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18 | Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism. |
| AID558581 | Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1245719 | Bactericidal activity against Streptococcus pyogenes 12-207 expressing mef incubated for 20 to 24 hrs followed by sub-culturing for 24 hrs in absence of compound | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID1498842 | Antibacterial activity against methicillin-sensitive Streptococcus pyogenes 12-8 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID19403 | Calculated partition coefficient (logD) | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID678722 | Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID533852 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium abscessus after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID1549364 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC49619 assessed as reduction in microbial growth by CLSI based two-fold broth dilution method | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID543828 | Antimicrobial activity against Borrelia spielmanii isolate TIsar2 after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID519668 | Inhibition of PAR2-mediated SLIGKV-NH2-induced interleukin-8 production in normal human epidermal keratinocytes up to 100 uM preincubated for 24 hrs by ELISA | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes. |
| AID508378 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae harboring mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID558218 | Antimicrobial activity against Mycobacterium abscessus isolate MC1028 at day 9 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID528974 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID557659 | Antimicrobial activity against Mycobacterium abscessus isolate MC719 at day 9 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID567470 | Antimicrobial activity against gBLNAS Haemophilus influenzae by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae. |
| AID138314 | The compound was evaluated in vivo for the therapeutic efficacy at 0.32 mg/kg in mouse infection model; 0/8 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative. |
| AID558225 | Antimicrobial activity against Mycobacterium abscessus isolate MC879-2 at day 5 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID558587 | Antimicrobial activity against Streptococcus pneumoniae 19A by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1550822 | Antimicrobial activity against inducibly erythromycin-resistant Staphylococcus aureus PU32 expressing i-ermA incubated in CAMHB medium for 20 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID571925 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-G616N mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID557924 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 at day 7 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID422661 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 15 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID528842 | Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID555115 | Half life in healthy human at 400 mg, po administered as single dose | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers. |
| AID1867274 | Antibacterial activity against Micrococcus luteus ATCC 9341 assessed as bacterial growth inhibition incubated for 18 hrs by microdilution method | 2022 | Journal of natural products, 05-27, Volume: 85, Issue:5 | Diterpenoids from |
| AID547666 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 29213 by broth microdilution method | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | Synthesis and antibacterial activity of C-12 pyrazolinyl spiro ketolides. |
| AID508396 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 1077 after 15 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID574934 | Enhancement of biofilm formation Staphylococcus epidermidis ATCC 35984 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID528845 | Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient wound assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID571434 | Antibacterial activity against Escherichia coli ATCC 25992 by Etest method in presence of 4 ug/ml NAB7064 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID85790 | In vitro inhibitory activity against Haemophilus AmpR (37) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID543820 | Antimicrobial activity against Borrelia spielmanii isolate PMew after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID79581 | In vitro minimum inhibitory concentration for antibacterial activity against Haemophilus influenzae ATCC 33533 (ampicillin-resistant strain that produces beta-lactamase) | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID1754231 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes R1 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. |
| AID557656 | Antimicrobial activity against Mycobacterium abscessus isolate MC724 at day 7 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID588216 | FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID161930 | In vitro inhibitory activity against Pneumococci EryRc (34) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID1427908 | Antibacterial activity against penicillin-susceptible Escherichia coli ATCC 25922 by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID508375 | Antibacterial activity against quinolone-susceptible Streptococcus pneumoniae after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID725377 | Antibacterial activity against erythromycin-resistant Streptococcus dysgalactiae A1 expressing efflux pump by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID1647123 | Ratio of MBC for erythromycin-resistant Streptococcus pneumoniae AB11 expressing ermB and me/A genes to MIC for erythromycin-resistant Streptococcus pneumoniae AB11 expressing ermB and me/A genes | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID372548 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in variable mutated locus Asn-526 or Arg-517 of ftsI gene by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID279248 | Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3243 with 23S rRNA A2059T mutation after 41 passages by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID1766090 | Antibacterial activity against penicillin-susceptible Bacillus subtilis ATCC9372 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 49 | Design, synthesis and antibacterial evaluation of novel 3-O-substituted 15-membered azalides possessing 1,2,3-triazole side chains. |
| AID524916 | Antimicrobial activity against Mycobacterium abscessus 390S assessed as inhibition of planktonic cell growth in depleted medium | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID557674 | Antimicrobial activity against Mycobacterium abscessus isolate MC724 at day 3 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID334263 | Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 at 625 ug/mL after 24 hrs by conventional well agar method | 2002 | Journal of natural products, Apr, Volume: 65, Issue:4 | Derrisin, a new rotenoid from Derris malaccensis plain and anti-Helicobacter pylori activity of its related constituents. |
| AID574707 | Enhancement of biofilm formation Staphylococcus epidermidis SW120 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID571439 | Antibacterial activity against Escherichia coli IH3080 by Etest method in presence of 4 ug/ml NAB7064 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID775006 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 by broth microdilution method | 2013 | European journal of medicinal chemistry, Nov, Volume: 69 | Synthesis and antibacterial activity of novel modified 5-O-mycaminose 14-membered ketolides. |
| AID520868 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU28 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID574703 | Enhancement of biofilm formation Staphylococcus epidermidis SW082 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID321878 | Lipophilicity, log D at pH 8.0 | 2008 | Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1 | A new insight into solid-state conformation of macrolide antibiotics. |
| AID1632646 | In vivo displacement of [11C]FMZ from rhesus monkey GABA-A receptor at 3.5 mg/kg, iv after 50 to 90 mins by PET analysis | 2016 | ACS medicinal chemistry letters, Aug-11, Volume: 7, Issue:8 | Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET. |
| AID560516 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate 11b091 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID425402 | Antibacterial activity Escherichia coli isolate HM413 isolated from ileo-colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID556348 | Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained from bronchial aspirations expressing 23S rRNA A2063G mutant gene and P1 RFLP type I gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. |
| AID292285 | Antimycobacterial activity against Mycobacterium avium ATCC 25291 by microplate Alamar blue assay | 2007 | Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15 | Growth inhibition of Mycobacterium bovis, Mycobacterium tuberculosis and Mycobacterium avium in vitro: effect of 1-beta-D-2'-arabinofuranosyl and 1-(2'-deoxy-2'-fluoro-beta-D-2'-ribofuranosyl) pyrimidine nucleoside analogs. |
| AID528978 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID534424 | Antibacterial activity against Mycobacterium bovis BCG-Pasteur | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. |
| AID557923 | Antimicrobial activity against Mycobacterium abscessus isolate MC724 at day 5 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID559558 | Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID571213 | Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of 0.5 ug/ml NAB739 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID117681 | Protective dose at which 50% of infected, treated mice survive | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID373005 | Antimycobacterial activity against Mycobacterium avium complex N018 infected C57BL/6J mouse assessed as liver bacterial count at 200 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID681132 | TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells | 2001 | The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2 | Rational use of in vitro P-glycoprotein assays in drug discovery. |
| AID1245711 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus PU32 expressing inducible ermA incubated for 20 hrs by two-fold microbroth dilution method | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID553820 | Antibacterial activity against Escherichia coli by CLSI method in presence of 2 mg/L tachyplesin 3 | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis. |
| AID322969 | Antimicrobial activity against clarithromycin resistant-Mycobacterium avium complex 101 infected C57BL/6 beige mouse liver assessed as bacterial load at 100 mg/kg once daily 6 days a week for 4 weeks | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium. |
| AID588212 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID518962 | Induction of erm(C) expression in Escherichia coli JM109 harboring Staphylococcus aureus erm(C)-containing pERMZ7 lacking codons 2 to 4 with additional mutations leader peptide cistrons reporter plasmid at 25 mg/ml after 36 hrs at 37 degC by disc-based be | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of erm(C) expression by noninducing antibiotics. |
| AID209880 | Cell free inhibiting activity against Streptococcus pneumoniae 5635(Wild type ribosomes for transcription/translation assay) | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. |
| AID261463 | Antibacterial activity against Streptococcus pneumoniae 280-962 | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Synthesis and antibacterial activity of novel C12 vinyl ketolides. |
| AID558623 | Antimicrobial activity against Streptococcus pneumoniae isolate 3412 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID114695 | Effective dose when administered subcutaneously in mice infected with Staphylococcus aureus NCTC-10649M. | 1998 | Journal of medicinal chemistry, May-07, Volume: 41, Issue:10 | Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues. |
| AID635188 | Antibacterial activity against efflux-mediated macrolide-resistant Staphylococcus aureus PK1 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID1487246 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing ermB gene | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID508454 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2368 harboring erm(B) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID334260 | Antibacterial activity against Micrococcus luteus ATCC 9341 at 625 ug/mL after 24 hrs by conventional well agar method | 2002 | Journal of natural products, Apr, Volume: 65, Issue:4 | Derrisin, a new rotenoid from Derris malaccensis plain and anti-Helicobacter pylori activity of its related constituents. |
| AID519671 | Toxicity in normal human epidermal keratinocytes assessed as effect on cell viability at 100 uM after 72 hrs by colorimetric assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes. |
| AID571438 | Antibacterial activity against Escherichia coli IH3080 by Etest method in presence of 2 ug/ml NAB7062 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID576337 | Antimicrobial activity against Chlamydia trachomatis serovar G infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID544526 | Antimicrobial activity against Borrelia garinii isolate M2094 after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID1444604 | Antibacterial activity against macrolide-resistant Staphylococcus aureus BAA976 expressing mef gene by broth microdilution method | 2017 | Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8 | Synthesis of clarithromycin ketolides chemically modified at the unreactive C10-methyl group. |
| AID340001 | Antimicrobial activity against Staphylococcus aureus | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Antibacterial activity of labdane diterpenoids from Stemodia foliosa. |
| AID479817 | Antimicrobial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives. |
| AID558202 | Antimicrobial activity against Mycobacterium abscessus isolate MAB30 at day 9 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID201246 | In vitro minimum inhibitory concentration for antibacterial activity against erythromycin-susceptible strain Staphylococcus aureus 209-JC | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID326073 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae NMU112 infected CBA/J mouse assessed as median survival time at 10 mg/kg, po relative to control | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. |
| AID508444 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 7127 harboring S20N mutation in L4 ribosomal protein and A105V mutation in L22 ribosomal protein after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1879670 | Antibacterial activity against Helicobacter pylori infected in C57/BL6 mouse assessed as bacterial load in stomach at 10 mg/kg administered twice daily via oral gavage starting from 7 days post inoculation and administered for 7 days (Rvb = 5.25 log10CFU) | 2022 | Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6 | Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens. |
| AID208136 | In vitro minimum inhibitory concentration against Streptococcus pneumoniae ATCC 6303. | 2000 | Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8 | Synthesis and antibacterial activity of novel 6-O-substituted erythromycin A derivatives. |
| AID1427917 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes R1 clinical isolate by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID1439724 | Ratio of MBC to MIC for Streptococcus pyogenes 01-968 expressing inducible ermA | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID512009 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 3469 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides. |
| AID704317 | Cellular uptake in normal human lung fibroblast at 3 to 20 uM after 3 hrs by by LC-MS/MS analysis relative to azithromycin | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID572274 | Antimicrobial activity against multiple drug-resistant Streptococcus pneumoniae ATCC 700677 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. |
| AID444050 | Fraction unbound in human plasma | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID554649 | Antimicrobial activity against Ureaplasma urealyticum isolate HPA6 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID678716 | Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID558081 | Inhibition of PAR2-mediated TNFalpha and SLIGKV-NH2-induced interleukin-8 production in normal human epidermal keratinocytes at 10 uM by ELISA | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes. |
| AID675202 | Antibacterial activity against Haemophilus influenzae ATCC 43095 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17 | Synthesis and antibacterial activity of 6-O-(heteroaryl-isoxazolyl)propynyl 2-fluoro ketolides. |
| AID322963 | Antimicrobial activity against macrolide-susceptible Mycobacterium avium by radiometric broth nanodilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium. |
| AID565297 | Antitubercular activity against Mycobacterium avium infected in C57BL/6J mouse assessed as reduction of CFU counts in spleen at 150 mg/kg, sc administered one month post-infection five times weekly for 2 months (Rvb = 9.4 +/- 0.2 log10CFU) | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | ATP synthase inhibition of Mycobacterium avium is not bactericidal. |
| AID725371 | Antibacterial activity against methicillin-sensitive, inducible MLS-resistant Staphylococcus aureus PU 64 expressing ermA gene by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID535344 | Antimicrobial activity against Streptococcus pneumoniae clinical isolates assessed as resistant isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID495321 | Antimicrobial activity against beta-lactamase-negative, ampicillin-sensitive Haemophilus influenzae by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance. |
| AID638884 | Antibacterial activity against Streptococcus pneumoniae 3579 expressing erm gene by NCCLS method | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens. |
| AID208142 | In vivo antibacterial activity of ATCC 6303 strain of Gram positive bacteria Streptococcus pneumoniae | 1998 | Journal of medicinal chemistry, May-07, Volume: 41, Issue:10 | Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues. |
| AID501674 | Antimicrobial activity against Streptococcus pyogenes Finland 2 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID625280 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID508381 | Antibacterial activity against macrolide-susceptible Streptococcus pyogenes after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID261455 | Antibacterial activity against Staphylococcus aureus 33591 | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Synthesis and antibacterial activity of novel C12 vinyl ketolides. |
| AID717687 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus 09U035 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides. |
| AID681131 | TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells | 2001 | Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2 | Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. |
| AID556155 | Antimicrobial activity against Streptococcus pneumoniae assessed as resistant isolates broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae. |
| AID555111 | Cmax in healthy human at 400 mg, po administered as single dose | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers. |
| AID285326 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 43300 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci. |
| AID428140 | Antimicrobial activity against Streptococcus pneumoniae PC13 transformant harboring 136-bp deletion in erm(B) gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation. |
| AID1474166 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID25233 | AUC (area under curve) after oral dosing by gavage needle at 30 mg/kg in C57BL/6NTac female mice | 2002 | Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19 | Novel structures derived from 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 2. |
| AID534337 | Antimicrobial activity against Burkholderia pseudomallei Bp216 harboring mini-Tn7T after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID574689 | Enhancement of biofilm formation Staphylococcus epidermidis SW032 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID569033 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing the erm and mef gene by broth microdilution method | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains. |
| AID261456 | Antibacterial activity against Staphylococcus epidermidis 14990 | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Synthesis and antibacterial activity of novel C12 vinyl ketolides. |
| AID548475 | Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm, graRm mutant gene after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID1221965 | Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979 | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2 | Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. |
| AID571208 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 0.25 ug/ml NAB739 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID368981 | Tmax in human interstitial-space fluid of subcutaneous adipose tissue at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID502377 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae ERSP-2 expressing ermB and mef by the broth microdilution method | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | A new series of macrolide derivatives with 4''-O-saccharide substituents. |
| AID208784 | In vitro antibacterial activity against MLS-B resistant Streptococcus pneumoniae 221 strain encoded by an erm B gene | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Synthesis and antibacterial activity of acylides (3-O-acyl-erythromycin derivatives): a novel class of macrolide antibiotics. |
| AID582611 | Drug uptake in human THP1 cells after 24 hrs in presence of gemfibrozil | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID425985 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 20 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID535642 | Antimicrobial activity against Group B streptococcus serotype VI N4 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility. |
| AID66555 | In vitro inhibitory activity against enterococci EryRi (19) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID535775 | Antimicrobial activity against Mycobacterium ulcerans 1059 harboring pTY60K containing pMH94 carrying the luxAB gene under the hsp60 promoter after 14 days determined according to RLU count by real-time luminescence method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. |
| AID576344 | Bactericidal activity against Chlamydia trachomatis serovar F infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID571657 | Ratio of the MIC for Enterobacter cloacae CCUG52947 in the absence of NAB7067 to MIC for Enterobacter cloacae CCUG52947 in the presence of 4 ug/ml of NAB7067 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID296271 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 01-1091 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID558630 | Antimicrobial activity against Streptococcus pneumoniae isolate 4747 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID502379 | Antibacterial activity against Streptococcus pyogenes ERSPy-1 expressing mef by the broth microdilution method | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | A new series of macrolide derivatives with 4''-O-saccharide substituents. |
| AID535773 | Antimicrobial activity against Mycobacterium ulcerans 1059 harboring pTY60K carrying the luxAB gene under the hsp60 promoter agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. |
| AID296270 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 01-1005 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID545915 | Antimicrobial activity against Escherichia coli ATCC 25922 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID540210 | Clearance in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID557900 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 at day 9 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID368769 | Protein binding in human plasma at 500 mg, po bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID309083 | Antibacterial activity against erythromycin-sensitive Staphylococcus aureus PK2 MLSc | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18 | A novel ketolide class: Synthesis and antibacterial activity of a lead compound. |
| AID368989 | Drug uptake in human adipose tissue assessed as in vivo drug recovery by microdialysis | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID508471 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2011 harboring mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1550829 | Ratio of MBC to MIC for mef-encoded erythromycin resistant Streptococcus pneumoniae PU09 | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID574691 | Enhancement of biofilm formation Staphylococcus epidermidis SW058 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID508441 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 1076 harboring erm(B) and mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID560511 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b5k3578 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID1677808 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC43300 incubated for 24 hrs by CLSI-based broth microdilution method | 2020 | Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21 | Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus. |
| AID508405 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 3665 harboring mef(A) gene after 26 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1778125 | Antimicrobial activity against Bacillus anthracis assessed as microbial growth inhibition by CLSI-protocol based broth microdilution assay | 2021 | Journal of natural products, 04-23, Volume: 84, Issue:4 | Opportunities and Limitations for Assigning Relative Configurations of Antibacterial Bislactones using GIAO NMR Shift Calculations. |
| AID571665 | Ratio of the MIC for Pseudomonas aeruginosa ATCC 27853 in the absence of NAB7075 to MIC for Pseudomonas aeruginosa ATCC 27853 in the presence of 4 ug/ml of NAB7075 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID554551 | Antimicrobial activity against Mycobacterium smegmatis transformed with erm allele Mycobacterium abscessus isolate MAB30 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID735598 | Antibacterial activity against MLS-resistant (constitutive) Streptococcus pyogenes A2 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID1549374 | Bactericidal activity against azithromycin-susceptible Haemophilus influenzae ATCC 49247 pretreated followed by subculture in absence of compound measured after 24 hrs | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID1414190 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by broth microdilution based CLSI method | 2018 | European journal of medicinal chemistry, Nov-05, Volume: 159 | Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators. |
| AID85793 | In vitro inhibitory activity against Haemophilus AmpS (43) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID569036 | Antimicrobial activity against erythromycin-susceptible Streptococcus pyogenes S2 by broth microdilution method | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains. |
| AID501672 | Antimicrobial activity against Streptococcus pyogenes 3565 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID508377 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae harboring erm(B) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1417281 | Antibacterial activity against penicillin-susceptible Pseudomonas aeruginosa ATCC 27853 after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID207076 | In vitro inhibitory activity against Staphylococcus aureus (EryRc 011CB20) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID1488451 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 harboring mef gene after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID422659 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 29 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID635189 | Antibacterial activity against efflux-mediated macrolide-resistant Streptococcus pneumoniae Ci137 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID340007 | Antimicrobial activity against Mycobacterium phlei | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Antibacterial activity of labdane diterpenoids from Stemodia foliosa. |
| AID297687 | Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by microplate alamar blue assay | 2007 | Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19 | Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides. |
| AID444057 | Fraction escaping hepatic elimination in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID528967 | Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient blood assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID558233 | Antimicrobial activity against Mycobacterium abscessus isolate MC879-2 at day 3 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID425403 | Antibacterial activity Escherichia coli isolate HM419 isolated from ileo-colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID688518 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19 | Synthesis and structure-activity relationship of a novel class of 15-membered macrolide antibiotics known as '11a-azalides'. |
| AID508382 | Antibacterial activity against Streptococcus pyogenes harboring erm(B) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID501299 | Antibacterial activity against inducible resistance to macrolide and constitutive resistance to lincosamide Streptococcus pneumoniae 134 GR M by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID508365 | Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID470193 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 by standard dilution assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin. |
| AID553830 | Antibacterial activity against Escherichia coli clinical isolates by CLSI method in presence of 2 mg/L tachyplesin 3 | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis. |
| AID125510 | The ratio of the number of Mongolian gerbils in which Helicobacter pylori was not detected to that of Mongolian gerbils tested (percent) was represented as clearance rate at 30 mg/kg dose | 1998 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16 | Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents. |
| AID547668 | Antibacterial activity against erythromycin-susceptible Haemophilus influenzae 5096 by broth microdilution method | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | Synthesis and antibacterial activity of C-12 pyrazolinyl spiro ketolides. |
| AID510557 | Antimicrobial activity against Chlamydophila pneumoniae infected in human Hep2 cells after 72 hrs by twofold serial dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. |
| AID574700 | Enhancement of biofilm formation Staphylococcus epidermidis SW036 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID724771 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID571436 | Antibacterial activity against Escherichia coli IH3080 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID571649 | Antibacterial activity against Proteus vulgaris ATCC 13315 by Etest method in presence of 4 ug/ml NAB7074 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1677794 | Bacteriostatic activity against penicillin-resistant Staphylococcus aureus assessed as ratio of MBC to MIC | 2020 | Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21 | Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus. |
| AID554543 | Antimicrobial activity against Mycobacterium smegmatis transformed with erm allele Mycobacterium abscessus isolate MC719 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID508380 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae harboring mutation in L4 ribosomal protein after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID309082 | Antibacterial activity against erythromycin-sensitive Staphylococcus aureus ATCC 13709 | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18 | A novel ketolide class: Synthesis and antibacterial activity of a lead compound. |
| AID1245726 | Ratio of MBC to MIC against Streptococcus pyogenes 01-968 expressing inducible ermA | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID1550824 | Antimicrobial activity against inducibly erythromycin resistant Staphylococcus aureus PU64 expressing i-ermA incubated in CAMHB medium for 20 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID508402 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 3665 harboring mef(A) gene after 14 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1427910 | Antibacterial activity against penicillin-susceptible Pseudomonas aeruginosa ATCC 27853 by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID554541 | Antimicrobial activity against Mycobacterium smegmatis transformed with erm allele Mycobacterium abscessus isolate MC879 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID535360 | Antimicrobial activity against Haemophilus influenzae clinical isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID565310 | Antibacterial activity against Mycoplasma genitalium G37 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID1539177 | Antibacterial activity against penicillin-susceptible Bacillus subtilis ATCC 9372 incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID161937 | In vitro inhibitory activity against Pneumococci EryRc (34) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID1550832 | Ratio of MBC to MIC for inducibly erythromycin resistant Streptococcus pyogenes 01-968 expressing i-ermA | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID545926 | Antimicrobial activity against in Klebsiella pneumoniae ATCC 13883 in presence of NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID309091 | Antibacterial activity against Haemophilus influenzae ATCC 49247 | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18 | A novel ketolide class: Synthesis and antibacterial activity of a lead compound. |
| AID88105 | The compound was evaluated in vitro for the minimum inhibitory concentration against Helicobacter pylori (FP1757). | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative. |
| AID781249 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 12-5 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. |
| AID543825 | Antimicrobial activity against Borrelia spielmanii isolate PAnz after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID322965 | Antimicrobial activity against Mycobacterium avium complex 101 infected C57BL/6 beige mouse liver assessed as bacterial load at 100 mg/kg once daily 6 days a week for 4 weeks | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium. |
| AID23733 | Calculated partition coefficient (clogP) | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID557794 | Antimicrobial activity against Streptococcus pyogenes clinical isolate expressing mef(E) gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Characterization of macrolide efflux pump mef subclasses detected in clinical isolates of Streptococcus pyogenes isolated between 1999 and 2005. |
| AID572844 | Antimicrobial activity against Helicobacter pylori TS1900 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. |
| AID1549363 | Antibacterial activity against MLS-resistant Staphylococcus aureus PU 32 expressing inducible ermA gene assessed as reduction in microbial growth by CLSI based two-fold broth dilution method | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID428139 | Antimicrobial activity against wild-type Streptococcus pneumoniae PC13 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation. |
| AID519670 | Toxicity in normal human epidermal keratinocytes assessed as effect on cell viability at 10 uM after 72 hrs by colorimetric assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes. |
| AID533205 | Antimicrobial activity against Haemophilus influenzae clinical isolates assessed as susceptible isolates by PK/PD technique | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID558207 | Antimicrobial activity against Mycobacterium abscessus isolate MC1082 at day 14 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID508388 | Antibacterial activity against macrolide-resistant Streptococcus pyogenes harboring erm(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID699541 | Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. |
| AID207391 | In vitro antibacterial activity against erythromycin-susceptible Staphylococcus aureus 209P-JC strain | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Synthesis and antibacterial activity of acylides (3-O-acyl-erythromycin derivatives): a novel class of macrolide antibiotics. |
| AID559368 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID560515 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate 13b16 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID372549 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in highly mutated locus Ser-385 of ftsI gene by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID1473739 | Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID644453 | Antibacterial activity against methicillin-susceptible, inducible MLS-resistant Staphylococcus epidermidis E1 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID279271 | Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 2527 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID279245 | Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3676 after 44 passages by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID533857 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium mageritense after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID678713 | Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID279202 | Antibacterial activity against Streptococcus pneumoniae 3009 by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID321868 | Cmax in human at 500 mg, po administered as single dose | 2008 | Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1 | A new insight into solid-state conformation of macrolide antibiotics. |
| AID558227 | Antimicrobial activity against Mycobacterium abscessus isolate MC879-2 at day 7 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID297688 | Antimycobacterial activity against Mycobacterium tuberculosis H37Ra at 0.5-1 uM by microplate alamar blue assay | 2007 | Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19 | Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides. |
| AID425964 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 after 48 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID557911 | Antimicrobial activity against Mycobacterium abscessus isolate MC724 at day 14 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID416130 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing erm and mef genes by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6 | Synthesis and antibacterial activity of 4'',11-di-O-arylalkylcarbamoyl azithromycin derivatives. |
| AID203445 | In vitro inhibitory activity against Streptococci EryR (27) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID285159 | Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. |
| AID510852 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae PU-27 expressing erm gene by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activities of 6-O-methylerythromycin A 9-O-(3-aryl-2-propenyl) oxime ketolide, 2,3-enol ether, and alkylide analogues. |
| AID508456 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2368 harboring erm(B) gene after 6 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID256362 | Inhibition of growth of Mycobacterium bovis was determined using microplate alamar blue assay with compound dissolved in DMSO; ND = Not determined | 2005 | Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22 | Design and studies of novel 5-substituted alkynylpyrimidine nucleosides as potent inhibitors of mycobacteria. |
| AID368798 | AUC (0 to 24 hrs) in human plasma at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID524914 | Antimicrobial activity against Mycobacterium abscessus 390S assessed as inhibition of planktonic cell growth in replete medium | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID560506 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b3k2345 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID588217 | FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID565303 | Antitubercular activity against Mycobacterium avium infected in C57BL/6J mouse assessed as reduction of CFU counts in spleen at 200 mg/kg, po administered one month post-infection five times weekly for 4 months (Rvb = 8.9 +/- 0.3 log10CFU) | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | ATP synthase inhibition of Mycobacterium avium is not bactericidal. |
| AID567800 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes 01-533 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID87965 | Minimum inhibitory concentration that inhibited macroscopic colony growth of Helicobacter pylori | 1999 | Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15 | Anti-Helicobacter pylori agents. 3. 2-[(Arylalkyl)guanidino]-4-furylthiazoles. |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID1323725 | Growth inhibition of Mycobacterium avium ATCC 25291 at 2 ug/ml after 6 days by microplate alamar blue assay | 2016 | Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21 | Investigation of C-5 alkynyl (alkynyloxy or hydroxymethyl) and/or N-3 propynyl substituted pyrimidine nucleoside analogs as a new class of antimicrobial agents. |
| AID558214 | Antimicrobial activity against Mycobacterium abscessus isolate MAB30 at day 7 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID368988 | Total clearance in human plasma at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID285327 | Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis ATCC 29212 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci. |
| AID502523 | Inhibition of Helicobacter pylori-induced inflammation in human AGS cells assessed as reduction of NF-kappaB activity at 2.5 uM after 6 hrs by luciferase reporter gene assay relative to control | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Identification of 3',4',5'-trimethoxychalcone analogues as potent inhibitors of Helicobacter pylori-induced inflammation in human gastric epithelial cells. |
| AID209624 | In vitro minimum inhibitory concentration against Streptococcus pyogenes 930 using standard agar dilution method | 2000 | Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8 | Synthesis and antibacterial activity of novel 6-O-substituted erythromycin A derivatives. |
| AID557943 | Antimicrobial activity against Mycobacterium abscessus isolate MC719 at day 5 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID547658 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 5158 by broth microdilution method | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | Synthesis and antibacterial activity of C-12 pyrazolinyl spiro ketolides. |
| AID508413 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 1635 harboring erm(A) gene after 14 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID582674 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 at pH 5.5 to 7.4 after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID297684 | Antimycobacterial activity against Mycobacterium avium ATCC 25291 at 2 uM by microplate alamar blue assay | 2007 | Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19 | Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides. |
| AID368789 | Terminal half life in fasting human plasma unbound fraction at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID368791 | Terminal half life in fasting human interstitial-space fluid of skeletal muscle at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID66410 | In vitro inhibitory activity against enterococci EryRc (23); ND=not determined | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID1245727 | Ratio of MBC to MIC against Streptococcus pyogenes 12-207 expressing mef | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID557792 | Antimicrobial activity against Streptococcus pyogenes clinical isolate expressing mosaic variant of mef gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Characterization of macrolide efflux pump mef subclasses detected in clinical isolates of Streptococcus pyogenes isolated between 1999 and 2005. |
| AID131226 | Mouse protection tests for effective dose against Streptococcus pneumoniae 6303 ((erythromycin susceptible strain)) infected mice | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. |
| AID425973 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 50 passages by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID781257 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 12-11 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. |
| AID571654 | Ratio of the MIC for Klebsiella pneumoniae in the absence of NAB7064 to MIC for Klebsiella pneumoniae in the presence of 4 ug/ml of NAB7064 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID640476 | Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as growth inhibition at 0.5 to 100 ug/ml by microplate alamar blue assay | 2012 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2 | Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs. |
| AID138317 | The compound was evaluated in vivo for the therapeutic efficacy at 1.0 mg/kg in mouse infection model; 0/8 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative. |
| AID730744 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 1279-07 harboring cfr gene assessed as growth inhibition | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6 | Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates. |
| AID543831 | Antimicrobial activity against Borrelia burgdorferi isolate LW2 after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID576342 | Bactericidal activity against Chlamydia trachomatis serovar D infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID735599 | Antibacterial activity against erythromycin-resistant Streptococcus dysgalactiae A1 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID977603 | pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID576340 | Antimicrobial activity against Chlamydia trachomatis serovar J infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID422657 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID557671 | Antimicrobial activity against Mycobacterium abscessus isolate MC719 at day 3 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID87934 | Antibacterial activity was evaluated against Helicobacter pylori (13001). | 1998 | Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14 | Discovery of a novel benzyloxyisoquinoline derivative with potent anti-Helicobacter pylori activity. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID565313 | Antibacterial activity against Mycoplasma genitalium TW10-5G by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID292286 | Antimycobacterial activity against Mycobacterium avium ATCC 25291 at 2 ug/mL by microplate Alamar blue assay | 2007 | Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15 | Growth inhibition of Mycobacterium bovis, Mycobacterium tuberculosis and Mycobacterium avium in vitro: effect of 1-beta-D-2'-arabinofuranosyl and 1-(2'-deoxy-2'-fluoro-beta-D-2'-ribofuranosyl) pyrimidine nucleoside analogs. |
| AID717677 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 09D016 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides. |
| AID368797 | AUC (0 to 8 hrs) in human interstitial-space fluid of skeletal muscle at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID717684 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 09A011 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides. |
| AID681126 | TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells | 2001 | Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2 | Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. |
| AID508367 | Antibacterial activity against penicillin-resistant Streptococcus pneumoniae after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID678712 | Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID725372 | Antibacterial activity against methicillin-resistant, constitutive MLS-resistant Staphylococcus aureus PU 20 expressing ermC gene by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID571664 | Ratio of the MIC for Proteus vulgaris ATCC 13315 in the absence of NAB7074 to MIC for Proteus vulgaris ATCC 13315 in the presence of 4 ug/ml of NAB7074 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1487250 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID560514 | Antimicrobial activity against SCCmec type IV vancomycin-intermediate Staphylococcus aureus isolate 06b41 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID1498150 | Antibacterial activity against penicillin-susceptible Escherichia coli ATCC 25922 incubated for 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID470190 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 by standard dilution assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin. |
| AID588214 | FDA HLAED, liver enzyme composite activity | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID293533 | Antimycobacterial activity against Mycobacterium avium ATCC 25291 at 2 ug/mL after 24 to 48 hrs by MABA | 2007 | Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5 | Studies on acyclic pyrimidines as inhibitors of mycobacteria. |
| AID508369 | Antibacterial activity against Streptococcus pneumoniae harboring erm(B) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID571658 | Ratio of the MIC for Enterobacter cloacae in the absence of NAB7068 to MIC for Enterobacter cloacae in the presence of 4 ug/ml of NAB7068 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1632651 | Displacement of [3H]FMZ from GABA-A receptor in rat brain at 10 uM preincubated for 30 mins followed by FMZ addition measured up to 16 mins | 2016 | ACS medicinal chemistry letters, Aug-11, Volume: 7, Issue:8 | Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET. |
| AID1193492 | Thermodynamic equilibrium solubility, log S of the compound in water at RT after 4 hrs by 96 well plate method | 2015 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7 | Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery. |
| AID547663 | Antibacterial activity against erythromycin-resistant Staphylococcus aureus 5676 by broth microdilution method | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | Synthesis and antibacterial activity of C-12 pyrazolinyl spiro ketolides. |
| AID1439737 | Bacteriostatic activity against erythromycin-susceptible Moraxella catarrhalis 11B366 after 20 hrs by two-fold microbroth dilution method | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID502376 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis MRSE-1 by the broth microdilution method | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | A new series of macrolide derivatives with 4''-O-saccharide substituents. |
| AID588218 | FDA HLAED, lactate dehydrogenase (LDH) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID572847 | Antimicrobial activity against clarithromycin-susceptible Helicobacter pylori ATCC 700392 transformant harboring 23S rRNA of Helicobacter pylori TS1900 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. |
| AID582684 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 infected in human THP1 cells assessed as decrease of CFU after 24 hrs relative to initial inoculum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID558204 | Antimicrobial activity against Mycobacterium abscessus isolate MC1082 at day 9 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID425967 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID132635 | The compound was tested in vivo for antibacterial activity against inducibly erythromycin resistant Streptococcus pneumoniae 030RO1 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID567797 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes 07U084 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID1549380 | Selectivity ratio of MBC to MIC for MLS/methicillin-resistant Staphylococcus aureus PU 32 expressing inducible ermA gene | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID368793 | Total clearance in fasting human plasma at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID1439718 | Ratio of MBC to MIC for erythromycin-resistant Streptococcus pneumoniae ATCC 49619 | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID565322 | Antibacterial activity against Mycoplasma genitalium M6280 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID508370 | Antibacterial activity against Streptococcus pneumoniae harboring mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID548255 | Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSn mutant gene after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID571663 | Ratio of the MIC for Proteus mirabilis ATCC 29906 in the absence of NAB7073 to MIC for Proteus mirabilis ATCC 29906 in the presence of 4 ug/ml of NAB7073 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID528848 | Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID1632649 | In vivo displacement of [11C]FMZ from rhesus monkey GABA-A receptor assessed late distribution volume ratio to early distribution volume ratio of [3H]-FMZ at 7 mg/kg, iv by Logan plot analysis (Rvb = 115 to 121 %) | 2016 | ACS medicinal chemistry letters, Aug-11, Volume: 7, Issue:8 | Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET. |
| AID595939 | Antibacterial activity against Bacillus subtilis | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID559554 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID297685 | Antimycobacterial activity against Mycobacterium bovis BCG by microplate alamar blue assay | 2007 | Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19 | Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides. |
| AID557915 | Antimicrobial activity against Mycobacterium abscessus isolate MC720 at day 3 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID519673 | Effect on PAR2 gene expression in normal human epidermal keratinocytes assessed as effect on cell viability at 100 uM after 72 hrs | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes. |
| AID558627 | Antimicrobial activity against Streptococcus pneumoniae isolate 3587 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID535772 | Antimicrobial activity against Mycobacterium ulcerans 1059 agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. |
| AID735592 | Antibacterial activity against methicillin-resistant, coagulase-negative, MLS-resistant (constitutive) Staphylococcus aureus PU 19 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID381658 | Antibacterial activity against standard Staphylococcus aureus after 20 hrs by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13-hydroxy analogues. |
| AID781251 | Antibacterial activity against erythromycin-sensitive Streptococcus pneumoniae 12-10 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. |
| AID508379 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae harboring erm(B) and mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID533860 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium porcinum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID554523 | Antimicrobial activity against Mycobacterium abscessus isolate MC1448 at day 14 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID557645 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 at day 5 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1245714 | Antimicrobial activity against Streptococcus pyogenes 12-207 expressing mef incubated for 20 to 24 hrs by two-fold microbroth dilution method | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID528836 | Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient wound assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID557896 | Antimicrobial activity against Mycobacterium abscessus isolate MC719 at day 7 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID548473 | Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSn mutant gene after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID572846 | Antimicrobial activity against compound-resistant Helicobacter pylori harboring 23S rRNA mutant gene | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. |
| AID368774 | AUC (0 to 24 hrs) in fasting human plasma at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID557906 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 at day 14 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID768667 | Antibacterial activity against Mycobacterium avium assessed as growth inhibition at 2 ug/mL relative to control | 2013 | Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17 | Synthesis of novel isothiazolopyridines and their in vitro evaluation against Mycobacterium and Propionibacterium acnes. |
| AID1417288 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing ermB and mefA genes after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID88731 | In vitro antibacterial activity against erythromycin-susceptible Hemophilus influenzae ATCC 43095 strain | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Synthesis and antibacterial activity of acylides (3-O-acyl-erythromycin derivatives): a novel class of macrolide antibiotics. |
| AID1498835 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes 11 N369 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID529897 | Antimicrobial activity against Leptospira interrogans serovar Pyrogenes isolate 5 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID535356 | Antimicrobial activity against Streptococcus pyogenes clinical isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID589114 | Mechanism based inhibition of human cytochrome P450 3A4 | 2005 | Current drug metabolism, Oct, Volume: 6, Issue:5 | Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. |
| AID576335 | Antimicrobial activity against Chlamydia trachomatis serovar E infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID735595 | Antibacterial activity against methicillin-resistant, MLS-resistant (inducible) Staphylococcus aureus PU 32 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID368807 | Cmax in human interstitial-space fluid of skeletal muscle at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID559556 | Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID525099 | Bacteriostatic activity against Mycobacterium abscessus 390R infected in human monocyte-derived macrophage assessed as inhibition of planktonic cell growth at 4 ug/ml treated 24 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID558234 | Antimicrobial activity against Mycobacterium abscessus isolate MC1448 at day 3 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID576350 | Antimicrobial activity against Chlamydia trachomatis Ic Cal-8 serovar D infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID368786 | Tmax in fasting human interstitial-space fluid of subcutaneous adipose tissue at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID576346 | Bactericidal activity against Chlamydia trachomatis serovar H infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID408340 | Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique | 2008 | Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11 | Support vector machines classification of hERG liabilities based on atom types. |
| AID309087 | Antibacterial activity against erythromycin-sensitive Streptococcus pyogenes 3565 | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18 | A novel ketolide class: Synthesis and antibacterial activity of a lead compound. |
| AID558185 | Antimicrobial activity against Mycobacterium abscessus isolate MC1028 at day 7 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID557662 | Antimicrobial activity against Mycobacterium abscessus isolate MC724 at day 9 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID138319 | The compound was evaluated in vivo for the therapeutic efficacy at 3.2 mg/kg in mouse infection model; 0/8 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative. |
| AID368801 | AUC (0 to 24 hrs) in human interstitial-space fluid of skeletal muscle at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID1536960 | Inhibition of fMLP/cytochalasin A-stimulated elastase release in human neutrophils assessed as elastase level at 2.5 uM preincubated for 15 mins followed by fMLP/cytochalasin A stimulation and measured after 15 mins by SAAVNA substrate based spectrophotom | 2019 | Journal of natural products, 02-22, Volume: 82, Issue:2 | Eupatoriopicrin Inhibits Pro-inflammatory Functions of Neutrophils via Suppression of IL-8 and TNF-alpha Production and p38 and ERK 1/2 MAP Kinases. |
| AID555113 | AUC (0 to infinity) in healthy human at 400 mg, po administered as single dose | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers. |
| AID1498158 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes R1 after 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID508423 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2686 harboring mutation in L4 ribosomal protein after 25 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID571455 | Antibacterial activity against Escherichia coli NCTC13353 by Etest method in presence of 4 ug/ml NAB7062 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID368788 | Terminal half life in fasting human plasma at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID554516 | Antimicrobial activity against Mycobacterium abscessus isolate MC879-2 at day 5 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1245708 | Antimicrobial activity against Streptococcus pneumoniae 07P390 expressing constitutive ermB incubated for 20 to 24 hrs by two-fold microbroth dilution method | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID508384 | Antibacterial activity against Streptococcus pyogenes harboring erm(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID369664 | Ratio of MIC for Campylobacter jejuni 001B-22 carrying A2075G mutation in 23S rRNA to MIC for Campylobacter jejuni 001B-22 cmeB::kanamycin-resistant mutant | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni. |
| AID567471 | Antimicrobial activity against gLow-BLNAR Haemophilus influenzae by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae. |
| AID402034 | Antimicrobial activity against Clarithromycin-resistant Helicobacter pylori TS648 after 4 days by twofold plate dilution method | 2005 | Journal of natural products, Jun, Volume: 68, Issue:6 | Anti-Helicobacter pylori compounds from Santalum album. |
| AID571656 | Ratio of the MIC for Klebsiella oxytoca CCUG51683 in the absence of NAB7066 to MIC for Klebsiella oxytoca CCUG51683 in the presence of 4 ug/ml of NAB7066 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1417287 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing ermB gene after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID279561 | Antimicrobial activity against Haemophilus influenzae BLNAS strains | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea. |
| AID545928 | Antimicrobial activity against Enterobacter cloacae ATCC 23355 by Etest method in presence of 2 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID565330 | Antibacterial activity against Mycoplasma genitalium M6284 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID209625 | In vitro minimum inhibitory concentration against Streptococcus pyogenes EES61 using standard agar dilution method | 2000 | Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8 | Synthesis and antibacterial activity of novel 6-O-substituted erythromycin A derivatives. |
| AID444056 | Fraction escaping gut-wall elimination in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID571394 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 0.5 ug/ml NAB739 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID625287 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID270426 | Antibacterial activity against Staphylococcus epidermidis 14990 by broth microdilution method | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and antibacterial activity of C12 des-methyl ketolides. |
| AID725376 | Antibacterial activity against constitutive MLS-resistant Streptococcus pyogenes A2 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID1539181 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing the ermB and mefA incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID528841 | Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID508437 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 3009 harboring mutation in 23S rRNA after 25 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID416127 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6 | Synthesis and antibacterial activity of 4'',11-di-O-arylalkylcarbamoyl azithromycin derivatives. |
| AID1439716 | Bacteriostatic activity against erythromycin-resistant Streptococcus pneumoniae ATCC 49619 after 20 to 24 hrs by two-fold microbroth dilution method | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID372993 | Antimycobacterial activity against Mycobacterium intracellular JATA52-01 infected C57BL/6J mouse assessed as lung bacterial count at 200 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID1539173 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID747247 | Antibacterial activity against Escherichia coli ATCC 25922 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11 | Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives. |
| AID114193 | Effective dose in vivo, in mouse inoculated intraperitoneally with 1.47*10e3 CFU of erythromycin susceptible strain Streptococcus pneumoniae IID553 | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID1867272 | Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as bacterial growth inhibition incubated for 18 hrs by microdilution method | 2022 | Journal of natural products, 05-27, Volume: 85, Issue:5 | Diterpenoids from |
| AID571643 | Antibacterial activity against Enterobacter cloacae by Etest method in presence of 4 ug/ml NAB7068 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID501675 | Antimicrobial activity against Streptococcus pneumoniae 58 spain by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID508473 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 237 harboring mutation in L4 ribosomal protein after 20 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID318660 | Antibacterial activity against Peptostreptococcus asaccharolyticus GAI 5534 by broth microdilution method | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7 | Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens. |
| AID545931 | Antimicrobial activity against Acinetobacter baumannii ATCC 19606 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID567796 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 07A066 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID425995 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 50 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID510855 | Antibacterial activity against erythromycin-resistant Staphylococcus aureus PU-32 expressing erm(A) gene by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activities of 6-O-methylerythromycin A 9-O-(3-aryl-2-propenyl) oxime ketolide, 2,3-enol ether, and alkylide analogues. |
| AID533854 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium peregrinum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID260057 | Inhibitory activity against Helicobacter pylori NCTC-10638 | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3 | Design, synthesis, and anti-Helicobacter pylori activity of erythromycin A (E)-9-oxime ether derivatives. |
| AID543823 | Antimicrobial activity against Borrelia spielmanii isolate PHap after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID569030 | Antimicrobial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains. |
| AID557925 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 at day 7 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID717674 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes 09Q149 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides. |
| AID1549378 | Selectivity ratio of MBC to MIC for MLS-resistant Streptococcus pyogenes 01-968 expressing inducible ermB gene | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID203442 | In vitro inhibitory activity against Staphylococci EryRi (65) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID559360 | Antimicrobial activity against compound-susceptible Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1444602 | Antibacterial activity against macrolides/lincosamides/streptogramines-resistant Streptococcus pneumoniae BAA1402 expressing mef and erm genes by broth microdilution method | 2017 | Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8 | Synthesis of clarithromycin ketolides chemically modified at the unreactive C10-methyl group. |
| AID554654 | Antimicrobial activity against Ureaplasma parvum SV6 isolate HPA23 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID428138 | Antimicrobial activity against telithromycin-resistant Streptococcus pneumoniae isolate P1501016 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation. |
| AID479820 | Antimicrobial activity against erythromycin-susceptible Staphylococcus aureus ATCC 29213 | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives. |
| AID559550 | Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1766089 | Antibacterial activity against vancomycin-susceptible Enterococcus faecalis ATCC29212 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 49 | Design, synthesis and antibacterial evaluation of novel 3-O-substituted 15-membered azalides possessing 1,2,3-triazole side chains. |
| AID604043 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing erm and mef gene by broth microdilution method | 2011 | European journal of medicinal chemistry, Jul, Volume: 46, Issue:7 | Synthesis and antibacterial activity of novel 4″-O-benzimidazolyl clarithromycin derivatives. |
| AID508442 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 1635 harboring erm(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID501293 | Antibacterial activity against Haemophilus influenzae ATCC 49247 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID644442 | Antibacterial activity against penicillin-, constitutive MLS-resistant Streptococcus pneumoniae PU 11 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID775002 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 09-13 by broth microdilution method | 2013 | European journal of medicinal chemistry, Nov, Volume: 69 | Synthesis and antibacterial activity of novel modified 5-O-mycaminose 14-membered ketolides. |
| AID1498151 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes after 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID208126 | In vitro inhibitory activity against Streptococcus pneumoniae (EryRc 030SJ1) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID554530 | Antimicrobial activity against Mycobacterium abscessus isolate MC879-2 at day 9 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID261464 | Antibacterial activity against Streptococcus pneumoniae Erm 6849 | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Synthesis and antibacterial activity of novel C12 vinyl ketolides. |
| AID422942 | Antimicrobial activity against macrolide-susceptible Mycoplasma pneumoniae isolated from pediatric patients with community-acquired pneumonia after 10 to 14 days by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. |
| AID781256 | Antibacterial activity against erythromycin-sensitive Streptococcus pyogenes ATCC 19625 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. |
| AID296272 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 01-1004 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID496384 | Antibacterial activity against nontypeable beta-lactamase-negative ampicillin-resistant Haemophilus influenzae 4437 infected in mouse ddY assessed as decrease in viable bacterial count at 100 mg/kg, po bid for 3 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. |
| AID572282 | Antimicrobial activity against methicillin susceptible Staphylococcus aureus ATCC 49951 infected in po dosed NMRI mouse treated 1 and 5 hrs post infection | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. |
| AID161281 | Inhibition of human Potassium channel HERG expressed in mammalian cells | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16 | Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. |
| AID554548 | Antimicrobial activity against Mycobacterium smegmatis transformed with erm allele Mycobacterium abscessus isolate MC720 preincubated with 2 ug/ml erythromycin for 20 to 24 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID425975 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID1632644 | Displacement of [3H]FMZ from GABA-A receptor in rat brain after 30 mins by autoradiography | 2016 | ACS medicinal chemistry letters, Aug-11, Volume: 7, Issue:8 | Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET. |
| AID368802 | Ratio of AUC (0 to 24 hrs) in human interstitial-space fluid of subcutaneous adipose tissue to free AUC (0 to 24 hrs) in human plasma at 50 mg, po bid | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID725381 | Antibacterial activity against erythromycin-sensitive Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID544522 | Antimicrobial activity against Borrelia afzelii isolate FEM1 after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID508420 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2686 harboring mutation in L4 ribosomal protein after 14 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1487248 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing ermB/mefA gene | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID576351 | Antimicrobial activity against Chlamydia trachomatis Bour serovar E infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID1766093 | Antibacterial activity against penicillin-resistant Staphylococcus aureus by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 49 | Design, synthesis and antibacterial evaluation of novel 3-O-substituted 15-membered azalides possessing 1,2,3-triazole side chains. |
| AID440651 | Antibacterial activity against multidrug-susceptible Haemophilus influenzae 1325 infected in po dosed Mongolian gerbil otitis media model assessed as reduction of bacterial infection administered 18 hrs postinfection TID for 2 days measured on day 4 posti | 2009 | Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23 | Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. |
| AID559365 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID576339 | Antimicrobial activity against Chlamydia trachomatis serovar I infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID28290 | Maximum concentration in the serum of mice following a single oral dose of 10 mg/kg (data represent mean in 3 mice) | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID270434 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae erm 6849 by broth microdilution method | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and antibacterial activity of C12 des-methyl ketolides. |
| AID520873 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU69 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID574702 | Enhancement of biofilm formation Staphylococcus epidermidis SW071 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID557396 | Antimicrobial activity against Helicobacter pylori ATCC 43504 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. |
| AID571432 | Antibacterial activity against Escherichia coli ATCC 25992 by Etest method in presence of 1 ug/ml NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID322986 | Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae with 23S rRNA A2063G mutant isolate 6 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. |
| AID373006 | Antimycobacterial activity against Mycobacterium avium complex N018 infected C57BL/6J mouse assessed as lung bacterial count at 200 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID470191 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes by standard dilution assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin. |
| AID557941 | Antimicrobial activity against Mycobacterium abscessus isolate MC724 at day 14 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID725368 | Antibacterial activity against methicillin-resistant, constitutive MLS-resistant Staphylococcus epidermidis E 2 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID1427911 | Antibacterial activity against erythromycin/penicillin-susceptible Bacillus subtilis ATCC 9372 by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID368768 | Protein binding in human plasma at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID699540 | Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. |
| AID558188 | Antimicrobial activity against Mycobacterium abscessus isolate MC1028 at day 9 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID588219 | FDA HLAED, gamma-glutamyl transferase (GGT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID208478 | The compound was tested in vitro for antibacterial activity against erythromycin susceptible Streptococcus pneumoniae 032UC1 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID576352 | Antimicrobial activity against Chlamydia trachomatis 580 serovar H infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID571660 | Ratio of the MIC for Acinetobacter baumannii ATCC 19606 in the absence of NAB7070 to MIC for Acinetobacter baumannii ATCC 19606 in the presence of 4 ug/ml of NAB7070 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID558232 | Antimicrobial activity against Mycobacterium abscessus isolate MC1448 at day 14 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID285160 | Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. |
| AID508387 | Antibacterial activity against macrolide-resistant Streptococcus pyogenes harboring mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID422664 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 50 passages by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID574694 | Enhancement of biofilm formation Staphylococcus epidermidis SW085 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID1867275 | Antibacterial activity against Bacillus subtilis ATCC 6633 assessed as bacterial growth inhibition incubated for 18 hrs by microdilution method | 2022 | Journal of natural products, 05-27, Volume: 85, Issue:5 | Diterpenoids from |
| AID201405 | In vitro minimum inhibitory concentration for antibacterial activity against erythromycin susceptible strain Staphylococcus aureus Smith | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID679511 | TP_TRANSPORTER: inhibition of theophylline uptake in OAT2-expressing oocytes | 2005 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 33, Issue:5 | Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. |
| AID557893 | Antimicrobial activity against Mycobacterium abscessus isolate MC724 at day 5 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID638882 | Antibacterial activity against Streptococcus pneumoniae 6303 by NCCLS method | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens. |
| AID1444603 | Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method | 2017 | Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8 | Synthesis of clarithromycin ketolides chemically modified at the unreactive C10-methyl group. |
| AID440642 | Antibacterial activity against multidrug-resistant Streptococcus pneumoniae 1175 harboring mefA gene by NCCLS method | 2009 | Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23 | Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. |
| AID557639 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 at day 3 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID557651 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 at day 7 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID548472 | Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID557918 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 at day 5 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID535364 | Antimicrobial activity against Haemophilus influenzae clinical isolates assessed as resistant isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID256055 | Minimum inhibitory concentration against Mycobacterium avium (ATCC 25291) | 2005 | Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22 | Design and studies of novel 5-substituted alkynylpyrimidine nucleosides as potent inhibitors of mycobacteria. |
| AID565331 | Antibacterial activity against Mycoplasma genitalium M6287 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID565325 | Antibacterial activity against Mycoplasma genitalium M6328 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID510558 | Antimicrobial activity against Chlamydia trachomatis after 72 hrs by fluorescence assay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. |
| AID1724706 | Antibacterial activity against Acinetobacter baumannii AB5075 assessed as reduction in microbial growth after 6 days by broth microdilution method | 2020 | ACS medicinal chemistry letters, Sep-10, Volume: 11, Issue:9 | Augmenting the Activity of Macrolide Adjuvants against |
| AID422944 | Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae harboring A2064G transition in domain V of 23S rRNA isolated from pediatric patients with community-acquired pneumonia after 10 to 14 days by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. |
| AID565308 | Antibacterial activity against Mycoplasma genitalium by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID426383 | Antimicrobial activity against erythromycin-resistant Streptococcus pyogenes 07Z016 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID557939 | Antimicrobial activity against Mycobacterium abscessus isolate MC720 at day 14 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID425987 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 33 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID1419575 | Chromatographic hydrophobicity, logD of the compound at pH 7.4 by by fast-gradient RP-HPLC method | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Around the macrolide - Impact of 3D structure of macrocycles on lipophilicity and cellular accumulation. |
| AID519672 | Effect on PAR2 gene expression in normal human epidermal keratinocytes assessed as effect on cell viability at 10 uM after 72 hrs | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes. |
| AID422674 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 21 passages with gemifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID512008 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides. |
| AID571428 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 0.5 ug/ml NAB739 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID730748 | Antibacterial activity against macrolides, lincosamides, streptogramin B and methicillin-resistant Staphylococcus epidermidis 1105-00 assessed as growth inhibition | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6 | Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates. |
| AID1417283 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID528966 | Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient urine assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID558610 | Antimicrobial activity against Streptococcus pneumoniae isolate 1424 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1539175 | Antibacterial activity against penicillin-susceptible Escherichia coli ATCC 25922 incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID624626 | Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells | 2001 | The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2 | Rational use of in vitro P-glycoprotein assays in drug discovery. |
| AID1498830 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 11X315 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID296281 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes 01-804 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID544532 | Antimicrobial activity against Borrelia clinical isolate after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID207715 | In vitro antibacterial activity against constitutively MLS B resistant Staphylococcus aureus SR138 strain | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Synthesis and antibacterial activity of acylides (3-O-acyl-erythromycin derivatives): a novel class of macrolide antibiotics. |
| AID1245712 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus PU20 expressing constitutive ermC incubated for 20 hrs by two-fold microbroth dilution method | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID422943 | Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae harboring A2063G transition in domain V of 23S rRNA isolated from pediatric patients with community-acquired pneumonia after 10 to 14 days by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. |
| AID559372 | Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID425407 | Antibacterial activity against mucosa-associated Escherichia coli isolate HM456 isolated from patient with irritable bowel syndrome or sporadic polyps after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID735597 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes A3 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID444053 | Renal clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID554547 | Antimicrobial activity against Mycobacterium smegmatis transformed with erm allele Mycobacterium abscessus isolate MC719 preincubated with 2 ug/ml erythromycin for 20 to 24 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID87944 | Determined the lowest drug concentration that inhibited macroscopic colonial growth against Helicobacter pylori. | 2000 | Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17 | Anti-Helicobacter pylori agents. 4. 2-(Substituted guanidino)-4-phenylthiazoles and some structurally rigid derivatives. |
| AID533858 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium alvei after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID558631 | Antimicrobial activity against Streptococcus pneumoniae isolate 4755 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID543830 | Antimicrobial activity against Borrelia burgdorferi B31 after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID560551 | Antimicrobial activity against Helicobacter pylori clinical isolate expressing 23S rRNA A2142G mutant by Etest | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia. |
| AID1550823 | Antimicrobial activity against constitutively erythromycin resistant Staphylococcus aureus PU20 expressing c-ermC incubated in CAMHB medium for 20 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID201267 | In vitro minimum inhibitory concentration for antibacterial activity against Staphylococcus aureus B1 (inducibly MLSb-resistant strain encoded by the erm(C) gene) | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID625291 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID574692 | Enhancement of biofilm formation Staphylococcus epidermidis SW061 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID479818 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae PU11 encoded by erm and mef gene | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives. |
| AID1193494 | Thermodynamic equilibrium solubility, log S of the compound in simulated gastric fluid at pH 1.2 at RT after 4 hrs by 96 well plate method | 2015 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7 | Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery. |
| AID543826 | Antimicrobial activity against Borrelia spielmanii isolate PMai after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID704312 | Cellular uptake in human BSMC assessed as compound retention at 3 to 20 uM incubated for 3 hrs followed by drug washout measured after 3 hrs by LC-MS/MS analysis relative to initial drug accumulation | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID372559 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-susceptible Haemophilus influenzae type b without amino acid substitutions in ftsI gene and bla gene assessed as resistance rate by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID501300 | Antibacterial activity against inducible resistance to macrolide, licosamide and streptogramin Streptococcus pyogenes 2 Finland by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID644443 | Antibacterial activity against efflux,penicillin-susceptible Streptococcus pneumoniae PU 09 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID558603 | Antimicrobial activity against Streptococcus pneumoniae isolate 37 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID557669 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 at day 3 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID567790 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae 07H252 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID206482 | The compound was tested in vitro for antibacterial activity against constitutively erythromycin resistant Staphylococcus aureus 011CB20 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID565312 | Antibacterial activity against Mycoplasma genitalium R32 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID678742 | TP_TRANSPORTER: inhibition of Vinblastine efflux (Vinblastine: 0.002 uM, Clarithromycin: 100 uM) in P388/S and P388/ADR cells | 2000 | Clinical and experimental pharmacology & physiology, Aug, Volume: 27, Issue:8 | Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. |
| AID681581 | TP_TRANSPORTER: inhibition of Fluo-3-AM efflux in NIH-3T3-G185 cells | 2001 | Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2 | Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. |
| AID558626 | Antimicrobial activity against Streptococcus pneumoniae isolate 3481 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID425984 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID1498832 | Antibacterial activity against erythromycin-sensitive Streptococcus pneumoniae 11G364 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID1536967 | Inhibition of LPS-induced delay of apoptosis in human neutrophils assessed as late apoptotic cells at 2.5 uM preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb | 2019 | Journal of natural products, 02-22, Volume: 82, Issue:2 | Eupatoriopicrin Inhibits Pro-inflammatory Functions of Neutrophils via Suppression of IL-8 and TNF-alpha Production and p38 and ERK 1/2 MAP Kinases. |
| AID334258 | Antibacterial activity against Helicobacter pylori 31A after 48 hrs by serial doubling dilution method | 2002 | Journal of natural products, Apr, Volume: 65, Issue:4 | Derrisin, a new rotenoid from Derris malaccensis plain and anti-Helicobacter pylori activity of its related constituents. |
| AID285329 | Antimicrobial activity against Streptococcus pyogenes ATCC 19615 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci. |
| AID544524 | Antimicrobial activity against Borrelia afzelii isolate G1039 after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID261468 | Antibacterial activity against Haemophilus influenzae 2762 | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Synthesis and antibacterial activity of novel C12 vinyl ketolides. |
| AID425972 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID1459150 | Metabolic stability in rat liver microsomes assessed as parent compound remaining at 1 uM after 60 mins in presence of NADP by LC-MS/MS analysis | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID704319 | Cellular uptake in human NHBE at 3 to 20 uM after 3 hrs by by LC-MS/MS analysis relative to azithromycin | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID501677 | Antimicrobial activity against Haemophilus influenzae ATCC 49247 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID1647120 | Bactericidal activity against penicillin-susceptible Bacillus subtilis ATCC 9372 | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID559362 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1419576 | Drug accumulation in human NCI-H292 cells at 3 to 10 uM incubated for 3 hrs by LC-MS analysis relative to azithromycin | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Around the macrolide - Impact of 3D structure of macrocycles on lipophilicity and cellular accumulation. |
| AID558216 | Antimicrobial activity against Mycobacterium abscessus isolate MC1082 at day 7 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1550837 | Bactericidal activity against inducibly erythromycin-resistant and methicillin resistant Staphylococcus aureus PU32 expressing i-ermA assessed as reduction in colony formation incubated in CAMHB medium for 20 hrs followed by 24 hrs subculturing in the med | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID496391 | Antiinflammatory activity against nontypeable beta-lactamase-negative ampicillin-resistant Haemophilus influenzae 4437 infected in mouse ddY assessed as decrease in MIP-2 level in bronchoalveolar lavage fluid at 40 mg/kg, po bid for 3 days relative to con | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. |
| AID221230 | The compound has been evaluated for the in vivo efficacy that protect 50%of mice from lethal infection by Haemophilus influenzae AmpR 351RD7 after oral administration | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID475099 | Antibacterial activity against Streptococcus pneumoniae 11 expressing mefA efflux pump after 20 hrs by agar dilution method | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4'' positions: Improved antibacterial activities. |
| AID704320 | Cellular uptake in human PMNC at 3 to 20 uM after 3 hrs by by LC-MS/MS analysis relative to azithromycin | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID557921 | Antimicrobial activity against Mycobacterium abscessus isolate MC720 at day 5 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1754234 | Antibacterial activity against penicillin-susceptible Bacillus subtilis ATCC9372 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. |
| AID203439 | In vitro inhibitory activity against Staphylococci EryRc (13) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID496392 | Antiinflammatory activity against nontypeable beta-lactamase-negative ampicillin-resistant Haemophilus influenzae 4437 infected in mouse ddY assessed as decrease in MIP-2 level in bronchoalveolar lavage fluid at 100 mg/kg, po bid for 3 days relative to co | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. |
| AID205383 | Antibacterial activity was evaluated against Serratia marcescens (3013) | 1998 | Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14 | Discovery of a novel benzyloxyisoquinoline derivative with potent anti-Helicobacter pylori activity. |
| AID569034 | Antimicrobial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 by broth microdilution method | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains. |
| AID112358 | In Vivo evaluation for its effective dose against Staphylococcus aureus (011GO25 EryRi. | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID28289 | Maximum concentration in the lung of mice following a single oral dose of 10 mg/kg (data represent mean in 3 mice) | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID559358 | Antimicrobial activity against compound-resistant Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID368773 | AUC (0 to 8 hrs) in fasting human interstitial-space fluid of skeletal muscle at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID416848 | Antimycobacterial activity against Mycobacterium ulcerans isolate CU001 infected in BALB/c mouse left hind foot-pad assessed as bacterial load at 100 mg/kg, po administered for 5 days per week measured after 8 weeks | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. |
| AID588208 | Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset | 2010 | Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5 | Predicting phospholipidosis using machine learning. |
| AID681579 | TP_TRANSPORTER: inhibition of Tetramethylrosamine efflux in NIH-3T3-G185 cells | 2001 | Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2 | Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. |
| AID321869 | Tmax in human at 500 mg, po administered as single dose | 2008 | Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1 | A new insight into solid-state conformation of macrolide antibiotics. |
| AID637553 | Antibacterial activity against Streptococcus pneumoniae 994 expressing mef gene by NCCLS method | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens. |
| AID368796 | AUC (0 to 8 hrs) in human interstitial-space fluid of subcutaneous adipose tissue at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID475102 | Antibacterial activity against Streptococcus pyogenes 3 expressing mefA efflux pump after 20 hrs by agar dilution method | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4'' positions: Improved antibacterial activities. |
| AID283557 | Antimicrobial activity against Streptococcus pneumoniae R6 with L4 69GTG71 to TPS mutation | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. |
| AID547664 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus 26001 by broth microdilution method | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | Synthesis and antibacterial activity of C-12 pyrazolinyl spiro ketolides. |
| AID567795 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 07R066 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID520871 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU57 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID540212 | Mean residence time in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID279263 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3676 with GyrA E85G, GyrB S478I and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID28298 | Maximum plasma concentration (Cmax) after oral dosing by gavage needle at 30 mg/kg in C57BL/6NTac female mice | 2002 | Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19 | Novel structures derived from 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 2. |
| AID208468 | The compound has been evaluated for the antibacterial activity against Streptococcus pneumoniae EryRc 030SJ1 strains | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID322984 | Antimicrobial activity against macrolide-susceptible Mycoplasma pneumoniae M129 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. |
| AID558182 | Antimicrobial activity against Mycobacterium abscessus isolate MC1028 at day 5 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1502707 | Antimycobacterial activity against Mycobacterium avium 104 mc'2 3 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID1536972 | Inhibition of LPS-stimulated TNFalpha production in human neutrophils at 2.5 uM after 24 hrs by ELISA | 2019 | Journal of natural products, 02-22, Volume: 82, Issue:2 | Eupatoriopicrin Inhibits Pro-inflammatory Functions of Neutrophils via Suppression of IL-8 and TNF-alpha Production and p38 and ERK 1/2 MAP Kinases. |
| AID557640 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 at day 3 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1498153 | Antibacterial activity against erythromycin-susceptible Bacillus subtilis ATCC 9372 after 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID558583 | Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID571389 | Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of 0.25 ug/ml NAB739 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID369652 | Antibacterial activity against Campylobacter jejuni 001B-22 cmeB::kanamycin-resistant mutant by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni. |
| AID644441 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID644446 | Antibacterial activity against constitutive MLS-resistant Streptococcus pyogenes A 2 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID524824 | Antibacterial activity against erythromycin resistant Campylobacter sp. by agar plate dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. |
| AID296268 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 01-429 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID534341 | Antimicrobial activity against Burkholderia pseudomallei Bp227 harboring deleted (bpeAB-oprA)::FRT gene after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID557904 | Antimicrobial activity against Mycobacterium abscessus isolate MC723 at day 9 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID548253 | Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID321871 | Elimination half life in human at 500 mg, po administered as single dose | 2008 | Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1 | A new insight into solid-state conformation of macrolide antibiotics. |
| AID575170 | Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 200 uM by spectrofluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates. |
| AID543821 | Antimicrobial activity against Borrelia spielmanii isolate PSig2 after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID557658 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 at day 9 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID318665 | Antibacterial activity against Propionibacterium granulosum GAI 7414 by broth microdilution method | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7 | Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens. |
| AID512006 | Antibacterial activity against erythromycin-resistant, methicillin-susceptible Staphylococcus aureus A265 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides. |
| AID559563 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID747239 | Antibacterial activity against drug-resistant Pseudomonas aeruginosa by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11 | Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives. |
| AID207487 | Antibacterial activity was evaluated against Staphylococcus aureus (209P JC-1) | 1998 | Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14 | Discovery of a novel benzyloxyisoquinoline derivative with potent anti-Helicobacter pylori activity. |
| AID425405 | Antibacterial activity against mucosa-associated Escherichia coli isolate HM428 isolated from patient with irritable bowel syndrome or sporadic polyps after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID545930 | Antimicrobial activity against in Enterobacter cloacae ATCC 23355 in presence of NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID1439742 | Ratio of MBC to MIC against erythromycin-susceptible Moraxella catarrhalis 13L332 | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID321876 | Protein binding in human plasma | 2008 | Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1 | A new insight into solid-state conformation of macrolide antibiotics. |
| AID1222793 | Dissociation constant, pKa of the compound | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Which metabolites circulate? |
| AID735602 | Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae PU09 harboring mef gene by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID406621 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea. |
| AID426378 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae 05Z006 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID717685 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 09N120 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides. |
| AID285328 | Antimicrobial activity against vancomycin-resistant Enterococcus faecalis ATCC 51299 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci. |
| AID422679 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 25 passages by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID340005 | Antimicrobial activity against Micrococcus luteus | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Antibacterial activity of labdane diterpenoids from Stemodia foliosa. |
| AID565305 | Antitubercular activity against Mycobacterium avium infected in C57BL/6J mouse assessed as reduction of CFU counts in spleen at 200 mg/kg, po administered one month post-infection five times weekly for 1 month (Rvb = 7.4 +/- 1.7 log10CFU) | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | ATP synthase inhibition of Mycobacterium avium is not bactericidal. |
| AID557898 | Antimicrobial activity against Mycobacterium abscessus isolate MC723 at day 7 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID704308 | Cellular uptake in human NCI-H292 cells assessed as compound retention at 3 to 20 uM incubated for 3 hrs followed by drug washout measured after 3 hrs by LC-MS/MS analysis relative to initial drug accumulation | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID1439735 | Bactericidal activity against methicillin-resistant Staphylococcus aureus PU32 expressing inducible ermA incubated for 20 hrs followed by sub-culturing for 24 hrs in absence of compound | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID1778126 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus assessed as microbial growth inhibition by CLSI-protocol based broth microdilution assay | 2021 | Journal of natural products, 04-23, Volume: 84, Issue:4 | Opportunities and Limitations for Assigning Relative Configurations of Antibacterial Bislactones using GIAO NMR Shift Calculations. |
| AID368771 | Free AUC (0 to 8 hrs) in fasting human plasma at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID781258 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 12-4 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| AID279560 | Antimicrobial activity against Haemophilus influenzae strains that are normal flora | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea. |
| AID558620 | Antimicrobial activity against Streptococcus pneumoniae isolate 3282 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID243151 | Inhibitory concentration against potassium channel HERG | 2005 | Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11 | A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. |
| AID775000 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 09-3 by broth microdilution method | 2013 | European journal of medicinal chemistry, Nov, Volume: 69 | Synthesis and antibacterial activity of novel modified 5-O-mycaminose 14-membered ketolides. |
| AID283555 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. |
| AID318664 | Antibacterial activity against Propionibacterium acnes GAI 5568 by broth microdilution method | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7 | Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens. |
| AID977600 | pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1764399 | Unbound plasma concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis | 2021 | Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5 | Development of an |
| AID558212 | Antimicrobial activity against Mycobacterium abscessus isolate MC1028 at day 5 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID624629 | Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay | 2001 | The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2 | Rational use of in vitro P-glycoprotein assays in drug discovery. |
| AID1677795 | Bacteriostatic activity against methicillin-resistant Staphylococcus aureus ATCC43300 assessed as ratio of MBC to MIC | 2020 | Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21 | Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus. |
| AID528844 | Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID483705 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 expressing mef gene by broth microdilution method | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Synthesis and antibacterial activity of novel 4''-O-arylalkylcarbamoyl and 4''-O-((arylalkylamino)-4-oxo-butyl)carbamoyl clarithromycin derivatives. |
| AID675199 | Antibacterial activity against Streptococcus pneumoniae 210 expressing mefA efflux pump by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17 | Synthesis and antibacterial activity of 6-O-(heteroaryl-isoxazolyl)propynyl 2-fluoro ketolides. |
| AID717679 | Antibacterial activity against erythromycin-sensitive Streptococcus pneumoniae 09H065 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides. |
| AID374398 | Antimicrobial activity against Escherichia coli ATCC 25922 after 16 to 18 hrs by agar dilution method | 2009 | European journal of medicinal chemistry, Apr, Volume: 44, Issue:4 | Synthesis and antibacterial evaluation of novel 4-alkyl substituted phenyl beta-aldehyde ketone derivatives. |
| AID1245710 | Antimicrobial activity against Streptococcus pyogenes 01-968 expressing inducible ermA incubated for 20 to 24 hrs by two-fold microbroth dilution method | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID554545 | Antimicrobial activity against Mycobacterium smegmatis transformed with erm allele Mycobacterium abscessus isolate MC879 preincubated with 2 ug/ml erythromycin for 20 to 24 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID508448 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 2132 after 50 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID309088 | Antibacterial activity against Streptococcus pyogenes MLSi | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18 | A novel ketolide class: Synthesis and antibacterial activity of a lead compound. |
| AID560505 | Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate b2k4781 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID554521 | Antimicrobial activity against Mycobacterium abscessus isolate MC1448 at day 9 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID131225 | Mouse protection tests for effective dose against Staphylococcus aureus 10649 ((erythromycin susceptible strain)) infected mice | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. |
| AID425617 | Cmax in healthy human at 500 mg administered orally | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID558222 | Antimicrobial activity against Mycobacterium abscessus isolate MC1082 at day 14 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID545921 | Antimicrobial activity against Escherichia coli IH3080 by Etest method in presence of 4 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID637555 | Antibacterial activity against Haemophilus influenzae 38 by NCCLS method | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens. |
| AID576353 | Antimicrobial activity against Chlamydia trachomatis UW-36 serovar J infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID1498152 | Antibacterial activity against penicillin-susceptible Pseudomonas aeruginosa ATCC 27853 incubated for 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID554538 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 on day 10 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1539178 | Antibacterial activity against penicillin-resistant Staphylococcus aureus ATCC 31007 incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID1691400 | Antibacterial activity against MLSB/methicillin-resistant Staphylococcus aureus 15B196 assessed as reduction in microbial growth | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID1550840 | Bactericidal activity against erythromycin-susceptible Moraxella catarrhalis 13L332 assessed as reduction in colony formation incubated in CAMHB medium for 20 hrs followed by 24 hrs subculturing in the medium without test compound | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID1473741 | Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID368790 | Terminal half life in fasting human interstitial-space fluid of subcutaneous adipose tissue at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID444054 | Oral bioavailability in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID545939 | Ratio of MIC for Acinetobacter baumannii ATCC 19606 to MIC for Acinetobacter baumannii ATCC 19606 in presence of 4 ug/ml of NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID557646 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 at day 5 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID381660 | Antibacterial activity against ermA-constitutive resistant Staphylococcus aureus after 20 hrs by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13-hydroxy analogues. |
| AID735590 | Antibacterial activity against methicillin-resistant, MLS-resistant (constitutive) Staphylococcus epidermidis E2 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID557905 | Antimicrobial activity against Mycobacterium abscessus isolate MC724 at day 9 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID502779 | Antibacterial activity against Helicobacter pylori Hp 26695 | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Identification of 3',4',5'-trimethoxychalcone analogues as potent inhibitors of Helicobacter pylori-induced inflammation in human gastric epithelial cells. |
| AID571391 | Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of 0.125 ug/ml NAB739 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID87937 | Antibacterial activity was evaluated against Helicobacter pylori (FP1757). | 1998 | Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14 | Discovery of a novel benzyloxyisoquinoline derivative with potent anti-Helicobacter pylori activity. |
| AID372994 | Antimycobacterial activity against Mycobacterium intracellular JATA52-01 infected C57BL/6J mouse assessed as liver bacterial count at 200 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dos | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID558608 | Antimicrobial activity against Streptococcus pneumoniae isolate 1394 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID85808 | The compound was tested in vitro for antibacterial activity against Haemophilus influenza 351HT3 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID535641 | Antimicrobial activity against Group B streptococcus serotype V C1 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility. |
| AID322988 | Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae with 23S rRNA A2064G mutant isolate 4 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. |
| AID425601 | Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate HM605 in mouse J774A1 cells isolated from colonic mucosal biopsies of patient with Crohn's disease assessed as intracellular killing of bacteria at 10% compound Cmax a | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID1439721 | Ratio of MBC to MIC for penicillin-susceptible Streptococcus pneumoniae PU09 | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID534419 | Antibacterial activity against Mycobacterium bovis BCG-Connaught | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. |
| AID279562 | Antimicrobial activity against Haemophilus influenzae BLPAR strains | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea. |
| AID508458 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2094 harboring erm(A) gene after 43 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID508476 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 237 harboring mutation in L4 ribosomal protein after 50 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID574688 | Enhancement of biofilm formation Staphylococcus epidermidis SW029 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID548474 | Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm mutant gene after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID558609 | Antimicrobial activity against Streptococcus pneumoniae isolate 1397 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1536973 | Inhibition of LPS-stimulated TNFalpha production in human neutrophils at 50 uM after 24 hrs by ELISA | 2019 | Journal of natural products, 02-22, Volume: 82, Issue:2 | Eupatoriopicrin Inhibits Pro-inflammatory Functions of Neutrophils via Suppression of IL-8 and TNF-alpha Production and p38 and ERK 1/2 MAP Kinases. |
| AID368784 | Tmax in fasting human plasma at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID262170 | Antibacterial activity against macrolide-sensitive Escherichia coli HN818 | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6 | Synthesis and biological investigation of new 4''-malonyl tethered derivatives of erythromycin and clarithromycin. |
| AID114195 | Effective dose in vivo, in mouse inoculated intraperitoneally with 5.80*10e7 CFU of erythromycin susceptible strain Staphylococcus aureus Smith | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID422690 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3413 after 30 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID114693 | Effective dose when administered orally in mice infected with Staphylococcus aureus NCTC-10649M. | 1998 | Journal of medicinal chemistry, May-07, Volume: 41, Issue:10 | Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues. |
| AID1691391 | Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae PU09 harboring mef gene assessed as reduction in microbial growth | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID208467 | The compound has been evaluated for the antibacterial activity against Streptococcus pneumoniae EryRc 030PW23c strains | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID1487241 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID1439741 | Bactericidal activity against erythromycin-susceptible Moraxella catarrhalis 13L332 incubated for 20 hrs followed by sub-culturing for 24 hrs in absence of compound | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID1868044 | Antibacterial activity against Staphylococcus aureus PU32 by microbroth dilution method | 2022 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 68 | Design and synthesis of novel macrolones bridged with linkers from 11,12-positions of macrolides. |
| AID512011 | Antibacterial activity against ampicillin-resistant Haemophilus influenzae 3300 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides. |
| AID565810 | Antimicrobial activity against Neisseria meningitidis by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection. |
| AID1498155 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 harboring ermB gene after 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID557928 | Antimicrobial activity against Mycobacterium abscessus isolate MC723 at day 7 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID161933 | In vitro inhibitory activity against Pneumococci PenR (65) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID1439740 | Bacteriostatic activity against erythromycin-susceptible Moraxella catarrhalis 13L332 after 20 hrs by two-fold microbroth dilution method | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID571392 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of NAB739 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID121253 | Survival rate of mouse inoculated intraperitoneally with 5.05*10e7 CFU of erythromycin-susceptible strain Streptococcus pneumoniae IID553 after treatment with 3 mg of compound | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID296279 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 03-458 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID559770 | Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate 4sy32 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID558617 | Antimicrobial activity against Streptococcus pneumoniae isolate 3260 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID679343 | TP_TRANSPORTER: transepithelial transport of digoxin (apical to basal) (Digoxin: 20-30uM) in MDR1-expressing LLC-GA5-COL150 cell | 2004 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 32, Issue:8 | Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein. |
| AID508429 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 7127 harboring S20N mutation in L4 ribosomal protein and A105V mutation in L22 ribosomal protein after 15 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID368990 | Drug uptake in human Skeletal muscles assessed as in vivo drug recovery by microdialysis | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID547665 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 6538p by broth microdilution method | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | Synthesis and antibacterial activity of C-12 pyrazolinyl spiro ketolides. |
| AID425398 | Antibacterial activity against Escherichia coli isolate HM154 isolated from colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID557901 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 at day 9 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID571639 | Antibacterial activity against Klebsiella pneumoniae by Etest method in presence of 4 ug/ml NAB7064 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID556349 | Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae ATCC 15531 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. |
| AID1488449 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 harboring harboring mef and erm gene after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID206465 | The compound has been evaluated for the antibacterial activity against Staphylococcus aureus EryS 011UC4 strains | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID406622 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae isolates assessed as percent susceptible isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea. |
| AID704316 | Cellular uptake in human MDM at 3 to 20 uM after 3 hrs by by LC-MS/MS analysis relative to azithromycin | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID1245720 | Bactericidal activity against azithromycin-susceptible and ampicillin-resistant Haemophilus influenzae 11P037 incubated for 20 to 24 hrs followed by sub-culturing for 24 hrs in absence of compound | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID373001 | Antimycobacterial activity against Mycobacterium avium complex N016 infected C57BL/6J mouse assessed as spleen bacterial count at 200 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID1221961 | Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979 | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2 | Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. |
| AID422652 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID571644 | Antibacterial activity against Citrobacter freundii ATCC 8090 by Etest method in presence of 4 ug/ml NAB7069 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID88104 | The compound was evaluated in vitro for the minimum inhibitory concentration against Helicobacter pylori (9005). | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative. |
| AID576336 | Antimicrobial activity against Chlamydia trachomatis serovar F infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID781259 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 12-5 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. |
| AID604044 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jul, Volume: 46, Issue:7 | Synthesis and antibacterial activity of novel 4″-O-benzimidazolyl clarithromycin derivatives. |
| AID724506 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID321870 | AUC in human at 500 mg, po administered as single dose | 2008 | Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1 | A new insight into solid-state conformation of macrolide antibiotics. |
| AID557895 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 at day 7 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID558601 | Antimicrobial activity against Streptococcus pneumoniae isolate 24 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID261454 | Antibacterial activity against Staphylococcus aureus 29213 | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Synthesis and antibacterial activity of novel C12 vinyl ketolides. |
| AID679105 | TP_TRANSPORTER: transepithelial transport in MDR1-expressing MDCK cells | 2004 | The Journal of pharmacology and experimental therapeutics, Oct, Volume: 311, Issue:1 | Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption. |
| AID87952 | Minimum inhibitory concentration against Helicobacter pylori (Helicobacter pylori) ARHp strain 80 | 2002 | Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19 | Novel structures derived from 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 2. |
| AID559363 | Antimicrobial activity against compound-susceptible Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1245731 | Ratio of MBC to MIC against erythromycin-susceptible Moraxella catarrhalis 11B366 | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID1550827 | Ratio of MBC to MIC for erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID279564 | Antimicrobial activity against Haemophilus influenzae BLPACR strains | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea. |
| AID437309 | Antibacterial activity against erythromycin-resistant Staphylococcus pneumoniae AB11 encoded by erm and mef gene | 2009 | European journal of medicinal chemistry, Oct, Volume: 44, Issue:10 | Synthesis and antibacterial activity of novel 15-membered macrolide derivatives: 4''-carbamate, 11,12-cyclic carbonate-4''-carbamate and 11,4''-di-O-arylcarbamoyl analogs of azithromycin. |
| AID425404 | Antibacterial activity against Escherichia coli isolate HM95 isolated from ileal mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID560521 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate xa07029 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID535340 | Antimicrobial activity against Streptococcus pneumoniae clinical isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID1193497 | Thermodynamic equilibrium solubility, log S of the compound PBS at pH 7.4 at RT after 24 hrs by shake-flask method | 2015 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7 | Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery. |
| AID368803 | Ratio of AUC (0 to 24 hrs) in human interstitial-space fluid of skeletal muscle to free AUC (0 to 24 hrs) in human plasma at 50 mg, po bid | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID704310 | Cellular uptake in human MDM assessed as compound retention at 3 to 20 uM incubated for 3 hrs followed by drug washout measured after 3 hrs by LC-MS/MS analysis relative to initial drug accumulation | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID1498848 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID558201 | Antimicrobial activity against Mycobacterium abscessus isolate MC1082 at day 7 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID283556 | Antimicrobial activity against Streptococcus pneumoniae R6 with L4 mutation | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. |
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| AID276338 | Antimicrobial activity against Helicobacter pylori DSMZ 4867 | 2006 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21 | In vitro inhibitory activity of boropinic acid against Helicobacter pylori. |
| AID535635 | Antimicrobial activity against Group B streptococcus serotype VI R5 harboring F395L, V405A, R433H, H438Y, and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility. |
| AID203448 | In vitro inhibitory activity against Streptococci EryRi (98) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID479977 | Antimicrobial activity against erythromycin-susceptible Staphylococcus aureus PU19 encoded by erm(A) gene | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives. |
| AID572270 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. |
| AID577494 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus SH1000 by CLSI broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. |
| AID547661 | Antibacterial activity against erythromycin-resistant Staphylococcus aureus AD-08 by broth microdilution method | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | Synthesis and antibacterial activity of C-12 pyrazolinyl spiro ketolides. |
| AID557917 | Antimicrobial activity against Mycobacterium abscessus isolate MC724 at day 3 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID381663 | Antibacterial activity against susceptible Streptococcus pneumoniae after 20 hrs by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13-hydroxy analogues. |
| AID571449 | Antibacterial activity against Enterobacter cloacae ATCC 23355 ATCC 13883 by Etest method in presence of 1 ug/ml NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID368805 | Free Cmax in human plasma at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID372981 | Antimycobacterial activity against Mycobacterium avium complex N018 after 14 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID508436 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 3009 harboring mutation in 23S rRNA after 20 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID571209 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 0.125 ug/ml NAB739 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID426381 | Antimicrobial activity against erythromycin-resistant Streptococcus pyogenes 07Z011 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID372999 | Antimycobacterial activity against Mycobacterium avium complex N016 infected C57BL/6J mouse assessed as lung bacterial count at 200 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID524915 | Antimicrobial activity against Mycobacterium abscessus 390S assessed as inhibition of resuspended biofilm formation in replete medium | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID221222 | The compound has been evaluated for the in vivo efficacy that protect 50% of mice from lethal infection by Staphylococcus aureus EryS 011HT17 strains after oral administration | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID571442 | Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID520423 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU18 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID1498840 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis ATCC 12228 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID1764400 | Unbound brain concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis | 2021 | Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5 | Development of an |
| AID318667 | Antibacterial activity against Mycoplasma pneumoniae Mac by broth microdilution method | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7 | Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens. |
| AID554535 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 on day 4 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID372555 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in highly mutated locus Ser-385 of ftsI gene assessed as susceptibility rate by broth microdilution metho | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID528970 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient wound assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID270430 | Antibacterial activity against Streptococcus pyogenes 8668 by broth microdilution method | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and antibacterial activity of C12 des-methyl ketolides. |
| AID725370 | Antibacterial activity against methicillin-resistant, constitutive MLS-resistant, coagulase-deficient Staphylococcus haemolyticus PU 19 expressing ermA gene by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID529901 | Antimicrobial activity against Leptospira interrogans serovar Icterohaemorrhagiae isolate 10 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID554650 | Antimicrobial activity against Ureaplasma urealyticum isolate HPA12 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID270429 | Antibacterial activity against Enterococcus faecalis bc11148-2 by broth microdilution method | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and antibacterial activity of C12 des-methyl ketolides. |
| AID557919 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 at day 5 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID495551 | Antimicrobial activity against Haemophilus influenzae isolate by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance. |
| AID558217 | Antimicrobial activity against Mycobacterium abscessus isolate MAB30 at day 9 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID1617787 | Antibacterial activity against Helicobacter pylori CIP 103995 incubated for 72 hrs under microaerophilic conditions by broth microdilution method | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structural Characterization and Anti-infective Activity of 9,10-Seco-29-norcycloartane Glycosides Isolated from the Flowers of the Peruvian Medicinal Plant |
| AID381671 | Antibacterial activity against standard Haemophilus influenzae after 20 hrs by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13-hydroxy analogues. |
| AID1647122 | Ratio of MBC for penicillin-susceptible Bacillus subtilis ATCC 9372 to MIC for penicillin-susceptible Bacillus subtilis ATCC 9372 | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID475098 | Antibacterial activity against Streptococcus pneumoniae 10 expressing mefA efflux pump after 20 hrs by agar dilution method | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4'' positions: Improved antibacterial activities. |
| AID553824 | Antibacterial activity against 1x10'9 CFU Escherichia coli ATCC 25922 infected Wistar rat assessed as rat mortality at 60 mg/kg, iv administered immediately after bacterial challenge measured 72 hrs postinfection (Rvb mortality = 100%) | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis. |
| AID557920 | Antimicrobial activity against Mycobacterium abscessus isolate MC719 at day 5 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1439727 | Ratio of MBC to MIC for Streptococcus pyogenes 12-207 expressing mef | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID571431 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of NAB739 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1724707 | Antibacterial activity against Acinetobacter baumannii AB5075 assessed as reduction in microbial growth after 9 days by broth microdilution method | 2020 | ACS medicinal chemistry letters, Sep-10, Volume: 11, Issue:9 | Augmenting the Activity of Macrolide Adjuvants against |
| AID368794 | AUC (0 to 8 hrs) in human plasma at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID1764402 | Unbound brain-to-plasma concentration ratio in P-gp knock out Sprague-Dawley rat | 2021 | Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5 | Development of an |
| AID557935 | Antimicrobial activity against Mycobacterium abscessus isolate MC724 at day 9 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID574933 | Antimicrobial activity against Staphylococcus epidermidis SW027 expressing icaA gene assessed as enhancement of biofilm formation at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID279205 | Antibacterial activity against Streptococcus pneumoniae 3665 by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID747240 | Antibacterial activity against drug-resistant Salmonella typhi by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11 | Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives. |
| AID68048 | In vitro antibacterial activity against erythromycin-susceptible Enterococcus faecalis ATCC 29212 strain | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Synthesis and antibacterial activity of acylides (3-O-acyl-erythromycin derivatives): a novel class of macrolide antibiotics. |
| AID508407 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 1076 harboring erm(B) and mef(A) gene after 18 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID560519 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate zj07028 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID565328 | Antibacterial activity against Mycoplasma genitalium M6282 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID1498831 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 11C176 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID571395 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 0.25 ug/ml NAB739 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1210301 | Apparent intrinsic clearance in Sprague-Dawley rat hepatocytes assessed per 10'6 cells at 0.1 to 10 uM up to 90 mins by media-loss method | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Utility of drug depletion-time profiles in isolated hepatocytes for accessing hepatic uptake clearance: identifying rate-limiting steps and role of passive processes. |
| AID1459151 | Metabolic stability in human liver microsomes assessed as parent compound remaining at 1 uM after 60 mins in presence of NADP by LC-MS/MS analysis | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID402027 | Antimicrobial activity against Helicobacter pylori ATCC 43504 after 4 days by twofold plate dilution method | 2005 | Journal of natural products, Jun, Volume: 68, Issue:6 | Anti-Helicobacter pylori compounds from Santalum album. |
| AID203425 | In vitro inhibitory activity against Staphylococci EryRi (65) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID256056 | Minimum inhibitory concentration against Mycobacterium bovis; ND = Not determined | 2005 | Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22 | Design and studies of novel 5-substituted alkynylpyrimidine nucleosides as potent inhibitors of mycobacteria. |
| AID422683 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 37 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID545919 | Antimicrobial activity against Escherichia coli IH3080 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID558228 | Antimicrobial activity against Mycobacterium abscessus isolate MC1448 at day 7 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID557660 | Antimicrobial activity against Mycobacterium abscessus isolate MC720 at day 9 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID132624 | The compound was tested in vivo for antibacterial activity against AmpR beta(+) Haemophilus influenza 351RD7 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID565231 | Antimicrobial activity against Mycobacterium chelonae 9917 harboring pZS01 carrying mspA gene by resazurine microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs. |
| AID422665 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID496387 | Antiinflammatory activity against nontypeable beta-lactamase-negative ampicillin-resistant Haemophilus influenzae 4437 infected in mouse ddY assessed as decrease in neutrophil count in bronchoalveolar lavage fluid at 40 mg/kg, po bid for 3 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. |
| AID554524 | Antimicrobial activity against Mycobacterium abscessus isolate MC879-2 at day 3 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1532165 | Apparent permeability in human Caco2 cells | 2018 | Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24 | Lipophilic Permeability Efficiency Reconciles the Opposing Roles of Lipophilicity in Membrane Permeability and Aqueous Solubility. |
| AID558231 | Antimicrobial activity against Mycobacterium abscessus isolate MC879-2 at day 14 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID296267 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 01-433 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID207220 | In vitro minimum inhibitory concentration against Staphylococcus aureus A5177. | 2000 | Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8 | Synthesis and antibacterial activity of novel 6-O-substituted erythromycin A derivatives. |
| AID735591 | Antibacterial activity against methicillin-susceptible, MLS-resistant (inducible) Staphylococcus epidermidis E1 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID132625 | The compound was tested in vivo for antibacterial activity against AmpR beta(-) Haemophilus influenza 351TO19 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID717675 | Antibacterial activity against erythromycin-sensitive Streptococcus pyogenes 09U070 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides. |
| AID240820 | Inhibitory concentration against IKr potassium channel | 2004 | Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18 | The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents. |
| AID1417280 | Antibacterial activity against penicillin-susceptible Escherichia coli ATCC 25922 after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID132633 | The compound was tested in vivo for antibacterial activity against erythromycin susceptible Streptococcus pyogenes 02A1UC1 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID1329753 | Antibacterial activity against Propionibacterium acnes ATCC 6919 after 24 hrs by broth microdilution method | |||
| AID1459119 | Antibacterial activity against erythromycin susceptible Streptococcus pneumoniae infected in mouse assessed as increase in mouse survival administered orally 1 hr post infection | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID747248 | Antibacterial activity against Staphylococcus aureus ATCC 25923 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11 | Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives. |
| AID558582 | Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID560502 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate gz06051 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID322985 | Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae with 23S rRNA A2063G mutant isolate 1 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. |
| AID508376 | Antibacterial activity against quinolone-resistant Streptococcus pneumoniae after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID704321 | Cellular uptake in human NHBE assessed as compound retention at 3 to 20 uM incubated for 3 hrs followed by drug washout measured after 3 hrs by LC-MS/MS analysis relative to initial drug accumulation | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID625292 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID369648 | Antibacterial activity against Campylobacter jejuni UA709 carrying A2074C mutation in 23S rRNA by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni. |
| AID279206 | Antibacterial activity against Streptococcus pneumoniae 3243 by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID565318 | Antibacterial activity against Mycoplasma genitalium M2300 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID704318 | Cellular uptake in human BSMC at 3 to 20 uM after 3 hrs by by LC-MS/MS analysis relative to azithromycin | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID624622 | Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells | 2001 | The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2 | Rational use of in vitro P-glycoprotein assays in drug discovery. |
| AID1473738 | Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| AID571211 | Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of NAB739 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID1439717 | Bactericidal activity against erythromycin-resistant Streptococcus pneumoniae ATCC 49619 incubated for 20 to 24 hrs followed by sub-culturing for 24 hrs in absence of compound | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID558210 | Antimicrobial activity against Mycobacterium abscessus isolate MC1082 at day 3 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID572269 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 49951 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. |
| AID495323 | Antimicrobial activity against Beta-lactamase-negative, ampicillin-resistant Haemophilus influenzae by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance. |
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| AID1439745 | Ratio of MBC to MIC against azithromycin-susceptible Haemophilus influenzae ATCC 49247 | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID717678 | Antibacterial activity against erythromycin-sensitive Streptococcus pneumoniae 09H071 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides. |
| AID545911 | Antimicrobial activity against Escherichia coli ATCC 25922 in presence of 16 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID1550821 | Antimicrobial activity against erythromycin-susceptible Staphylococcus aureus ATCC 29213 incubated in CAMHB medium for 20 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID1487245 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes isolate R2 | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID532023 | Antimicrobial activity against Mycobacterium ulcerans ATCC 19423 harboring pTY60K containing pMH94 carrying the luxAB gene under the hsp60 promoter after 7 days determined according to CFU count by bioluminescence method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. |
| AID1439732 | Bactericidal activity against methicillin-resistant Staphylococcus aureus PU20 expressing constitutive ermC incubated for 20 hrs followed by sub-culturing for 24 hrs in absence of compound | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID565230 | Antimicrobial activity against Mycobacterium chelonae 9917 by resazurine microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs. |
| AID1498833 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 11 J011 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID603986 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing erm gene by broth microdilution method | 2011 | European journal of medicinal chemistry, Jul, Volume: 46, Issue:7 | Synthesis and antibacterial activity of novel 4″-O-benzimidazolyl clarithromycin derivatives. |
| AID1221962 | Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979 | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2 | Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. |
| AID132627 | The compound was tested in vivo for antibacterial activity against constitutively erythromycin resistant Streptococcus pneumoniae 030Cr29 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID558224 | Antimicrobial activity against Mycobacterium abscessus isolate MC1448 at day 3 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID510854 | Antibacterial activity against erythromycin-resistant Staphylococcus aureus PU-19 expressing erm(A) gene by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activities of 6-O-methylerythromycin A 9-O-(3-aryl-2-propenyl) oxime ketolide, 2,3-enol ether, and alkylide analogues. |
| AID577491 | fCmax in Staphylococcus aureus in in vitro pharmacokinetic/pharmacodynamic model at 250 mg every 12 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. |
| AID725378 | Antibacterial activity against penicillin-susceptible, constitutive MLS-resistant Streptococcus pneumoniae PU 27 expressing erm gene by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID565296 | Antitubercular activity against Mycobacterium avium infected in C57BL/6J mouse assessed as reduction of CFU counts in spleen at 25 mg/kg, po administered one month post-infection five times weekly for 3 months (Rvb = 7.9 +/- 0.7 log10CFU) | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | ATP synthase inhibition of Mycobacterium avium is not bactericidal. |
| AID535359 | Antimicrobial activity against Streptococcus pyogenes clinical isolates assessed as resistant isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID558615 | Antimicrobial activity against Streptococcus pneumoniae isolate 2874 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID544525 | Antimicrobial activity against Borrelia garinii isolate PSth after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID425966 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 after 50 passages by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID426380 | Antimicrobial activity against erythromycin-susceptible Streptococcus pyogenes 07U086 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID1724681 | Antibacterial activity against Acinetobacter baumannii AB5075 assessed as reduction in microbial growth incubated for 16 hrs by broth microdilution method | 2020 | ACS medicinal chemistry letters, Sep-10, Volume: 11, Issue:9 | Augmenting the Activity of Macrolide Adjuvants against |
| AID574709 | Antimicrobial activity against Staphylococcus epidermidis SW036 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID678714 | Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID576349 | Bactericidal activity against Chlamydia trachomatis serovar K infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID1502709 | Antimycobacterial activity against Mycobacterium avium ATCC 25291 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID678750 | TP_TRANSPORTER: inhibition of Cyclosporin A efflux (CsA: 0.005 uM, Clarithromycin: 100 uM) in P388/S and P388/ADR cells | 2000 | Clinical and experimental pharmacology & physiology, Aug, Volume: 27, Issue:8 | Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. |
| AID1549381 | Antibacterial activity against MLS-resistant Staphylococcus aureus PU 20 expressing constitutive ermC gene assessed as reduction in microbial growth by CLSI based two-fold broth dilution method | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID554655 | Antimicrobial activity against Ureaplasma parvum SV14 isolate HPA32 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID640333 | Antimycobacterial activity against Mycobacterium bovis BCG assessed as growth inhibition at 0.5 to 100 ug/ml by microplate alamar blue assay | 2012 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2 | Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs. |
| AID1550839 | Antimicrobial activity against erythromycin-susceptible Moraxella catarrhalis 13L332 incubated in CAMHB medium for 20 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID572271 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus NB01021 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. |
| AID422645 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID557652 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 at day 7 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID571210 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID86128 | In vitro inhibitory activity against Haemophilus influenzae (351HT3) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID553828 | Toxicity in Wistar rat assessed as effect on physiological parameters at 1 mg/kg, iv | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis. |
| AID554652 | Antimicrobial activity against Ureaplasma parvum SV1 isolate HPA18 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID1427909 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes clinical isolate by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID582682 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 assessed as decrease of CFU after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID261467 | Antibacterial activity against Haemophilus influenzae 49247 | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Synthesis and antibacterial activity of novel C12 vinyl ketolides. |
| AID529894 | Antimicrobial activity against Leptospira interrogans serovar Grippotyphosa isolate 2 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID548256 | Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm mutant gene after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID571450 | Antibacterial activity against Enterobacter cloacae ATCC 23355 ATCC 13883 by Etest method in presence of 2 ug/ml NAB7062 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID554656 | Antimicrobial activity against Ureaplasma parvum isolate UHWJM after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID558604 | Antimicrobial activity against Streptococcus pneumoniae isolate 1055 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID560499 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate 5zjsau3 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID1597725 | Half life in human at 300 mg bid | 2019 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16 | Sleep modulating agents. |
| AID781326 | pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X | 2014 | Pharmaceutical research, Apr, Volume: 31, Issue:4 | Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds. |
| AID85784 | In vitro inhibitory activity against Haemophilus AmpR (37) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID422649 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID704315 | Cellular uptake in human T lymphocytes at 3 to 20 uM after 3 hrs by by LC-MS/MS analysis relative to azithromycin | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID535647 | Antimicrobial activity against Group B Streptococcus serotype V 2603 V/R harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility. |
| AID545934 | Antimicrobial activity against in Acinetobacter baumannii ATCC 19606 in presence of NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID373007 | Antimycobacterial activity against Mycobacterium avium complex N018 infected C57BL/6J mouse assessed as spleen bacterial count at 200 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID571429 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 1 ug/ml NAB739 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1414195 | Bactericidal activity against Staphylococcus aureus ATCC 25923 incubated for 24 hrs followed by plating onto tryptic soy agar plates and further incubated for 24 hrs by broth microdilution based CLSI method | 2018 | European journal of medicinal chemistry, Nov-05, Volume: 159 | Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators. |
| AID558189 | Antimicrobial activity against Mycobacterium abscessus isolate MC1082 at day 9 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID559370 | Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID534343 | Antimicrobial activity against Burkholderia pseudomallei Bp173 harboring mini-Tn7T after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID296283 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes 03-680 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID557913 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 at day 3 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID558230 | Antimicrobial activity against Mycobacterium abscessus isolate MC1448 at day 9 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1550826 | Bactericidal activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 assessed as reduction in colony formation incubated in CAMHB medium for 20 to 24 hrs followed by 24 hrs subculturing in the medium without test compound | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID557931 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 at day 9 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID558195 | Antimicrobial activity against Mycobacterium abscessus isolate MC1082 at day 3 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID681130 | TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells | 2001 | The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2 | Rational use of in vitro P-glycoprotein assays in drug discovery. |
| AID508411 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 1635 harboring erm(A) gene after 32 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID425406 | Antibacterial activity against mucosa-associated Escherichia coli isolate HM454 isolated from patient with irritable bowel syndrome or sporadic polyps after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID1498841 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 13-3 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID540213 | Half life in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID1439736 | Ratio of MBC to MIC against methicillin-resistant Staphylococcus aureus PU32 expressing inducible ermA | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID1193493 | Thermodynamic equilibrium solubility, log S of the compound in PBS at pH 7.4 at RT after 4 hrs by 96 well plate method | 2015 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7 | Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery. |
| AID368983 | Terminal half life in human plasma at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID635190 | Antibacterial activity against efflux-mediated macrolide-resistant Streptococcus pyogenes 3 Finland by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID557676 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 at day 5 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID508414 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 1635 harboring erm(A) gene after 49 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID470194 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 by standard dilution assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin. |
| AID557648 | Antimicrobial activity against Mycobacterium abscessus isolate MC720 at day 5 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1439729 | Bactericidal activity against azithromycin susceptible/ampicillin-resistant Haemophilus influenzae 11P307 incubated for 20 to 24 hrs followed by sub-culturing for 24 hrs in absence of compound | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID207219 | In vitro minimum inhibitory concentration against Staphylococcus aureus 6538P using standard agar dilution method | 2000 | Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8 | Synthesis and antibacterial activity of novel 6-O-substituted erythromycin A derivatives. |
| AID533853 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium chelonae after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID502378 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes 8902 expressing ermB by the broth microdilution method | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | A new series of macrolide derivatives with 4''-O-saccharide substituents. |
| AID508453 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2368 harboring erm(B) gene after 8 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID510851 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae PU-09 expressing mef gene by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activities of 6-O-methylerythromycin A 9-O-(3-aryl-2-propenyl) oxime ketolide, 2,3-enol ether, and alkylide analogues. |
| AID1459141 | Protein binding in mouse plasma at 1 ug/ml by LC-MS/MS analysis | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID1193499 | Thermodynamic equilibrium solubility, log S of the compound simulated intestinal fluid at pH 6.8 at RT after 24 hrs by shake-flask method | 2015 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7 | Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery. |
| AID1754232 | Antibacterial activity against penicillin-susceptible Pseudomonas aeruginosa ATCC 27853 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. |
| AID544527 | Antimicrobial activity against Borrelia garinii isolate G1 after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID508366 | Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1550816 | Antimicrobial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 incubated in CAMHB medium for 20 to 24 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID296282 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes 01-740 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID577495 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315 by CLSI broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. |
| AID1193500 | Thermodynamic equilibrium solubility, log S of the compound | 2015 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7 | Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery. |
| AID207077 | In vitro inhibitory activity against Staphylococcus aureus (EryRi 011GO25i) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID279267 | Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3243 with 23S rRNA A2059T mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID557938 | Antimicrobial activity against Mycobacterium abscessus isolate MC719 at day 14 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1498847 | Antibacterial activity against extended spectrum beta-lactamases non-producing Escherichia coli ATCC 25922 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID574704 | Enhancement of biofilm formation Staphylococcus epidermidis SW088 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID658057 | Antibacterial activity against Streptococcus pyogenes ATCC 700294 after 24 hrs at 37 degC by CLSI protocol based microdilution method | 2012 | Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10 | Novel desosamine-modified 14- and 15-membered macrolides without antibacterial activity. |
| AID1488458 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID127511 | Antibacterial activity was evaluated against M.(B).catarrhalis (6014) | 1998 | Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14 | Discovery of a novel benzyloxyisoquinoline derivative with potent anti-Helicobacter pylori activity. |
| AID535342 | Antimicrobial activity against Streptococcus pneumoniae clinical isolates assessed as susceptible isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID559562 | Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID559564 | Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID283550 | Antimicrobial activity against Streptococcus pneumoniae BSF-11524 isolate with erm(B) and L4 mutation | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. |
| AID202098 | In vitro minimum inhibitory concentration for antibacterial activity against Streptococcus pneumoniae 211 (MLSb-resistant strain encoded by the erm(B) gene) | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID112359 | In Vivo evaluation for its effective dose against Staphylococcus aureus (011UC4). | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID557650 | Antimicrobial activity against Mycobacterium abscessus isolate MC724 at day 5 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID558621 | Antimicrobial activity against Streptococcus pneumoniae isolate 3346 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID571652 | Ratio of the MIC for Escherichia coli NCTC13353 in the absence of NAB7062 to MIC for Escherichia coli NCTC13353 in the presence of 4 ug/ml of NAB7062 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID508445 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 3009 harboring mutation in 23S rRNA after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID635180 | Antibacterial activity against erythromycin-sensitive Streptococcus pneumoniae SP030 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID1417282 | Antibacterial activity against penicillin-susceptible Bacillus subtilis ATCC 9372 after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID567473 | Antimicrobial activity against gBLPAR-TEM1 Haemophilus influenzae by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae. |
| AID25994 | Area under the curve was determined for the compound from the lung of mice following a single oral dose of 10 mg/kg (data represent mean in 3 mice) | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID1550844 | Ratio of MBC to MIC for azithromycin-susceptible Haemophilus influenzae ATCC 49247 | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID545938 | Ratio of MIC for Enterobacter cloacae ATCC 23355 to MIC for Enterobacter cloacae ATCC 23355 in presence of 4 ug/ml of NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID574701 | Enhancement of biofilm formation Staphylococcus epidermidis SW070 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID1764401 | Ratio of drug concentration in brain to plasma of P-gp knock out Sprague-Dawley rat | 2021 | Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5 | Development of an |
| AID508468 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2011 harboring mef(A) gene after 50 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID559367 | Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID368778 | Ratio of AUC (0 to 24 hrs) in fasting human interstitial-space fluid of subcutaneous adipose tissue to free AUC (0 to 24 hrs) in fasting human plasma at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID678717 | Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID318657 | Antibacterial activity against Staphylococcus saccharolyticus GAI 5520 by broth microdilution method | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7 | Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens. |
| AID510849 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activities of 6-O-methylerythromycin A 9-O-(3-aryl-2-propenyl) oxime ketolide, 2,3-enol ether, and alkylide analogues. |
| AID520872 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU67 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID444058 | Volume of distribution at steady state in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID730383 | Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as growth inhibition | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6 | Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates. |
| AID208616 | The compound was tested in vitro for antibacterial activity against 40 strains of constitutively erythromycin resistant Streptococcus pneumoniae Value is 40/40 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID528846 | Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient urine assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID558616 | Antimicrobial activity against Streptococcus pneumoniae isolate 2880 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1867247 | Antibacterial activity against multidrug resistant Helicobacter pylori HP159 assessed as bacterial growth inhibition incubated for 3 days by broth microdilution method | |||
| AID535362 | Antimicrobial activity against Haemophilus influenzae clinical isolates assessed as susceptible isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID501669 | Antimicrobial activity against macrolide, licosamide streptogramin-resistant Staphylococcus aureus 90265/97 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID422651 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 26 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID560501 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate gz06040 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID571766 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-N616 mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID372982 | Antimycobacterial activity against Mycobacterium avium complex N084 after 14 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID658056 | Antibacterial activity against Streptococcus pneumoniae ATCC 149619 after 24 hrs at 37 degC by CLSI protocol based microdilution method | 2012 | Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10 | Novel desosamine-modified 14- and 15-membered macrolides without antibacterial activity. |
| AID1278501 | Antibacterial activity against Escherichia coli at 15 ug/ml by disc diffusion method | 2016 | Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5 | Metal-based biologically active azoles and β-lactams derived from sulfa drugs. |
| AID560509 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b4k6307 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID1488456 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID554556 | Antimicrobial activity against Mycobacterium smegmatis transformed with erm allele Mycobacterium abscessus isolate MC1082 preincubated with 2 ug/ml erythromycin for 20 to 24 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID557647 | Antimicrobial activity against Mycobacterium abscessus isolate MC719 at day 5 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID557927 | Antimicrobial activity against Mycobacterium abscessus isolate MC720 at day 7 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1691394 | Antibacterial activity against MLSB-resistant Streptococcus pneumoniae 07P390 harboring ermB gene assessed as reduction in microbial growth | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID582610 | Drug uptake in human THP1 cells after 24 hrs in presence of verapamil | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID1439731 | Bacteriostatic activity against methicillin-resistant Staphylococcus aureus PU20 expressing constitutive ermC after 20 hrs by two-fold microbroth dilution method | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID501678 | Antimicrobial activity against macrolide-resistant Streptococcus pyogenes Finland 2 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID437308 | Antibacterial activity against erythromycin-resistant Staphylococcus pneumoniae A22072 encoded by mef gene | 2009 | European journal of medicinal chemistry, Oct, Volume: 44, Issue:10 | Synthesis and antibacterial activity of novel 15-membered macrolide derivatives: 4''-carbamate, 11,12-cyclic carbonate-4''-carbamate and 11,4''-di-O-arylcarbamoyl analogs of azithromycin. |
| AID681580 | TP_TRANSPORTER: inhibition of JC-1 efflux in NIH-3T3-G185 cells | 2001 | Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2 | Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. |
| AID368980 | Tmax in human plasma unbound fraction at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID296276 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID296274 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 01-1059 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID207559 | In vitro antibacterial activity against inducibly MLS B resistant Staphylococcus aureus B1 strain | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Synthesis and antibacterial activity of acylides (3-O-acyl-erythromycin derivatives): a novel class of macrolide antibiotics. |
| AID422672 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 19 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID545920 | Antimicrobial activity against Escherichia coli IH3080 by Etest method in presence of 2 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID132630 | The compound was tested in vivo for antibacterial activity against constitutively erythromycin resistant Streptococcus pneumoniae 030SJ6 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID261458 | Antibacterial activity against Enterococcus faecalis 29212 | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Synthesis and antibacterial activity of novel C12 vinyl ketolides. |
| AID372547 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-susceptible Haemophilus influenzae type b without amino acid substitutions in ftsI gene and bla gene by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID545937 | Ratio of MIC for Klebsiella pneumoniae ATCC 13883 to MIC for Klebsiella pneumoniae ATCC 13883 in presence of 4 ug/ml of NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID402028 | Antimicrobial activity against Helicobacter pylori SS1 after 4 days by twofold plate dilution method | 2005 | Journal of natural products, Jun, Volume: 68, Issue:6 | Anti-Helicobacter pylori compounds from Santalum album. |
| AID1550830 | Antimicrobial activity against inducibly erythromycin resistant Streptococcus pyogenes 01-968 expressing i-ermA incubated in CAMHB medium for 20 to 24 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID543827 | Antimicrobial activity against Borrelia spielmanii A14S after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID508409 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 1076 harboring erm(B) and mef(A) gene after 14 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID582681 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 assessed as decrease of CFU after 24 hrs relative to initial inoculum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID735600 | Antibacterial activity against MLS-resistant (constitutive), penicillin-susceptible Streptococcus pneumoniae PU27 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID368979 | Tmax in human plasma at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID535643 | Antimicrobial activity against Group B streptococcus serotype III N3 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility. |
| AID533855 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium fortuitum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID781263 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus 12-32 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. |
| AID203428 | In vitro inhibitory activity against Streptococci EryR (27) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID529893 | Antimicrobial activity against Leptospira interrogans serovar Bataviae isolate 1 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID1539180 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing the ermB incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID1502713 | Antimycobacterial activity against Mycobacterium avium isolate MAV4 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID279243 | Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3665 after 26 passages by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID528835 | Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID1632643 | Negative allosteric modulation of GABA-A receptor (unknown origin) at 300 uM by whole cell patch clamp assay | 2016 | ACS medicinal chemistry letters, Aug-11, Volume: 7, Issue:8 | Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET. |
| AID208604 | The compound was tested in vitro for antibacterial activity against inducibly erythromycin resistant Streptococcus pneumoniae 030J5i | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID209879 | Cell free inhibiting activity against Streptococcus pneumoniae 1813 (methylated ribosomes for transcription/translation assay) | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. |
| AID425596 | Antibacterial activity against extracellular Escherichia coli isolate HM605 isolated from colonic mucosal biopsies of patient with Crohn's disease at 0.01 to 10 ug/ml after 3 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID535634 | Antimicrobial activity against Group B streptococcus serotype VI R6 harboring F395L, V405A, R433H, H438Y, A374V and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility. |
| AID525097 | Antimicrobial activity against Mycobacterium abscessus 390S infected in human monocyte-derived macrophage assessed as reduction in viable bacteria count at 10 times MIC by trypan blue exclusion assay | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID567793 | Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis 07C134 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID270432 | Antibacterial activity against Streptococcus pneumoniae 297-749 by broth microdilution method | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and antibacterial activity of C12 des-methyl ketolides. |
| AID781253 | Antibacterial activity against erythromycin-sensitive Streptococcus pneumoniae 12-4 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. |
| AID1632642 | Negative allosteric modulation of GABA-A receptor (unknown origin) at 3 uM by whole cell patch clamp assay | 2016 | ACS medicinal chemistry letters, Aug-11, Volume: 7, Issue:8 | Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET. |
| AID571456 | Antibacterial activity against Klebsiella pneumoniae CCUG45421 by Etest method in presence of 4 ug/ml NAB7063 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID558180 | Antimicrobial activity against Mycobacterium abscessus isolate MC1082 at day 3 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID334262 | Antibacterial activity against Escherichia coli ATCC 10536 at 625 ug/mL after 24 hrs by conventional well agar method | 2002 | Journal of natural products, Apr, Volume: 65, Issue:4 | Derrisin, a new rotenoid from Derris malaccensis plain and anti-Helicobacter pylori activity of its related constituents. |
| AID571655 | Ratio of the MIC for Klebsiella oxytoca ATCC 13182 in the absence of NAB7065 to MIC for Klebsiella oxytoca ATCC 13182 in the presence of 4 ug/ml of NAB7065 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID87935 | Antibacterial activity was evaluated against Helicobacter pylori (8007). | 1998 | Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14 | Discovery of a novel benzyloxyisoquinoline derivative with potent anti-Helicobacter pylori activity. |
| AID426376 | Antimicrobial activity against erythromycin-susceptible Streptococcus pneumoniae 07H252 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID1647105 | Antibacterial activity against penicillin-susceptible Escherichia coli ATCC 25922 by standard broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID558206 | Antimicrobial activity against Mycobacterium abscessus isolate MC1028 at day 14 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID565317 | Antibacterial activity against Mycoplasma genitalium M2282 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID604042 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 expressing mef gene by broth microdilution method | 2011 | European journal of medicinal chemistry, Jul, Volume: 46, Issue:7 | Synthesis and antibacterial activity of novel 4″-O-benzimidazolyl clarithromycin derivatives. |
| AID334259 | Antibacterial activity against Bacillus subtilis ATCC 6633 at 625 ug/mL after 24 hrs by conventional well agar method | 2002 | Journal of natural products, Apr, Volume: 65, Issue:4 | Derrisin, a new rotenoid from Derris malaccensis plain and anti-Helicobacter pylori activity of its related constituents. |
| AID558209 | Antimicrobial activity against Mycobacterium abscessus isolate MC1028 at day 3 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID279258 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID422644 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 44 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID209919 | The compound has been evaluated for the antibacterial activity against Streptococcus pyogenes EryS 02A1UC1. | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID508371 | Antibacterial activity against Streptococcus pneumoniae harboring erm(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID381661 | Antibacterial activity against ermB-inducible resistant Staphylococcus aureus after 20 hrs by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13-hydroxy analogues. |
| AID508462 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2094 harboring erm(A) gene after 6 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1549367 | Selectivity ratio of MBC to MIC for erythromycin-susceptible Streptococcus pneumoniae ATCC49619 | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID545908 | Antimicrobial activity against Escherichia coli ATCC 25922 in presence of 2 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID402030 | Antimicrobial activity against Helicobacter pylori Sa-2 isolate after 4 days by twofold plate dilution method | 2005 | Journal of natural products, Jun, Volume: 68, Issue:6 | Anti-Helicobacter pylori compounds from Santalum album. |
| AID571440 | Ratio of the MIC for Escherichia coli IH3080 in the absence of NAB7061 to MIC for Escherichia coli IH3080 in the presence of 4 ug/ml of NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1539182 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes 2 clinical isolate incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID1498844 | Antibacterial activity against clarithromycin-sensitive Moraxella catarrhalis 12-1 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID543824 | Antimicrobial activity against Borrelia spielmanii isolate PJes after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID747246 | Antibacterial activity against Escherichia coli ATCC 35218 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11 | Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives. |
| AID1444605 | Antibacterial activity against inducibly macrolides/lincosamides/streptogramines-resistant Staphylococcus aureus BAA977 expressing erm gene by broth microdilution method | 2017 | Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8 | Synthesis of clarithromycin ketolides chemically modified at the unreactive C10-methyl group. |
| AID296280 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes 01-469 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID560522 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate gz07030 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID588220 | Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset | 2008 | Toxicology mechanisms and methods, , Volume: 18, Issue:2-3 | Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. |
| AID529899 | Antimicrobial activity against Leptospira weilii isolate 8 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID717689 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides. |
| AID624628 | Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM | 2001 | The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2 | Rational use of in vitro P-glycoprotein assays in drug discovery. |
| AID567474 | Antimicrobial activity against gBLPACR-1 Haemophilus influenzae by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae. |
| AID717682 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 09R476 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides. |
| AID369650 | Antibacterial activity against Campylobacter jejuni 001B-40 carrying A2075G mutation in 23S rRNA by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni. |
| AID558184 | Antimicrobial activity against Mycobacterium abscessus isolate MAB30 at day 7 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID554539 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 on day 14 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID557897 | Antimicrobial activity against Mycobacterium abscessus isolate MC720 at day 7 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID558606 | Antimicrobial activity against Streptococcus pneumoniae isolate 1147 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID425986 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 41 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID560520 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate sh07043 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID554527 | Antimicrobial activity against Mycobacterium abscessus isolate MC1448 at day 5 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID132632 | The compound was tested in vivo for antibacterial activity against erythromycin susceptible Streptococcus pneumoniae 032UC1 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID1245713 | Antimicrobial activity against azithromycin-susceptible and ampicillin-resistant Haemophilus influenzae 11P037 incubated for 20 to 24 hrs by two-fold microbroth dilution method | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID565320 | Antibacterial activity against Mycoplasma genitalium M2341 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID206486 | The compound was tested in vitro for antibacterial activity against inducibly erythromycin resistant Staphylococcus aureus 011GO25i | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID208469 | The compound has been evaluated for the antibacterial activity against Streptococcus pneumoniae EryS 032UC1 strains | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID557933 | Antimicrobial activity against Mycobacterium abscessus isolate MC720 at day 9 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID340004 | Antimicrobial activity against Bacillus anthracis | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Antibacterial activity of labdane diterpenoids from Stemodia foliosa. |
| AID638881 | Antibacterial activity against Streptococcus pneumoniae by NCCLS method | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens. |
| AID1550841 | Ratio of MBC to MIC for erythromycin-susceptible Moraxella catarrhalis 13L332 | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID1488455 | Antibacterial activity against penicillin-susceptible Pseudomonas aeruginosa ATCC 27853 after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID1549370 | Bactericidal activity against penicillin-susceptible Streptococcus pneumoniae PU 09 expressing mef gene pretreated followed by subculture in absence of compound measured after 24 hrs | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID545933 | Antimicrobial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 4 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID545927 | Antimicrobial activity against Enterobacter cloacae ATCC 23355 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID425583 | Antibacterial activity against Escherichia coli isolate HM605 isolated from colonic mucosal biopsies of patient with Crohn's disease | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID571454 | Antibacterial activity against Escherichia coli by Etest method in presence of 4 ug/ml NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID279264 | Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3676 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID114698 | Effective dose when administered subcutaneously in mice infected with Streptococcus pneumoniae ATCC 6303 | 1998 | Journal of medicinal chemistry, May-07, Volume: 41, Issue:10 | Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues. |
| AID508434 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 7127 harboring S20N mutation in L4 ribosomal protein and A105V mutation in L22 ribosomal protein after 43 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID567791 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID508477 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 237 harboring mutation in L4 ribosomal protein after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID270424 | Antibacterial activity against Staphylococcus aureus 29213 by broth microdilution method | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and antibacterial activity of C12 des-methyl ketolides. |
| AID207373 | In vivo antibacterial activity in mice infected with Staphylococcus aureus NCTC-10649M. | 1998 | Journal of medicinal chemistry, May-07, Volume: 41, Issue:10 | Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues. |
| AID475091 | Antibacterial activity against Staphylococcus aureus 209P JC1 after 20 hrs by agar dilution method | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4'' positions: Improved antibacterial activities. |
| AID279269 | Antibacterial activity against levofloxacin resistance selected Streptococcus pneumoniae 19 with GyrA S81Y and ParC D83Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID479819 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae PU13 encoded by erm and mef gene | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives. |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID554553 | Antimicrobial activity against Mycobacterium smegmatis transformed with erm allele Mycobacterium abscessus isolate MC1082 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID197859 | Minimum against Staphylococcus aureus 10649 (erythromycin susceptible strain) | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. |
| AID496394 | Antiinflammatory activity against nontypeable beta-lactamase-negative ampicillin-resistant Haemophilus influenzae infected in mouse ddY assessed as inflammatory changes in lung at 100 mg/kg, po bid for 3 days relative to control | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. |
| AID554520 | Antimicrobial activity against Mycobacterium abscessus isolate MC879-2 at day 9 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID558197 | Antimicrobial activity against Mycobacterium abscessus isolate MC1028 at day 5 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID437307 | Antibacterial activity against erythromycin-resistant Staphylococcus pneumoniae B1 encoded by erm gene | 2009 | European journal of medicinal chemistry, Oct, Volume: 44, Issue:10 | Synthesis and antibacterial activity of novel 15-membered macrolide derivatives: 4''-carbamate, 11,12-cyclic carbonate-4''-carbamate and 11,4''-di-O-arylcarbamoyl analogs of azithromycin. |
| AID502781 | Antibacterial activity against multidrug-resistant Helicobacter pylori v1354 | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Identification of 3',4',5'-trimethoxychalcone analogues as potent inhibitors of Helicobacter pylori-induced inflammation in human gastric epithelial cells. |
| AID529902 | Antimicrobial activity against Leptospira interrogans serovar Pomona isolate 12 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID368804 | Cmax in human plasma at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID544528 | Antimicrobial activity against Staphylococcus aureus ATCC 29213 after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID558191 | Antimicrobial activity against Mycobacterium abscessus isolate MC1028 at day 14 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID508374 | Antibacterial activity against Streptococcus pneumoniae harboring mutation in 23S rRNA after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID558219 | Antimicrobial activity against Mycobacterium abscessus isolate MC1082 at day 9 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID582675 | Antibacterial activity against Listeria monocytogenes EGD at pH 5.5 to 7.4 after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID535646 | Antimicrobial activity against Group B Streptococcus serotype III NEM 316 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility. |
| AID576348 | Bactericidal activity against Chlamydia trachomatis serovar J infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID1550834 | Bactericidal activity against constitutively erythromycin resistant and methicillin-resistant Staphylococcus aureus PU20 expressing c-ermC assessed as reduction in colony formation incubated in CAMHB medium for 20 hrs followed by 24 hrs subculturing in th | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID1867276 | Antibacterial activity against Shigella flexneris ATCC 12022 assessed as bacterial growth inhibition incubated for 18 hrs by microdilution method | 2022 | Journal of natural products, 05-27, Volume: 85, Issue:5 | Diterpenoids from |
| AID781262 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 12-31 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. |
| AID625282 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1549366 | Antibacterial activity against azithromycin-susceptible Haemophilus influenzae ATCC 49247 assessed as reduction in microbial growth by CLSI based two-fold broth dilution method | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID270437 | Antibacterial activity against Haemophilus influenzae 49247 by broth microdilution method | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and antibacterial activity of C12 des-methyl ketolides. |
| AID545923 | Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID559557 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID475092 | Antibacterial activity against Streptococcus pneumoniae DP1 type 1 after 20 hrs by agar dilution method | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4'' positions: Improved antibacterial activities. |
| AID557940 | Antimicrobial activity against Mycobacterium abscessus isolate MC723 at day 14 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID208466 | The compound has been evaluated for the antibacterial activity against Streptococcus pneumoniae Ery Ri 030SJ 5i strains | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID279268 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 19 with GyrA S81F mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID635191 | Antibacterial activity against Haemophilus influenzae ATCC 49247 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID781250 | Antibacterial activity against erythromycin-sensitive Streptococcus pneumoniae 12-14 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. |
| AID161940 | In vitro inhibitory activity against Pneumococci PenR (65) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID781255 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes 11-2 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. |
| AID1867278 | Antibacterial activity against Escherichia coli ATCC 25922 assessed as bacterial growth inhibition incubated for 18 hrs by microdilution method | 2022 | Journal of natural products, 05-27, Volume: 85, Issue:5 | Diterpenoids from |
| AID1677796 | Bacteriostatic activity against Staphylococcus aureus ATCC25923 assessed as ratio of MBC to MIC | 2020 | Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21 | Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus. |
| AID554549 | Antimicrobial activity against Mycobacterium smegmatis transformed with erm allele Mycobacterium abscessus isolate MC879-2 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID528840 | Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID87961 | Minimum inhibitory concentration against Helicobacter pylori under acidic conditions at pH 5.0 | 2001 | Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25 | 3-(Arylacetylamino)-N-methylbenzamides: a novel class of selective anti-Helicobacter pylori agents. |
| AID1868039 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 by microbroth dilution method | 2022 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 68 | Design and synthesis of novel macrolones bridged with linkers from 11,12-positions of macrolides. |
| AID508438 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 3009 harboring mutation in 23S rRNA after 25 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID535776 | Antimicrobial activity against Mycobacterium ulcerans ATCC 19423 harboring pTY60K containing pMH94 carrying the luxAB gene under the hsp60 promoter after 7 days determined according to RLU count by real-time luminescence method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. |
| AID1754229 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. |
| AID425602 | Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate LF82 in mouse J774A1 cells isolated from chronic ileal lesions of patient with Crohn's disease assessed as intracellular killing of bacteria at 10% compound Cmax after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID576343 | Bactericidal activity against Chlamydia trachomatis serovar E infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID574690 | Enhancement of biofilm formation Staphylococcus epidermidis SW045 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID1632647 | In vivo displacement of [11C]FMZ from rhesus monkey GABA-A receptor at 7 mg/kg, iv after 50 to 90 mins by PET analysis | 2016 | ACS medicinal chemistry letters, Aug-11, Volume: 7, Issue:8 | Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET. |
| AID508451 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 2132 after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID558619 | Antimicrobial activity against Streptococcus pneumoniae isolate 3275 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1417284 | Antibacterial activity against penicillin-resistant Staphylococcus aureus ATCC 31007 after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID309085 | Antibacterial activity against Streptococcus pneumoniae 4636 MLSc | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18 | A novel ketolide class: Synthesis and antibacterial activity of a lead compound. |
| AID557910 | Antimicrobial activity against Mycobacterium abscessus isolate MC723 at day 14 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID572487 | Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae ATCC 700677 infected in po dosed BALB/c mouse administered twice daily for 3 days | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. |
| AID725367 | Antibacterial activity against methicillin-resistant, inducible MLS-resistant, coagulase-deficient Staphylococcus hominis E 3 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID533856 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium mucogenicum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID1414198 | Selectivity ratio of MBC for Staphylococcus aureus ATCC 25923 to MIC for Staphylococcus aureus ATCC 25923 | 2018 | European journal of medicinal chemistry, Nov-05, Volume: 159 | Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators. |
| AID475105 | Antibacterial activity against Haemophilus influenzae 3 after 20 hrs by agar dilution method | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4'' positions: Improved antibacterial activities. |
| AID571444 | Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of 2 ug/ml NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1868045 | Antibacterial activity against Haemophilus influenzae ATCC 49247 by microbroth dilution method | 2022 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 68 | Design and synthesis of novel macrolones bridged with linkers from 11,12-positions of macrolides. |
| AID426377 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae 07Z001 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID735589 | Antibacterial activity against methicillin-resistant, coagulase-negative, MLS-resistant (inducible) Staphylococcus epidermidis E3 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID1677805 | Antibacterial activity against penicillin-resistant Staphylococcus aureus incubated for 24 hrs by CLSI-based broth microdilution method | 2020 | Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21 | Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus. |
| AID1221963 | Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979 | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2 | Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. |
| AID557655 | Antimicrobial activity against Mycobacterium abscessus isolate MC723 at day 7 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1550831 | Bactericidal activity against inducibly erythromycin resistant Streptococcus pyogenes 01-968 expressing i-ermA assessed as reduction in colony formation incubated in CAMHB medium for 20 to 24 hrs followed by 24 hrs subculturing in the medium without test | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID296265 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus 01-431 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID565329 | Antibacterial activity against Mycoplasma genitalium M6283 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID571648 | Antibacterial activity against Proteus mirabilis ATCC 29906 by Etest method in presence of 4 ug/ml NAB7073 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID508432 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 7127 harboring S20N mutation in L4 ribosomal protein and A105V mutation in L22 ribosomal protein after 38 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID508461 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2094 harboring erm(A) gene after 6 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1647106 | Antibacterial activity against penicillin-susceptible Bacillus subtilis ATCC 9372 by standard broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID572848 | Antimicrobial activity against Helicobacter pylori S1900 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. |
| AID644455 | Antibacterial activity against methicillin-resistant, coagulase-negative, inducible MLS-resistant Staphylococcus hominis E3 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID340003 | Antimicrobial activity against Bacillus subtilis | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Antibacterial activity of labdane diterpenoids from Stemodia foliosa. |
| AID545909 | Antimicrobial activity against Escherichia coli ATCC 25922 in presence of 4 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID292282 | Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by microplate Alamar blue assay | 2007 | Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15 | Growth inhibition of Mycobacterium bovis, Mycobacterium tuberculosis and Mycobacterium avium in vitro: effect of 1-beta-D-2'-arabinofuranosyl and 1-(2'-deoxy-2'-fluoro-beta-D-2'-ribofuranosyl) pyrimidine nucleoside analogs. |
| AID523012 | Ratio of Kcat to Km for macrolide 2'-phosphotransferase 1 by PK/LDH-coupled assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Nucleotide selectivity of antibiotic kinases. |
| AID1691403 | Antibacterial activity against azithromycin-susceptible Haemophilus influenzae ATCC 49247 assessed as reduction in microbial growth | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID512007 | Antibacterial activity against erythromycin, methicillin-resistant Staphylococcus aureus A333 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides. |
| AID557665 | Antimicrobial activity against Mycobacterium abscessus isolate MC719 at day 14 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1549376 | Antibacterial activity against MLS-resistant Streptococcus pyogenes 01-968 expressing inducible ermB gene assessed as reduction in microbial growth by CLSI based two-fold broth dilution method | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID512005 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides. |
| AID321867 | Oral bioavailability in human at 500 mg administered as single dose | 2008 | Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1 | A new insight into solid-state conformation of macrolide antibiotics. |
| AID558226 | Antimicrobial activity against Mycobacterium abscessus isolate MC1448 at day 5 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1459143 | Protein binding in human plasma at 1 ug/ml by LC-MS/MS analysis | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID368806 | Cmax in human interstitial-space fluid of subcutaneous adipose tissue at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID496395 | Antibacterial activity against macrolide-resistant Haemophilus influenzae 4437 infected in NCI-H292 cells assessed as decrease in viable bacterial count at 64 ug/ml by 3-h invasion assay | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. |
| AID1502712 | Antimycobacterial activity against Mycobacterium avium isolate MAV3 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID425587 | Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate HM605 isolated from colonic mucosal biopsies of patient with Crohn's disease in mouse J774A1 cells assessed as intracellular killing of bacteria at 3 ug/ml after 3 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID535636 | Antimicrobial activity against Group B streptococcus serotype VI R4 harboring Q557E mutation in PBP 2X and T567I, Y262N mutations in PBP 2B by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility. |
| AID1427913 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID1498154 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID535645 | Antimicrobial activity against Group B Streptococcus serotype Ia N1 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility. |
| AID425607 | Cytotoxicity against mouse J774A1 cells assessed as macrophage number at 3 ug/ml after 3 hrs by total cell protein assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID571662 | Ratio of the MIC for Serratia marcescens ATCC 8100 in the absence of NAB7072 to MIC for Serratia marcescens ATCC 8100 in the presence of 4 ug/ml of NAB7072 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1193495 | Thermodynamic equilibrium solubility, log S of the compound in simulated intestinal fluid at pH 6.8 at RT after 4 hrs by 96 well plate method | 2015 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7 | Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery. |
| AID1764398 | Substrate activity at P-gp (unknown origin) assessed as net efflux ratio | 2021 | Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5 | Development of an |
| AID625284 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID279256 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3009 with GyrA S81F and ParC D83N mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID422650 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 38 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID576345 | Bactericidal activity against Chlamydia trachomatis serovar G infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID671431 | Antimycobacterial activity against Mycobacterium bovis BCG assessed as inhibition of microbial growth at 0.5 to 100 ug/ml incubated for 6 days by MABA method | 2012 | Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13 | Discovery of novel 5-(ethyl or hydroxymethyl) analogs of 2'-'up' fluoro (or hydroxyl) pyrimidine nucleosides as a new class of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium inhibitors. |
| AID557909 | Antimicrobial activity against Mycobacterium abscessus isolate MC720 at day 14 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID368776 | AUC (0 to 24 hrs) in fasting human interstitial-space fluid of subcutaneous adipose tissue at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID318662 | Antibacterial activity against Peptostreptococcus magnus GAI 5528 by broth microdilution method | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7 | Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens. |
| AID1539191 | Bactericidal activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing the ermB and mefA incubated for 24 hrs followed by re-plating on tryptic soy agar plates for 24 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID1221960 | Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979 | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2 | Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. |
| AID528973 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID19425 | HPLC capacity factor (k) | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID557926 | Antimicrobial activity against Mycobacterium abscessus isolate MC719 at day 7 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID558229 | Antimicrobial activity against Mycobacterium abscessus isolate MC879-2 at day 9 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID372995 | Antimycobacterial activity against Mycobacterium intracellular JATA52-01 infected C57BL/6J mouse assessed as spleen bacterial count at 200 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last do | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID501671 | Antimicrobial activity against Streptococcus pneumoniae SP030 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID554534 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 on day 4 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID261460 | Antibacterial activity against Streptococcus pyogenes 8668 | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Synthesis and antibacterial activity of novel C12 vinyl ketolides. |
| AID571659 | Ratio of the MIC for Citrobacter freundii ATCC 8090 in the absence of NAB7069 to MIC for Citrobacter freundii ATCC 8090 in the presence of 4 ug/ml of NAB7069 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID279272 | Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 37 with GyrA S81Y, GyrB E474K and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID554659 | Antimicrobial activity against Ureaplasma parvum SV1 isolate UHWQ3 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID558622 | Antimicrobial activity against Streptococcus pneumoniae isolate 3374 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID206077 | The compound was tested in vitro for antibacterial activity against 31 strains of erythromycin resistant Streptococci; Value is 1.2/40 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID554658 | Antimicrobial activity against Ureaplasma parvum isolate UHWP2 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID87960 | Minimum inhibitory concentration against Helicobacter pylori. | 2001 | Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25 | 3-(Arylacetylamino)-N-methylbenzamides: a novel class of selective anti-Helicobacter pylori agents. |
| AID1291987 | Antimycobacterial activity against Mycobacterium bovis BCG assessed as inhibition of mycobacterial replication after 6 days by microplate Alamar blue assay | 2016 | Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8 | Investigation of 4-amino-5-alkynylpyrimidine-2(1H)-ones as anti-mycobacterial agents. |
| AID544523 | Antimicrobial activity against Borrelia afzelii isolate G600 after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID381668 | Antibacterial activity against ermB-constitutive resistant Streptococcus pyogenes after 20 hrs by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13-hydroxy analogues. |
| AID557942 | Antimicrobial activity against Mycobacterium abscessus isolate MAB30 at day 3 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID644444 | Antibacterial activity against penicillin-susceptible, constitutive MLS-resistant Streptococcus pneumoniae PU 27 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID1245722 | Bactericidal activity against methicillin-resistant Staphylococcus aureus PU20 expressing constitutive ermC incubated for 20 hrs followed by sub-culturing for 24 hrs in absence of compound | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID25995 | Area under the curve was determined for the compound from the serum of mice following a single oral dose of 10 mg/kg (data represent mean in 3 mice) | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID425604 | Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate HM615 in mouse J774A1 cells isolated from colonic mucosal biopsies of patient with Crohn's disease assessed as intracellular killing of bacteria at 10% compound Cmax a | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID1488454 | Antibacterial activity against penicillin-susceptible Bacillus subtilis ATCC 9372 after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID121252 | Survival rate of mouse inoculated intraperitoneally with 5.05*10e7 CFU of erythromycin-susceptible strain Streptococcus pneumoniae IID553 after treatment with 0.3 mg of compound | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID1221957 | Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2 | Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. |
| AID524920 | Antimicrobial activity against Mycobacterium abscessus 390S assessed as inhibition of biofilm formation up to 128 ug/ml treated during lag-phase measured after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID1550825 | Antimicrobial activity against Staphylococcus epidermidis E1 incubated in CAMHB medium for 20 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID296277 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 03-451 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID559561 | Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID529892 | Antimicrobial activity against Leptospira interrogans isolate 7 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID559552 | Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1221982 | Fraction absorbed in human | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2 | Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. |
| AID279260 | Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 1077 with 23S rRNA A2058G mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID557936 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 at day 14 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID717683 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 09G291 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides. |
| AID1487244 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes isolate S2 | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID86127 | In vitro inhibitory activity against Haemophilus influenzae (351CB12) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID520869 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU33 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID565314 | Antibacterial activity against Mycoplasma genitalium TW10-6G by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID571396 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 0.125 ug/ml NAB739 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID681121 | TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing MDCKII cells | 2001 | The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2 | Rational use of in vitro P-glycoprotein assays in drug discovery. |
| AID1549379 | Bactericidal activity against MLS/methicillin-resistant Staphylococcus aureus PU 32 expressing inducible ermA gene pretreated followed by subculture in absence of compound measured after 24 hrs | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID368799 | Free AUC (0 to 24 hrs) in human plasma at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID658055 | Antibacterial activity against Staphylococcus aureus ATCC 13709 after 24 hrs at 37 degC by CLSI protocol based microdilution method | 2012 | Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10 | Novel desosamine-modified 14- and 15-membered macrolides without antibacterial activity. |
| AID1766094 | Antibacterial activity against Klebsiella pneumoniae ATCC10031 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 49 | Design, synthesis and antibacterial evaluation of novel 3-O-substituted 15-membered azalides possessing 1,2,3-triazole side chains. |
| AID270438 | Antibacterial activity against Haemophilus influenzae 2762 by broth microdilution method | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and antibacterial activity of C12 des-methyl ketolides. |
| AID567475 | Antimicrobial activity against gBLPACR-2 Haemophilus influenzae by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae. |
| AID1550817 | Antimicrobial activity against mef-encoded erythromycin resistant Streptococcus pneumoniae PU09 incubated in CAMHB medium for 20 to 24 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID125508 | The ratio of the number of Mongolian gerbils in which Helicobacter pylori was not detected to that of Mongolian gerbils tested (percent) was represented as clearance rate at 10 mg/kg dose | 1998 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16 | Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents. |
| AID529895 | Antimicrobial activity against Leptospira interrogans serovar Icterohaemorrhagiae isolate 3 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID1427914 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing ermB gene by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID508415 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 1635 harboring erm(A) gene after 49 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID368985 | Terminal half life in human subcutaneous interstitial-space fluid of adipose tissue at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID571640 | Antibacterial activity against Klebsiella oxytoca ATCC 13182 by Etest method in presence of 4 ug/ml NAB7065 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID368986 | Terminal half life in human interstitial-space fluid of skeletal muscle at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID501297 | Antibacterial activity against efflux-mediated macrolide-resistance Streptococcus pyogenes 2 Finland by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID202097 | In vitro minimum inhibitory concentration for antibacterial activity against Streptococcus pneumoniae 210 (efflux-resistant strain encoded by the mef(A) gene) | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID318661 | Antibacterial activity against Peptostreptococcus anaerobius GAI 5506 by broth microdilution method | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7 | Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens. |
| AID529904 | Antimicrobial activity against Leptospira interrogans serovar Canicola isolate 11 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID558607 | Antimicrobial activity against Streptococcus pneumoniae isolate 1384 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID529898 | Antimicrobial activity against Leptospira weilii isolate 6 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID374399 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 after 16 to 18 hrs by agar dilution method | 2009 | European journal of medicinal chemistry, Apr, Volume: 44, Issue:4 | Synthesis and antibacterial evaluation of novel 4-alkyl substituted phenyl beta-aldehyde ketone derivatives. |
| AID372983 | Antimycobacterial activity against Mycobacterium avium complex after 14 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID1754233 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. |
| AID557937 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 at day 14 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID565321 | Antibacterial activity against Mycoplasma genitalium M6257 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID19662 | Calculated partition coefficient (clogP) | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID279257 | Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3009 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID296273 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 01-1056 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID369649 | Antibacterial activity against Campylobacter jejuni 001B-22 carrying A2075G mutation in 23S rRNA by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni. |
| AID571447 | Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID717688 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus 09O077 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides. |
| AID548257 | Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm, graRm mutant gene after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID209626 | In vitro minimum inhibitory concentration against Streptococcus pyogenes PIU 2548 using standard agar dilution method | 2000 | Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8 | Synthesis and antibacterial activity of novel 6-O-substituted erythromycin A derivatives. |
| AID528838 | Antimicrobial activity against vancomycin-resistant Enterococcus sp. assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID576338 | Antimicrobial activity against Chlamydia trachomatis serovar H infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID112356 | In Vivo evaluation for its effective dose against Haemophilus influenzae (351GR1) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID1291988 | Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of mycobacterial replication after 6 days by microplate Alamar blue assay | 2016 | Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8 | Investigation of 4-amino-5-alkynylpyrimidine-2(1H)-ones as anti-mycobacterial agents. |
| AID534340 | Antimicrobial activity against Burkholderia pseudomallei Bp50 harboring deleted (amrRAB-oprA)::FRT gene after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID1439725 | Bacteriostatic activity against Streptococcus pyogenes 12-207 expressing mef after 20 to 24 hrs by two-fold microbroth dilution method | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID558187 | Antimicrobial activity against Mycobacterium abscessus isolate MAB30 at day 9 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID208134 | In vitro minimum inhibitory concentration against Streptococcus pneumoniae 5649. | 2000 | Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8 | Synthesis and antibacterial activity of novel 6-O-substituted erythromycin A derivatives. |
| AID68698 | In vitro inhibitory activity against Escherichia coli (250 UC5) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID774999 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 09-9 by broth microdilution method | 2013 | European journal of medicinal chemistry, Nov, Volume: 69 | Synthesis and antibacterial activity of novel modified 5-O-mycaminose 14-membered ketolides. |
| AID270425 | Antibacterial activity against Staphylococcus aureus 33591 by broth microdilution method | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and antibacterial activity of C12 des-methyl ketolides. |
| AID205876 | In vitro inhibitory activity against Staphylococcus epidermidis (EryRi 012GO11i) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID326069 | Reduction of pneumolysin production in Streptococcus pneumoniae NMU112 lysates at 5 ug/mL after 12 hrs by Western blot relative to control | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. |
| AID571200 | Antibacterial activity against Escherichia coli ATCC 25992 by Etest method in presence of NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID416128 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing erm gene by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6 | Synthesis and antibacterial activity of 4'',11-di-O-arylalkylcarbamoyl azithromycin derivatives. |
| AID1502711 | Antimycobacterial activity against Mycobacterium avium isolate MAV2 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID1498846 | Antibacterial activity against clarithromycin-resistant Moraxella catarrhalis 12-2 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID112357 | In Vivo evaluation for its effective dose against Haemophilus influenzae (351TO19 AmpR beta (-)) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID558208 | Antimicrobial activity against Mycobacterium abscessus isolate MAB30 at day 3 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID293531 | Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by MABA | 2007 | Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5 | Studies on acyclic pyrimidines as inhibitors of mycobacteria. |
| AID535639 | Antimicrobial activity against Group B streptococcus serotype VI R1 harboring F395L, V405A, R433H, H438Y, and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility. |
| AID717686 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 09L075 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides. |
| AID557934 | Antimicrobial activity against Mycobacterium abscessus isolate MC723 at day 9 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID534423 | Antibacterial activity against Mycobacterium bovis BCG-Moreau | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. |
| AID425981 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 49 passages by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID501670 | Antimicrobial activity against Staphylococcus aureus ATCC 13709 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID575169 | Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 1000 uM by spectrofluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates. |
| AID637554 | Antibacterial activity against Streptococcus pyogenes 19615 by NCCLS method | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens. |
| AID560508 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b3k5923 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID1245721 | Bactericidal activity against methicillin-resistant Staphylococcus aureus PU32 expressing inducible ermA incubated for 20 hrs followed by sub-culturing for 24 hrs in absence of compound | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID402032 | Antimicrobial activity against Helicobacter pylori TPH30 after 4 days by twofold plate dilution method | 2005 | Journal of natural products, Jun, Volume: 68, Issue:6 | Anti-Helicobacter pylori compounds from Santalum album. |
| AID559560 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1867277 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 assessed as bacterial growth inhibition incubated for 18 hrs by microdilution method | 2022 | Journal of natural products, 05-27, Volume: 85, Issue:5 | Diterpenoids from |
| AID322987 | Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae with 23S rRNA A2064G mutant isolate 2 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. |
| AID557932 | Antimicrobial activity against Mycobacterium abscessus isolate MC719 at day 9 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID571763 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-F628F mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID688519 | Antibacterial activity against MLSB-resistant Streptococcus pneumoniae 205 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19 | Synthesis and structure-activity relationship of a novel class of 15-membered macrolide antibiotics known as '11a-azalides'. |
| AID87953 | Minimum inhibitory concentration against Helicobacter pylori (Helicobacter pylori) ARHp strain 81 | 2002 | Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19 | Novel structures derived from 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 2. |
| AID1536945 | Anti-inflammatory activity in human PMN assessed as inhibition of fMLP/cytochalasin A-induced CD11b/CD18 expression by measuring CD11b/CD18 expression level at 50 uM preincubated for 30 mins followed by fMLP/cytochalasin A addition and measured after 30 m | 2019 | Journal of natural products, 02-22, Volume: 82, Issue:2 | Eupatoriopicrin Inhibits Pro-inflammatory Functions of Neutrophils via Suppression of IL-8 and TNF-alpha Production and p38 and ERK 1/2 MAP Kinases. |
| AID326091 | Antimicrobial activity against Streptococcus pneumoniae NMU112 infected in po dosed CBA/J mouse assessed as delaying in development of bacteremia relative to roxithromycin | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. |
| AID1498843 | Antibacterial activity against methicillin-resistant Streptococcus pyogenes 12-1 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID595938 | Antiparasitic activity against Toxoplasma gondii 2F-1 expressing yellow fluorescent protein infected in HFF after 4 days | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID725379 | Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae PU 09 expressing mef gene by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID326067 | Antimicrobial activity against Streptococcus pneumoniae NMUP45 | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. |
| AID545936 | Ratio of MIC for Escherichia coli IH3080 to MIC for Escherichia coli IH3080 in presence of 4 ug/ml of NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID1498845 | Antibacterial activity against extended spectrum beta-lactamases producing Klebsiella pneumoniae ATCC 700603 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID508428 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 7127 harboring S20N mutation in L4 ribosomal protein and A105V mutation in L22 ribosomal protein after 29 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID571451 | Antibacterial activity against Enterobacter cloacae ATCC 23355 ATCC 13883 by Etest method in presence of 4 ug/ml NAB7064 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID775003 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus 09-6 by broth microdilution method | 2013 | European journal of medicinal chemistry, Nov, Volume: 69 | Synthesis and antibacterial activity of novel modified 5-O-mycaminose 14-membered ketolides. |
| AID1439719 | Bacteriostatic activity against penicillin-susceptible Streptococcus pneumoniae PU09 after 20 to 24 hrs by two-fold microbroth dilution method | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID1459149 | Metabolic stability in mouse liver microsomes assessed as parent compound remaining at 1 uM after 60 mins in presence of NADP by LC-MS/MS analysis | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID724507 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing erm and mef genes by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID529903 | Antimicrobial activity against Leptospira kirschneri serovar Grippotyphosa isolate 13 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID496386 | Antiinflammatory activity against nontypeable beta-lactamase-negative ampicillin-resistant Haemophilus influenzae 4437 infected in mouse ddY assessed as decrease in total cell count in bronchoalveolar lavage fluid at 100 mg/kg, po bid for 3 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. |
| AID1417285 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes 2 after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID501298 | Antibacterial activity against inducible resistance to macrolide, licosamide and streptogramin Staphylococcus aureus 90256 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID1632650 | Displacement of [3H]FMZ from GABA-A receptor in rat brain assessed as Kd of [3H]-FMZ at 10 uM after 30 mins by autoradiography (Rvb = 0.66 +/- 0.12 nM) | 2016 | ACS medicinal chemistry letters, Aug-11, Volume: 7, Issue:8 | Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET. |
| AID557908 | Antimicrobial activity against Mycobacterium abscessus isolate MC719 at day 14 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID565311 | Antibacterial activity against Mycoplasma genitalium M30 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID571646 | Antibacterial activity against Acinetobacter baumannii by Etest method in presence of 4 ug/ml NAB7071 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID326068 | Antimicrobial activity against Streptococcus pneumoniae NMU605 | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. |
| AID635185 | Antibacterial activity against constitutive macrolide, licosamide and streptogramin-resistant Staphylococcus aureus PK2 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID402033 | Antimicrobial activity against Clarithromycin-resistant Helicobacter pylori TS281 after 4 days by twofold plate dilution method | 2005 | Journal of natural products, Jun, Volume: 68, Issue:6 | Anti-Helicobacter pylori compounds from Santalum album. |
| AID508417 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2686 harboring mutation in L4 ribosomal protein after 22 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID571768 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-I626M mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID1550843 | Bactericidal activity against azithromycin-susceptible Haemophilus influenzae ATCC 49247 assessed as reduction in colony formation incubated in HTM broth medium for 20 to 24 hrs followed by 24 hrs subculturing in the medium without test compound | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID508389 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 1077 after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1245707 | Antimicrobial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 incubated for 20 to 24 hrs by two-fold microbroth dilution method | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID548471 | Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID565326 | Antibacterial activity against Mycoplasma genitalium M6090 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID1502708 | Antimycobacterial activity against Mycobacterium avium 104 mc'2 4 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID635186 | Antibacterial activity against constitutive macrolide, licosamide and streptogramin-resistant Streptococcus pneumoniae 58 Spain by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID208127 | In vitro inhibitory activity against Streptococcus pneumoniae (EryRi 030SJ5i) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID557670 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 at day 3 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID525098 | Bacteriostatic activity against Mycobacterium abscessus 390S infected in human monocyte-derived macrophage assessed as inhibition of planktonic cell growth at 4 ug/ml treated 24 hrs postinfection | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID571441 | Antibacterial activity against Escherichia coli IH3080 by Etest method in presence of NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1245718 | Bactericidal activity against Streptococcus pyogenes 01-968 expressing inducible ermA incubated for 20 to 24 hrs followed by sub-culturing for 24 hrs in absence of compound | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID381664 | Antibacterial activity against ermB-constitutive resistant Streptococcus pneumoniae after 20 hrs by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13-hydroxy analogues. |
| AID540211 | Fraction unbound in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID1193498 | Thermodynamic equilibrium solubility, log S of the compound simulated gastric fluid at pH 1.2 at RT after 24 hrs by shake-flask method | 2015 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7 | Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery. |
| AID501673 | Antimicrobial activity against Streptococcus pneumoniae 134 GR-M by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID557675 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 at day 5 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID554537 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 on day 10 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID209616 | In vitro inhibitory activity against Streptococcus pyogenes (02A1UC1) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID206352 | The compound has been evaluated for the antibacterial activity against Staphylococcus aureus EryRc 011CB20 strains | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID496390 | Antiinflammatory activity against nontypeable beta-lactamase-negative ampicillin-resistant Haemophilus influenzae 4437 infected in mouse ddY assessed as decrease in IL1-beta level in bronchoalveolar lavage fluid at 100 mg/kg, po bid for 3 days relative to | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. |
| AID547659 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae 2860 by broth microdilution method | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | Synthesis and antibacterial activity of C-12 pyrazolinyl spiro ketolides. |
| AID374397 | Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 16 to 18 hrs by agar dilution method | 2009 | European journal of medicinal chemistry, Apr, Volume: 44, Issue:4 | Synthesis and antibacterial evaluation of novel 4-alkyl substituted phenyl beta-aldehyde ketone derivatives. |
| AID1632648 | In vivo displacement of [11C]FMZ from rhesus monkey GABA-A receptor assessed as late distribution volume ratio to early distribution volume ratio of [3H]-FMZ at 3.5 mg/kg, iv by Logan plot analysis (Rvb = 115 to 121 %) | 2016 | ACS medicinal chemistry letters, Aug-11, Volume: 7, Issue:8 | Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET. |
| AID558194 | Antimicrobial activity against Mycobacterium abscessus isolate MC1028 at day 3 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID292278 | Antimycobacterial activity against Mycobacterium bovis BCG by microplate Alamar blue assay | 2007 | Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15 | Growth inhibition of Mycobacterium bovis, Mycobacterium tuberculosis and Mycobacterium avium in vitro: effect of 1-beta-D-2'-arabinofuranosyl and 1-(2'-deoxy-2'-fluoro-beta-D-2'-ribofuranosyl) pyrimidine nucleoside analogs. |
| AID1245730 | Ratio of MBC to MIC against methicillin-resistant Staphylococcus aureus PU20 expressing constitutive ermC | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID635192 | Antibacterial activity against Moraxella catarrhalis ATCC 23246 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID475101 | Antibacterial activity against Streptococcus pyogenes 2 expressing constitutive ermB methylase after 20 hrs by agar dilution method | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4'' positions: Improved antibacterial activities. |
| AID1868041 | Antibacterial activity against Streptococcus pneumoniae PU09 by microbroth dilution method | 2022 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 68 | Design and synthesis of novel macrolones bridged with linkers from 11,12-positions of macrolides. |
| AID554533 | Antimicrobial activity against Mycobacterium abscessus isolate MC1448 at day 14 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID132628 | The compound was tested in vivo for antibacterial activity against constitutively erythromycin resistant Streptococcus pneumoniae 030MV2 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID571203 | Antibacterial activity against Escherichia coli ATCC 25992 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID112496 | In Vivo evaluation for its effective dose against Streptococcus pyogenes (02A1UC1) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID1647104 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 by standard broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID373144 | Antimycobacterial activity against Mycobacterium avium complex N084 infected C57BL/6J mouse assessed as spleen bacterial count at 200 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID1539174 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes 1 clinical isolate incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID1444600 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae BAA1402 expressing mef gene by broth microdilution method | 2017 | Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8 | Synthesis of clarithromycin ketolides chemically modified at the unreactive C10-methyl group. |
| AID554648 | Antimicrobial activity against Ureaplasma urealyticum isolate HPA3 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID576341 | Antimicrobial activity against Chlamydia trachomatis serovar K infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID1539192 | Ratio of MBC to MIC for erythromycin-susceptible Staphylococcus aureus ATCC 25923 | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID279261 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3665 with GyrA S81Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID368785 | Tmax in fasting human plasma unbound fraction at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID1549368 | Antibacterial activity against Streptococcus pneumoniae 07P390 expressing constitutive ermB gene assessed as reduction in microbial growth by CLSI based two-fold broth dilution method | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID422680 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID554554 | Antimicrobial activity against Mycobacterium smegmatis transformed with erm allele Mycobacterium abscessus isolate MAB30 preincubated with 2 ug/ml erythromycin for 20 to 24 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID572849 | Antimicrobial activity against Helicobacter pylori TF1 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. |
| AID704309 | Cellular uptake in human T lymphocytes assessed as compound retention at 3 to 20 uM incubated for 3 hrs followed by drug washout measured after 3 hrs by LC-MS/MS analysis relative to initial drug accumulation | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID571453 | Antibacterial activity against Enterobacter cloacae ATCC 23355 ATCC 13883 by Etest method in presence of NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1498834 | Antibacterial activity against erythromycin-sensitive Streptococcus pyogenes 11L264 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID557902 | Antimicrobial activity against Mycobacterium abscessus isolate MC719 at day 9 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID567806 | Antibacterial activity against erythromycin-susceptible Haemophilus influenzae 07O339 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID279259 | Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID1444601 | Antibacterial activity against macrolides/lincosamides/streptogramines resistant Streptococcus pneumoniae 3914 by broth microdilution method | 2017 | Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8 | Synthesis of clarithromycin ketolides chemically modified at the unreactive C10-methyl group. |
| AID279255 | Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 3009 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID508475 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 237 harboring mutation in L4 ribosomal protein after 43 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID572273 | Antimicrobial activity against Streptococcus pneumoniae ATCC 6303 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. |
| AID475100 | Antibacterial activity against Streptococcus pyogenes Cook after 20 hrs by agar dilution method | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4'' positions: Improved antibacterial activities. |
| AID529900 | Antimicrobial activity against Leptospira interrogans serovar Icterohaemorrhagiae isolate 9 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID372553 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-susceptible Haemophilus influenzae type b without amino acid substitutions in ftsI gene and bla gene assessed as susceptibility rate by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID1549375 | Selectivity ratio of MBC to MIC for azithromycin-susceptible Haemophilus influenzae ATCC 49247 | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID735596 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 29213 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID1439738 | Bactericidal activity against erythromycin-susceptible Moraxella catarrhalis 11B366 incubated for 20 hrs followed by sub-culturing for 24 hrs in absence of compound | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID132629 | The compound was tested in vivo for antibacterial activity against constitutively erythromycin resistant Streptococcus pneumoniae 030SJ1 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID520875 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolates isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID557916 | Antimicrobial activity against Mycobacterium abscessus isolate MC723 at day 3 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID557663 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 at day 14 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1459142 | Protein binding in rat plasma at 1 ug/ml by LC-MS/MS analysis | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID425988 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 29 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID368779 | Ratio of AUC (0 to 24 hrs) in fasting human interstitial-space fluid of skeletal muscle to free AUC (0 to 24 hrs) in fasting human plasma at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID547667 | Antibacterial activity against erythromycin-resistant Haemophilus influenzae 2412 by broth microdilution method | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | Synthesis and antibacterial activity of C-12 pyrazolinyl spiro ketolides. |
| AID635181 | Antibacterial activity against erythromycin-sensitive Streptococcus pyogenes 3565 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID567799 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes 03-233 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID1488457 | Antibacterial activity against penicillin-susceptible Escherichia coli ATCC 25922 after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID444052 | Hepatic clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1487243 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID558220 | Antimicrobial activity against Mycobacterium abscessus isolate MAB30 at day 14 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1691425 | Antibacterial activity against MLSB/methicillin/ciprofloxacin-resistant Staphylococcus aureus PU32 harboring ermA gene assessed as reduction in microbial growth relative to ciprofloxacin | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID1498157 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 harboring ermB and mefA genes after 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID425399 | Antibacterial activity against Escherichia coli isolate HM580 isolated from colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID747242 | Antibacterial activity against drug-resistant Escherichia coli by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11 | Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives. |
| AID571926 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-N623S-Q624S mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID508467 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2094 harboring erm(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID724770 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing erm gene by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID1549377 | Bactericidal activity against MLS-resistant Streptococcus pyogenes 01-968 expressing inducible ermB gene pretreated followed by subculture in absence of compound measured after 24 hrs | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID309092 | Antibacterial activity against Escherichia coli ATCC 25922 | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18 | A novel ketolide class: Synthesis and antibacterial activity of a lead compound. |
| AID208472 | The compound was tested in vitro for antibacterial activity against constitutively erythromycin resistant Streptococcus pneumoniae 030CR18c | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID528977 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient blood assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID571647 | Antibacterial activity against Serratia marcescens ATCC 8100 by Etest method in presence of 4 ug/ml NAB7072 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID483706 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB1-1 expressing erm and mef gene by broth microdilution method | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Synthesis and antibacterial activity of novel 4''-O-arylalkylcarbamoyl and 4''-O-((arylalkylamino)-4-oxo-butyl)carbamoyl clarithromycin derivatives. |
| AID681582 | TP_TRANSPORTER: inhibition of Calcein-AM efflux in NIH-3T3-G185 cells | 2001 | Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2 | Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. |
| AID553816 | Antibacterial activity against Escherichia coli ATCC 25922 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis. |
| AID545916 | Antimicrobial activity against Escherichia coli ATCC 25922 by Etest method in presence of 2 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID565306 | Antitubercular activity against Mycobacterium avium infected in C57BL/6J mouse assessed as reduction of CFU counts in spleen at 200 mg/kg, po administered one day post-infection five times weekly for 1 month (Rvb = 8.0 +/- 0.9 log10CFU) | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | ATP synthase inhibition of Mycobacterium avium is not bactericidal. |
| AID1550838 | Ratio of MBC to MIC for inducibly erythromycin-resistant and methicillin resistant Staphylococcus aureus PU32 expressing i-ermA | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID704313 | Cellular uptake in human PMNC assessed as compound retention at 3 to 20 uM incubated for 3 hrs followed by drug washout measured after 3 hrs by LC-MS/MS analysis relative to initial drug accumulation | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID570203 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 | 2011 | ACS medicinal chemistry letters, Mar-10, Volume: 2, Issue:3 | Synthesis and antibacterial activity of a novel class of 15-membered macrolide antibiotics, "11a-azalides". |
| AID512010 | Antibacterial activity against ampicillin-susceptible Haemophilus influenzae ATCC 49247 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides. |
| AID510555 | Antimicrobial activity against Chlamydia trachomatis after 72 hrs by twofold serial dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. |
| AID554522 | Antimicrobial activity against Mycobacterium abscessus isolate MC879-2 at day 14 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID603985 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jul, Volume: 46, Issue:7 | Synthesis and antibacterial activity of novel 4″-O-benzimidazolyl clarithromycin derivatives. |
| AID730750 | Antibacterial activity against macrolides, lincosamides, and streptogramin B-resistant Streptococcus pneumoniae 1243-00 assessed as growth inhibition | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6 | Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates. |
| AID1868040 | Antibacterial activity against Streptococcus pneumoniae 07P390 by microbroth dilution method | 2022 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 68 | Design and synthesis of novel macrolones bridged with linkers from 11,12-positions of macrolides. |
| AID675200 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 205 expressing ermB ribosomal methylase by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17 | Synthesis and antibacterial activity of 6-O-(heteroaryl-isoxazolyl)propynyl 2-fluoro ketolides. |
| AID1724705 | Antibacterial activity against Acinetobacter baumannii AB5075 assessed as reduction in microbial growth after 2 days by broth microdilution method | 2020 | ACS medicinal chemistry letters, Sep-10, Volume: 11, Issue:9 | Augmenting the Activity of Macrolide Adjuvants against |
| AID70128 | The compound was tested in vitro for antibacterial activity against Escherichia coli 250 UCS | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID571443 | Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of 1 ug/ml NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1329754 | Antibacterial activity against Streptococcus mitis NCIMB 13770 after 24 hrs by broth microdilution method | |||
| AID545924 | Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of 2 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID309086 | Antibacterial activity against Streptococcus pneumoniae CI137 M | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18 | A novel ketolide class: Synthesis and antibacterial activity of a lead compound. |
| AID422682 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 14 passages with clindamycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID1549369 | Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae PU 09 expressing mef gene assessed as reduction in microbial growth by CLSI based two-fold broth dilution method | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID524911 | Antimicrobial activity against Mycobacterium abscessus 390S after 96 hrs | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID625281 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID638883 | Antibacterial activity against Streptococcus pneumoniae 49619 by NCCLS method | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens. |
| AID644451 | Antibacterial activity against methicillin-susceptible, inducible MLS-resistant Staphylococcus aureus PU 64 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID635184 | Antibacterial activity against inducible macrolide, licosamide and streptogramin-resistant Streptococcus pyogenes Finland 11 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID560523 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate gs07022 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID501296 | Antibacterial activity against efflux-mediated macrolide-resistance Streptococcus pneumoniae Ci137 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID437306 | Antibacterial activity against erythromycin-susceptible Staphylococcus pneumoniae ATCC 49619 | 2009 | European journal of medicinal chemistry, Oct, Volume: 44, Issue:10 | Synthesis and antibacterial activity of novel 15-membered macrolide derivatives: 4''-carbamate, 11,12-cyclic carbonate-4''-carbamate and 11,4''-di-O-arylcarbamoyl analogs of azithromycin. |
| AID559551 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID479978 | Antimicrobial activity against erythromycin-susceptible Staphylococcus aureus PU32 encoded by erm(A) gene | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives. |
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID1498836 | Antibacterial activity against azithromycin-sensitive Haemophilus influenzae 11P042 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID558183 | Antimicrobial activity against Mycobacterium abscessus isolate MC1082 at day 5 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID625283 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID559361 | Antimicrobial activity against compound-resistant Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID635179 | Antibacterial activity against erythromycin-sensitive Staphylococcus aureus ATCC 13709 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID730747 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 1279-07-USA300 assessed as growth inhibition | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6 | Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates. |
| AID1487249 | Antibacterial activity against Escherichia coli ATCC 25922 | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID724502 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes RE clinical isolate by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID1539193 | Ratio of MBC to MIC for erythromycin-resistant Streptococcus pneumoniae AB11 expressing the ermB and mefA | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID545917 | Antimicrobial activity against Escherichia coli ATCC 25922 by Etest method in presence of 4 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID528968 | Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID221225 | The compound has been evaluated for the in vivo efficacy that protect 50% of mice from lethal infection by Streptococcus Pneumoniae EryRi 030SJ5i strains after oral administration | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID1291989 | Antimycobacterial activity against Mycobacterium avium ATCC 25291 assessed as inhibition of mycobacterial replication after 6 days by microplate Alamar blue assay | 2016 | Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8 | Investigation of 4-amino-5-alkynylpyrimidine-2(1H)-ones as anti-mycobacterial agents. |
| AID425990 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 41 passages by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID1778128 | Antimicrobial activity against Escherichia coli assessed as microbial growth inhibition by CLSI-protocol based broth microdilution assay | 2021 | Journal of natural products, 04-23, Volume: 84, Issue:4 | Opportunities and Limitations for Assigning Relative Configurations of Antibacterial Bislactones using GIAO NMR Shift Calculations. |
| AID509004 | Antimicrobial activity against Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. |
| AID560500 | Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate sh06024 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID571390 | Antibacterial activity against Acinetobacter baumannii F264 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1487247 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 expressing mefA gene | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID543822 | Antimicrobial activity against Borrelia spielmanii isolate PC-Eq17 after 72 hrs by colorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. |
| AID554517 | Antimicrobial activity against Mycobacterium abscessus isolate MC1448 at day 5 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID279238 | Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3009 after 25 passages by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID577493 | AUC (0 to 24 hrs) in Staphylococcus aureus in in vitro pharmacokinetic/pharmacodynamic model at 250 mg every 12 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. |
| AID725373 | Antibacterial activity against methicillin-resistant, inducible MLS-resistant Staphylococcus aureus PU 32 expressing ermA gene by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID572851 | Antimicrobial activity against Helicobacter pylori TF3 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. |
| AID381662 | Antibacterial activity against ermC-inducible resistant Staphylococcus aureus after 20 hrs by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13-hydroxy analogues. |
| AID571430 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 2 ug/ml NAB739 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID334261 | Antibacterial activity against Bacteroides fragilis ATCC 25285 at 625 ug/mL after 24 hrs by conventional well agar method | 2002 | Journal of natural products, Apr, Volume: 65, Issue:4 | Derrisin, a new rotenoid from Derris malaccensis plain and anti-Helicobacter pylori activity of its related constituents. |
| AID533861 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium septicum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID528969 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID369666 | Inactivation of CmeABC efflux pump in Campylobacter jejuni 25-19 assessed as change in erythromycin MIC by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni. |
| AID571927 | Ratio of MIC for Escherichia coli K-12 3-AG300 harboring acrB::rpsLneo mutant gene to MIC for Escherichia coli K-12 3-AG300 | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID781261 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis ATCC 12228 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. |
| AID558624 | Antimicrobial activity against Streptococcus pneumoniae isolate 3455 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID470192 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by standard dilution assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin. |
| AID534425 | Antibacterial activity against Mycobacterium bovis BCG-Glaxo | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. |
| AID334264 | Antifungal activity against Candida albicans ATCC 10231 at 625 ug/mL after 24 hrs by conventional well agar method | 2002 | Journal of natural products, Apr, Volume: 65, Issue:4 | Derrisin, a new rotenoid from Derris malaccensis plain and anti-Helicobacter pylori activity of its related constituents. |
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID1502706 | Antimycobacterial activity against Mycobacterium avium 104 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID1867246 | Antibacterial activity against multidrug resistant Helicobacter pylori G27 assessed as bacterial growth inhibition incubated for 3 days by broth microdilution method | |||
| AID557673 | Antimicrobial activity against Mycobacterium abscessus isolate MC723 at day 3 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID373142 | Antimycobacterial activity against Mycobacterium avium complex N084 infected C57BL/6J mouse assessed as lung bacterial count at 200 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID1439743 | Bacteriostatic activity against azithromycin-susceptible Haemophilus influenzae ATCC 49247 after 20 to 24 hrs by two-fold microbroth dilution method | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID322967 | Antimicrobial activity against Mycobacterium avium complex 101 infected C57BL/6 beige mouse spleen assessed as bacterial load at 100 mg/kg once daily 6 days a week for 4 weeks | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium. |
| AID781248 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 12-6 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. |
| AID368781 | Free Cmax in fasting human plasma at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID1754230 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. |
| AID571397 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID475096 | Antibacterial activity against Streptococcus pneumoniae 8 expressing inducible ermB methylase after 20 hrs by agar dilution method | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4'' positions: Improved antibacterial activities. |
| AID557899 | Antimicrobial activity against Mycobacterium abscessus isolate MC724 at day 7 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID112491 | In Vivo evaluation for its effective dose against Streptococcus pneumoniae (030RO1 EryRi) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID571930 | Ratio of MIC for Escherichia coli K-12 3-AG300 harboring AcrB-G616N mutant gene to MIC for Escherichia coli K-12 3-AG300 | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID576347 | Bactericidal activity against Chlamydia trachomatis serovar I infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID1417278 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes 1 after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID425994 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID508385 | Antibacterial activity against Streptococcus pyogenes harboring mutation in L4 ribosomal protein after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID495322 | Antimicrobial activity against Beta-lactamase-positive, ampicillin-resistant Haemophilus influenzae by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance. |
| AID534345 | Antimicrobial activity against Burkholderia pseudomallei Bp175 harboring mini-Tn7T-P1-bpeR+ after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID625285 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID724505 | Antibacterial activity against penicillin-resistant Staphylococcus aureus clinical isolate by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID132626 | The compound was tested in vivo for antibacterial activity against Haemophilus influenza 351GR1 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID501301 | Antibacterial activity against constitutive MLS resistance Streptococcus pneumoniae 58 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID534421 | Antibacterial activity against Mycobacterium bovis BCG-Denmark | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. |
| AID1502710 | Antimycobacterial activity against Mycobacterium avium isolate MAV1 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID1193496 | Thermodynamic equilibrium solubility, log S of the compound in water at RT after 24 hrs by shake-flask method | 2015 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7 | Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery. |
| AID425969 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 20 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID496511 | Antiinflammatory activity against nontypeable beta-lactamase-negative ampicillin-resistant Haemophilus influenzae 4437 infected in mouse ddY assessed as decrease in IL1-beta level in bronchoalveolar lavage fluid at 40 mg/kg, po bid for 3 days relative to | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. |
| AID207371 | In vivo Minimum inhibitory conc against erythromycin susceptible Staphylococcus aureus Smith strain by mouse protection test | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Synthesis and antibacterial activity of acylides (3-O-acyl-erythromycin derivatives): a novel class of macrolide antibiotics. |
| AID571928 | Ratio of MIC for Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB mutant gene to MIC for Escherichia coli K-12 3-AG300 | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID675198 | Antibacterial activity against eryhtromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17 | Synthesis and antibacterial activity of 6-O-(heteroaryl-isoxazolyl)propynyl 2-fluoro ketolides. |
| AID369665 | Ratio of MIC for Campylobacter jejuni 001B-40 carrying A2075G mutation in 23S rRNA to MIC for Campylobacter jejuni 001B-40 cmeB::kanamycin-resistant mutant | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni. |
| AID402029 | Antimicrobial activity against Helicobacter pylori Sa-1 isolate after 4 days by twofold plate dilution method | 2005 | Journal of natural products, Jun, Volume: 68, Issue:6 | Anti-Helicobacter pylori compounds from Santalum album. |
| AID553826 | Antibacterial activity against 1x10'9 CFU Escherichia coli ATCC 25922 infected Wistar rat assessed as rat bacterial count in peritoneal fluid at 50 mg/kg, iv administered immediately after bacterial challenge measured 72 hrs postinfection (Rvb= 8.86 logCF | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis. |
| AID426375 | Antimicrobial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID1439728 | Bacteriostatic activity against azithromycin-susceptible/ampicillin-resistant Haemophilus influenzae 11P307 after 20 to 24 hrs by two-fold microbroth dilution method | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID730745 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 1281-07 harboring cfr gene assessed as growth inhibition | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6 | Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates. |
| AID270427 | Antibacterial activity against Staphylococcus epidermidis f50654 by broth microdilution method | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and antibacterial activity of C12 des-methyl ketolides. |
| AID368984 | Terminal half life in human plasma unbound fraction at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID483704 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing erm gene by broth microdilution method | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Synthesis and antibacterial activity of novel 4''-O-arylalkylcarbamoyl and 4''-O-((arylalkylamino)-4-oxo-butyl)carbamoyl clarithromycin derivatives. |
| AID85947 | The compound was tested in vitro for antibacterial activity against 47 strains of Haemophilus influenza AmpS; Value is 1.2/5 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID644449 | Antibacterial activity against methicillin-, inducible MLS-resistant erythromycin-susceptible Staphylococcus aureus PU 32 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID1691397 | Antibacterial activity against MLSB/methicillin/ciprofloxacin-resistant Staphylococcus aureus PU32 harboring ermA gene assessed as reduction in microbial growth | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID416841 | Antimycobacterial activity against Mycobacterium ulcerans isolate CU001 infected in BALB/c mouse left hind foot-pad assessed as bacterial load per culture-positive foot-pad at 100 mg/kg, po administered for 5 days per week measured after 4 weeks | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. |
| AID87962 | Minimum inhibitory concentration against Helicobacter pylori under acidic conditions at pH 6.0 | 2001 | Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25 | 3-(Arylacetylamino)-N-methylbenzamides: a novel class of selective anti-Helicobacter pylori agents. |
| AID1766091 | Antibacterial activity against clinical isolate erythromycin-resistant Enterococcus faecium by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 49 | Design, synthesis and antibacterial evaluation of novel 3-O-substituted 15-membered azalides possessing 1,2,3-triazole side chains. |
| AID1439730 | Ratio of MBC to MIC for azithromycin susceptible/ampicillin-resistant Haemophilus influenzae 11P307 | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID567801 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID85787 | In vitro inhibitory activity against Haemophilus AmpS (43) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID558196 | Antimicrobial activity against Mycobacterium abscessus isolate MAB30 at day 5 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID678715 | Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID1498837 | Antibacterial activity against azithromycin-resistant Haemophilus influenzae 11Q373 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID775004 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus 15 by broth microdilution method | 2013 | European journal of medicinal chemistry, Nov, Volume: 69 | Synthesis and antibacterial activity of novel modified 5-O-mycaminose 14-membered ketolides. |
| AID567802 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 07D201 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID725375 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes A3 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID1482267 | Antibacterial activity against Escherichia coli MG1655 measured every 15 mins for 12 hrs | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure. |
| AID208474 | The compound was tested in vitro for antibacterial activity against constitutively erythromycin resistant Streptococcus pneumoniae 030PW23c | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID24865 | The negative logarithm of the fraction of singly charged molecules. | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID309090 | Antibacterial activity against Moraxella catarrhalis ATCC 23246 | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18 | A novel ketolide class: Synthesis and antibacterial activity of a lead compound. |
| AID203422 | In vitro inhibitory activity against Staphylococci EryRc (13) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID671437 | Antimycobacterial activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of microbial growth at 0.5 to 100 ug/ml incubated for 6 days by MABA method | 2012 | Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13 | Discovery of novel 5-(ethyl or hydroxymethyl) analogs of 2'-'up' fluoro (or hydroxyl) pyrimidine nucleosides as a new class of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium inhibitors. |
| AID545910 | Antimicrobial activity against Escherichia coli ATCC 25922 in presence of 8 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID558205 | Antimicrobial activity against Mycobacterium abscessus isolate MAB30 at day 14 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID425408 | Antibacterial activity against Escherichia coli K-12 after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID1647107 | Antibacterial activity against penicillin-susceptible Pseudomonas aeruginosa ATCC 27853 by standard broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID557641 | Antimicrobial activity against Mycobacterium abscessus isolate MC719 at day 3 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID368772 | AUC (0 to 8 hrs) in fasting human interstitial-space fluid of subcutaneous adipose tissue at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID1439720 | Bactericidal activity against penicillin-susceptible Streptococcus pneumoniae PU09 incubated for 20 to 24 hrs followed by sub-culturing for 24 hrs in absence of compound | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID1427912 | Antibacterial activity against penicillin-resistant Staphylococcus epidermidis clinical isolate by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID261457 | Antibacterial activity against Staphylococcus epidermidis f50654 | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Synthesis and antibacterial activity of novel C12 vinyl ketolides. |
| AID588209 | Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset | 2010 | Chemical research in toxicology, Jul-19, Volume: 23, Issue:7 | Developing structure-activity relationships for the prediction of hepatotoxicity. |
| AID372980 | Antimycobacterial activity against Mycobacterium avium complex N016 after 14 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID574708 | Antimicrobial activity against Staphylococcus epidermidis SW029 expressing icaA gene | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID567794 | Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis 07T202 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID1550828 | Bactericidal activity against mef-encoded erythromycin resistant Streptococcus pneumoniae PU09 assessed as reduction in colony formation incubated in CAMHB medium for 20 to 24 hrs followed by 24 hrs subculturing in the medium without test compound | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID79589 | Minimum bactericidal concentration against Helicobacter pylori ATCC 43504 | 2002 | Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19 | Novel structures derived from 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 1. |
| AID1647121 | Bactericidal activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing ermB and me/A genes | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID23096 | The negative logarithm of the fraction of neutral molecules | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID501676 | Antimicrobial activity against Streptococcus pyogenes 166 GR-Micro by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID1677804 | Antibacterial activity against Staphylococcus aureus clinical isolate incubated for 24 hrs by CLSI-based broth microdilution method | 2020 | Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21 | Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus. |
| AID747243 | Antibacterial activity against drug-resistant Staphylococcus epidermidis by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11 | Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives. |
| AID698056 | Antimicrobial activity against Helicobacter pylori 26695 ATCC 700392 at 50 ug/ml by disk agar diffusion method | 2012 | European journal of medicinal chemistry, Feb, Volume: 48 | Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells. |
| AID533859 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium smegmatis after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID368770 | AUC (0 to 8 hrs) in fasting human plasma at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID518967 | Induction of erm(C) expression in Escherichia coli JM109 harboring Staphylococcus aureus erm(C)-containing pERMZalpha reporter plasmid at 8 mg/ml after 36 hrs at 37 degC by disc-based beta-galactosidase reporter gene assay | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of erm(C) expression by noninducing antibiotics. |
| AID747241 | Antibacterial activity against drug-resistant Klebsiella pneumoniae by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11 | Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives. |
| AID296266 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus 01-481 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID368783 | Cmax in fasting human interstitial-space fluid of skeletal muscle at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID208141 | In vivo antibacterial activity in mice infected with Streptococcus pneumoniae ATCC 6303 | 1998 | Journal of medicinal chemistry, May-07, Volume: 41, Issue:10 | Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues. |
| AID279262 | Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3665 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID547662 | Antibacterial activity against erythromycin-resistant Staphylococcus aureus 5677 by broth microdilution method | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | Synthesis and antibacterial activity of C-12 pyrazolinyl spiro ketolides. |
| AID1867248 | Antibacterial activity against multidrug resistant Helicobacter pylori JRES00015 assessed as bacterial growth inhibition incubated for 3 days by broth microdilution method | |||
| AID520874 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU90 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID112494 | In Vivo evaluation for its effective dose against Streptococcus pneumoniae (032UC1) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID372988 | Antimycobacterial activity against Mycobacterium avium JATA51-01 infected C57BL/6J mouse assessed as liver bacterial count at 200 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID326074 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae NMU112 infected CBA/J mouse assessed as median survival time at 5 mg/kg, po relative to control | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. |
| AID422687 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3413 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID571651 | Ratio of the MIC for Escherichia coli in the absence of NAB7061 to MIC for Escherichia coli in the presence of 4 ug/ml of NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID293530 | Antimycobacterial activity against Mycobacterium bovis BCG by MABA | 2007 | Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5 | Studies on acyclic pyrimidines as inhibitors of mycobacteria. |
| AID781260 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 11-20 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. |
| AID554531 | Antimicrobial activity against Mycobacterium abscessus isolate MC1448 at day 9 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID571435 | Ratio of the MIC for Escherichia coli ATCC 25992 in the absence of NAB7061 to MIC for Escherichia coli ATCC 25992 in the presence of 4 ug/ml of NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID545907 | Antimicrobial activity against Escherichia coli ATCC 25922 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID735601 | Antibacterial activity against MLS-resistant (constitutive), penicillin-resistant Streptococcus pneumoniae PU11 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID528839 | Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient blood assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID557653 | Antimicrobial activity against Mycobacterium abscessus isolate MC719 at day 7 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID644454 | Antibacterial activity against methicillin-resistant, constitutive MLS-resistant Staphylococcus epidermidis E2 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID1439722 | Bacteriostatic activity against Streptococcus pyogenes 01-968 expressing inducible ermA after 20 to 24 hrs by two-fold microbroth dilution method | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID567792 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus ANS46 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID560504 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate bd4768 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID508393 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 1077 after 29 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID87936 | Antibacterial activity was evaluated against Helicobacter pylori (9005). | 1998 | Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14 | Discovery of a novel benzyloxyisoquinoline derivative with potent anti-Helicobacter pylori activity. |
| AID425397 | Antibacterial activity against Escherichia coli isolates isolated from patients with Crohn's disease at 5 ug/disk by susceptibility testing disk method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID87963 | Minimum inhibitory concentration against Helicobacter pylori under acidic conditions at pH 7.0 | 2001 | Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25 | 3-(Arylacetylamino)-N-methylbenzamides: a novel class of selective anti-Helicobacter pylori agents. |
| AID730749 | Antibacterial activity against macrolides, lincosamides, and streptogramin B-resistant Streptococcus pyogenes 1304-00 assessed as growth inhibition | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6 | Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates. |
| AID557643 | Antimicrobial activity against Mycobacterium abscessus isolate MC723 at day 3 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID283554 | Antimicrobial activity against Streptococcus pneumoniae PC13 isolate with L4 69GTG71 to TPS mutation | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. |
| AID261462 | Antibacterial activity against Streptococcus pneumoniae 297-749 | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Synthesis and antibacterial activity of novel C12 vinyl ketolides. |
| AID1488452 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 harboring erm gene after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID535638 | Antimicrobial activity against Group B streptococcus serotype VI R2 harboring F395L, V405A, R433H, H438Y, and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility. |
| AID560513 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b6k7974 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID781264 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. |
| AID535640 | Antimicrobial activity against Group B streptococcus serotype Ib C2 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility. |
| AID572283 | Antimicrobial activity against methicillin susceptible Staphylococcus aureus ATCC 49951 infected in sc dosed NMRI mouse treated 1 and 5 hrs post infection | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. |
| AID1221956 | Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2 | Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. |
| AID381659 | Antibacterial activity against susceptible Staphylococcus aureus after 20 hrs by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13-hydroxy analogues. |
| AID644445 | Antibacterial activity against efflux, erythromycin-resistant Streptococcus dysgalactiae A 1 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID717680 | Antibacterial activity against erythromycin-sensitive Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides. |
| AID279254 | Antibacterial activity against levofloxacin resistance selected Streptococcus pneumoniae 3009 with GyrA S81Y and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID571653 | Ratio of the MIC for Klebsiella pneumoniae CCUG45421 in the absence of NAB7063 to MIC for Klebsiella pneumoniae CCUG45421 in the presence of 4 ug/ml of NAB7063 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID595940 | Cytotoxicity against HFF after 48 hrs by MTS assay | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID1677800 | Bactericidal activity against Staphylococcus aureus ATCC25923 assessed as reduction in number of colony forming units incubated for 24 hrs followed by re-plating and reincubation on tryptic soy agar plate for 24 hrs | 2020 | Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21 | Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus. |
| AID112492 | In Vivo evaluation for its effective dose against Streptococcus pneumoniae (030SJ1 EryRc) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID69935 | Antibacterial activity was evaluated against Escherichia coli (NIHJ JC-2) | 1998 | Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14 | Discovery of a novel benzyloxyisoquinoline derivative with potent anti-Helicobacter pylori activity. |
| AID567805 | Antibacterial activity against erythromycin-susceptible Haemophilus influenzae 07O114 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID548254 | Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID88103 | The compound was evaluated in vitro for the minimum inhibitory concentration against Helicobacter pylori (16021). | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative. |
| AID557929 | Antimicrobial activity against Mycobacterium abscessus isolate MC724 at day 7 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID558192 | Antimicrobial activity against Mycobacterium abscessus isolate MC1082 at day 14 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID524918 | Antimicrobial activity against Mycobacterium abscessus 390S assessed as inhibition of biofilm formation up to 512 ug/ml after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID558618 | Antimicrobial activity against Streptococcus pneumoniae isolate 3263 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID368792 | Volume of distribution at terminal phase in fasting human plasma at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID545929 | Antimicrobial activity against Enterobacter cloacae ATCC 23355 by Etest method in presence of 4 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID1868043 | Antibacterial activity against Staphylococcus aureus 15B196 by microbroth dilution method | 2022 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 68 | Design and synthesis of novel macrolones bridged with linkers from 11,12-positions of macrolides. |
| AID534338 | Antimicrobial activity against Burkholderia pseudomallei Bp250 harboring mini-Tn7T-bpeA+B+ -oprB+ after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID1487242 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID678721 | Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID558613 | Antimicrobial activity against Streptococcus pneumoniae isolate 2686 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1566604 | Antibacterial activity against Escherichia coli ATCC 25922 incubated for 24 hrs by serial dilution method | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Structure-activity relationships of potentiators of the antibiotic activity of clarithromycin against Escherichia coli. |
| AID565315 | Antibacterial activity against Mycoplasma genitalium TW48-5G by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID557644 | Antimicrobial activity against Mycobacterium abscessus isolate MC724 at day 3 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID735594 | Antibacterial activity against methicillin-resistant, MLS-resistant (constitutive) Staphylococcus aureus PU 20 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID509007 | Antimicrobial activity against methicillin susceptible Staphylococcus aureus | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. |
| AID560552 | Antimicrobial activity against Helicobacter pylori clinical isolate expressing 23S rRNA A2143G mutant by Etest | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia. |
| AID559371 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID296269 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 01-483 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID1647109 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing ermB gene by standard broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID545925 | Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of 4 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID534339 | Antimicrobial activity against Burkholderia pseudomallei 1026b after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID554651 | Antimicrobial activity against Ureaplasma urealyticum isolate HPA17 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID296275 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 01-1090 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID569031 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing the erm gene by broth microdilution method | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains. |
| AID1647108 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing ermB and me/A genes by standard broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID571433 | Antibacterial activity against Escherichia coli ATCC 25992 by Etest method in presence of 2 ug/ml NAB7062 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID557672 | Antimicrobial activity against Mycobacterium abscessus isolate MC720 at day 3 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID508421 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2686 harboring mutation in L4 ribosomal protein after 14 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID557914 | Antimicrobial activity against Mycobacterium abscessus isolate MC719 at day 3 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID558213 | Antimicrobial activity against Mycobacterium abscessus isolate MC1082 at day 5 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID558203 | Antimicrobial activity against Mycobacterium abscessus isolate MC1028 at day 9 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID725369 | Antibacterial activity against methicillin-susceptible, inducible MLS-resistant Staphylococcus epidermidis E 1 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID483703 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Synthesis and antibacterial activity of novel 4''-O-arylalkylcarbamoyl and 4''-O-((arylalkylamino)-4-oxo-butyl)carbamoyl clarithromycin derivatives. |
| AID501294 | Antibacterial activity against constitutive MLS resistance sStreptococcus pyogenes 166 GR-Micro by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID368782 | Cmax in fasting human interstitial-space fluid of subcutaneous adipose tissue at 250 mg, po | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID558179 | Antimicrobial activity against Mycobacterium abscessus isolate MC1028 at day 3 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID534342 | Antimicrobial activity against Burkholderia pseudomallei Bp58 harboring deleted bpeR::FRT gene after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID1439744 | Bactericidal activity against azithromycin-susceptible Haemophilus influenzae ATCC 49247 incubated for 20 to 24 hrs followed by sub-culturing for 24 hrs in absence of compound | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID1245728 | Ratio of MBC to MIC against azithromycin-susceptible and ampicillin-resistant Haemophilus influenzae 11P037 | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID501679 | Antimicrobial activity against efflux-mediated macrolide-resistant Staphylococcus aureus PK1 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID545935 | Ratio of MIC for Escherichia coli ATCC 25922 to MIC for Escherichia coli ATCC 25922 in presence of 4 ug/ml of NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID112490 | In Vivo evaluation for its effective dose against Streptococcus pneumoniae (030MV2 EryRc) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID558199 | Antimicrobial activity against Mycobacterium abscessus isolate MAB30 at day 7 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID547660 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 1210 by broth microdilution method | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | Synthesis and antibacterial activity of C-12 pyrazolinyl spiro ketolides. |
| AID704311 | Cellular uptake in normal human lung fibroblasts assessed as compound retention at 3 to 20 uM incubated for 3 hrs followed by drug washout measured after 3 hrs by LC-MS/MS analysis relative to initial drug accumulation | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID508450 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 2132 after 28 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID381667 | Antibacterial activity against standard Streptococcus pyogenes after 20 hrs by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13-hydroxy analogues. |
| AID559771 | Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate 4sy39 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID558193 | Antimicrobial activity against Mycobacterium abscessus isolate MAB30 at day 3 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID554519 | Antimicrobial activity against Mycobacterium abscessus isolate MC1448 at day 7 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID557912 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 at day 3 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID416839 | Antimycobacterial activity against Mycobacterium ulcerans isolate CU001 | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. |
| AID422667 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID557666 | Antimicrobial activity against Mycobacterium abscessus isolate MC720 at day 14 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID406623 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae isolates assessed as percent resistant isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea. |
| AID572852 | Antimicrobial activity against Helicobacter pylori TF4 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. |
| AID558215 | Antimicrobial activity against Mycobacterium abscessus isolate MC1028 at day 7 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1245723 | Bactericidal activity against erythromycin-susceptible Moraxella catarrhalis 11B366 incubated for 20 hrs followed by sub-culturing for 24 hrs in absence of compound | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID510554 | Antimicrobial activity against Chlamydophila pneumoniae infected in human Hep2 cells after 72 hrs by fluorescence assay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. |
| AID554552 | Antimicrobial activity against Mycobacterium smegmatis transformed with erm allele Mycobacterium abscessus isolate MC1028 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1550833 | Antimicrobial activity against constitutively erythromycin resistant and methicillin resistant Staphylococcus aureus PU20 expressing c-ermC incubated in CAMHB medium for 20 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID422666 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 after 35 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID88249 | In vitro inhibitory activity evaluated against Helicobacter pylori (HP) | 1999 | Bioorganic & medicinal chemistry letters, Jan-18, Volume: 9, Issue:2 | In vitro susceptibility of Helicobacter pylori to trifluoromethyl ketones. |
| AID112493 | In Vivo evaluation for its effective dose against Streptococcus pneumoniae (030SJ6 EryRc) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID501295 | Antibacterial activity against efflux-mediated macrolide-resistance Staphylococcus aureus PK1 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID1498838 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID565228 | Antimicrobial activity against Mycobacterium chelonae ATCC 35752 by resazurine microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs. |
| AID1550818 | Antimicrobial activity against constitutively erythromycin resistant Streptococcus pneumoniae PU27 expressing c-erm incubated in CAMHB medium for 20 to 24 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID475097 | Antibacterial activity against Streptococcus pneumoniae 9 expressing inducible ermB methylase after 20 hrs by agar dilution method | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4'' positions: Improved antibacterial activities. |
| AID724769 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 expressing mef gene by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID574705 | Enhancement of biofilm formation Staphylococcus epidermidis SW099 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID572272 | Antimicrobial activity against Streptococcus pneumoniae ATCC 6301 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. |
| AID559364 | Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID202105 | In vitro minimum inhibitory concentration for antibacterial activity against erythromycin-susceptible strain Streptococcus pneumoniae IID553 | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID1539176 | Antibacterial activity against penicillin-susceptible Pseudomonas aeruginosa ATCC 27853 incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID1459118 | Antibacterial activity against erythromycin susceptible Staphylococcus aureus infected in mouse assessed as increase in mouse survival administered orally 1 hr post infection | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID557649 | Antimicrobial activity against Mycobacterium abscessus isolate MC723 at day 5 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1677797 | Bactericidal activity against Staphylococcus aureus clinical isolate assessed as reduction in number of colony forming units incubated for 24 hrs followed by re-plating and reincubation on tryptic soy agar plate for 24 hrs | 2020 | Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21 | Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus. |
| AID535644 | Antimicrobial activity against Group B streptococcus serotype Ib N2 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility. |
| AID560503 | Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate 6zjsau7 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID558211 | Antimicrobial activity against Mycobacterium abscessus isolate MAB30 at day 5 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID571393 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 1 ug/ml NAB739 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID565229 | Antimicrobial activity against Mycobacterium chelonae ATCC 35752 harboring pZS01 carrying mspA gene by resazurine microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs. |
| AID1498829 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 11B117 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID1766092 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC43300 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 49 | Design, synthesis and antibacterial evaluation of novel 3-O-substituted 15-membered azalides possessing 1,2,3-triazole side chains. |
| AID644452 | Antibacterial activity against methicillin-resistant, coagulase-negative, constitutive MLS-resistant Staphylococcus haemolyticus PU 19 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID425612 | Cytotoxicity against mouse J774A1 cells assessed as release of adenylate kinase at 100 ug/ml after 3 hrs by total cell protein assay relative to control | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID540209 | Volume of distribution at steady state in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID426382 | Antimicrobial activity against erythromycin-resistant Streptococcus pyogenes 07Z014 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID557642 | Antimicrobial activity against Mycobacterium abscessus isolate MC720 at day 3 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID534346 | Antimicrobial activity against Burkholderia pseudomallei Bp207 harboring deleted (bpeAB-oprA)::FRT gene after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID1647111 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 by standard broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID572284 | Antimicrobial activity against methicillin susceptible Staphylococcus aureus ATCC 13709 infected in po dosed NMRI mouse treated 1 and 5 hrs post infection | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. |
| AID624623 | Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells | 2001 | The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2 | Rational use of in vitro P-glycoprotein assays in drug discovery. |
| AID1498828 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus 11B122 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID571446 | Ratio of the MIC for Klebsiella pneumoniae ATCC 13883 in the absence of NAB7061 to MIC for Klebsiella pneumoniae ATCC 13883 in the presence of 4 ug/ml of NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID528837 | Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient urine assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID372978 | Antimycobacterial activity against Mycobacterium avium JATA51-01 after 14 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID554532 | Antimicrobial activity against Mycobacterium abscessus isolate MC879-2 at day 14 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID318658 | Antibacterial activity against Streptococcus intermedius GAI 7416 by broth microdilution method | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7 | Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens. |
| AID625289 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID256386 | Inhibition of growth of Mycobacterium avium (ATCC 25291) was determined using microplate alamar blue assay at 2 ug/mL concentration with compound dissolved in DMSO | 2005 | Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22 | Design and studies of novel 5-substituted alkynylpyrimidine nucleosides as potent inhibitors of mycobacteria. |
| AID112489 | In Vivo evaluation for its effective dose against Streptococcus pneumoniae (030Cr29 EryRc) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID571437 | Antibacterial activity against Escherichia coli IH3080 by Etest method in presence of 1 ug/ml NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID557892 | Antimicrobial activity against Mycobacterium abscessus isolate MC723 at day 5 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID747245 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11 | Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives. |
| AID554529 | Antimicrobial activity against Mycobacterium abscessus isolate MC1448 at day 7 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID558221 | Antimicrobial activity against Mycobacterium abscessus isolate MC1028 at day 14 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID528847 | Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient blood assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID571452 | Ratio of the MIC for Enterobacter cloacae ATCC 23355 in the absence of NAB7061 to MIC for Enterobacter cloacae ATCC 23355 ATCC 13883 in the presence of 4 ug/ml of NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1536968 | Inhibition of LPS-induced delay of apoptosis in human neutrophils assessed as necrotic cells at 2.5 uM preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 2.1 | 2019 | Journal of natural products, 02-22, Volume: 82, Issue:2 | Eupatoriopicrin Inhibits Pro-inflammatory Functions of Neutrophils via Suppression of IL-8 and TNF-alpha Production and p38 and ERK 1/2 MAP Kinases. |
| AID296264 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus 01-430 by broth microdilution method | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12 | Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. |
| AID681127 | TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells | 2001 | Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2 | Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. |
| AID1245715 | Antimicrobial activity against erythromycin-susceptible Moraxella catarrhalis 11B366 incubated for 20 hrs by two-fold microbroth dilution method | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID1439734 | Bacteriostatic activity against methicillin-resistant Staphylococcus aureus PU32 expressing inducible ermA after 20 hrs by two-fold microbroth dilution method | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID545922 | Antimicrobial activity against in Escherichia coli IH3080 in presence of NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID279273 | Antibacterial activity against Streptococcus pneumoniae assessed as period of suppression of bacterial growth | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID381666 | Antibacterial activity against mefE efflux-resistant Streptococcus pneumoniae after 20 hrs by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13-hydroxy analogues. |
| AID373000 | Antimycobacterial activity against Mycobacterium avium complex N016 infected C57BL/6J mouse assessed as liver bacterial count at 200 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1474167 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID557657 | Antimicrobial activity against Mycobacterium abscessus isolate MC879 at day 9 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID565327 | Antibacterial activity against Mycoplasma genitalium M6151 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID554657 | Antimicrobial activity against Ureaplasma parvum SV1 isolate UHWO10 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID644447 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes A 3 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID1691426 | Antibacterial activity against MLSB/methicillin-resistant Staphylococcus aureus 15B196 assessed as reduction in microbial growth relative to ciprofloxacin | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID208135 | In vitro minimum inhibitory concentration against Streptococcus pneumoniae 5737. | 2000 | Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8 | Synthesis and antibacterial activity of novel 6-O-substituted erythromycin A derivatives. |
| AID221224 | The compound has been evaluated for the in vivo efficacy that protect 50% of mice from lethal infection by Streptococcus Pneumoniae EryRc 030MV2 strains after oral administration | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID208619 | The compound was tested in vitro for antibacterial activity against 53 strains of Streptococcus pneumoniae PenR Value is 0.3/40 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID735593 | Antibacterial activity against methicillin-susceptible, MLS-resistant (inducible) Staphylococcus aureus PU 64 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID381669 | Antibacterial activity against mefE efflux-resistant Streptococcus pyogenes after 20 hrs by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13-hydroxy analogues. |
| AID508464 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2094 harboring erm(A) gene after 22 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID87951 | Minimum inhibitory concentration against Helicobacter pylori (Helicobacter pylori) ARHp strain 206 | 2002 | Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19 | Novel structures derived from 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 2. |
| AID567803 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 07P390 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID569037 | Antimicrobial activity against erythromycin-resistant Streptococcus pyogenes R2 by broth microdilution method | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains. |
| AID560512 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b6k1642 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID1245709 | Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae PU09 incubated for 20 to 24 hrs by two-fold microbroth dilution method | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID1444599 | Antibacterial activity against Streptococcus pneumoniae ATCC 4961 by broth microdilution method | 2017 | Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8 | Synthesis of clarithromycin ketolides chemically modified at the unreactive C10-methyl group. |
| AID279270 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 24 with GyrA S81Y, GyrB P413S and ParC S79F mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID326071 | Inhibition of pneumococcal surface protein A production in Streptococcus pneumoniae NMU112 lysates at 5 ug/mL after 12 hrs by Western blot relative to control | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. |
| AID208783 | In vitro antibacterial activity against erythromycin efflux resistant Streptococcus pneumoniae 210 strain | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Synthesis and antibacterial activity of acylides (3-O-acyl-erythromycin derivatives): a novel class of macrolide antibiotics. |
| AID372989 | Antimycobacterial activity against Mycobacterium avium JATA51-01 infected C57BL/6J mouse assessed as spleen bacterial count at 200 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID528972 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient blood assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID644450 | Antibacterial activity against methicillin-, constitutive MLS-resistant erythromycin-susceptible Staphylococcus aureus PU 20 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID340006 | Antimicrobial activity against Mycobacterium smegmatis | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Antibacterial activity of labdane diterpenoids from Stemodia foliosa. |
| AID635182 | Antibacterial activity against inducible macrolide, licosamide and streptogramin-resistant Staphylococcus aureus 90256/97 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID508398 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 1077 after 49 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID554540 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 on day 14 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID625286 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID283553 | Antimicrobial activity against Streptococcus pneumoniae PC13 isolate with L4 mutation | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. |
| AID1488453 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID518970 | Induction of erm(C) expression in Escherichia coli JM109 harboring Staphylococcus aureus erm(C)-containing pERMZdelta2-4 mutant leader peptide cistrons reporter plasmid at 25 mg/ml after 36 hrs at 37 degC by disc-based beta-galactosidase reporter gene ass | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of erm(C) expression by noninducing antibiotics. |
| AID68046 | In vitro antibacterial activity against erythromycin-susceptible Enterococcus faecium ATCC 19434 strain | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Synthesis and antibacterial activity of acylides (3-O-acyl-erythromycin derivatives): a novel class of macrolide antibiotics. |
| AID1536971 | Inhibition of LPS-stimulated IL-8 production in human neutrophils at 2.5 uM after 24 hrs by ELISA | 2019 | Journal of natural products, 02-22, Volume: 82, Issue:2 | Eupatoriopicrin Inhibits Pro-inflammatory Functions of Neutrophils via Suppression of IL-8 and TNF-alpha Production and p38 and ERK 1/2 MAP Kinases. |
| AID574706 | Enhancement of biofilm formation Staphylococcus epidermidis SW115 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID524913 | Antimicrobial activity against Mycobacterium abscessus 390S | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID416844 | Antimycobacterial activity against Mycobacterium ulcerans isolate CU001 infected in BALB/c mouse left hind foot-pad assessed as bacterial load at 100 mg/kg, po administered for 5 days per week measured after 4 weeks | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. |
| AID422686 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 37 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID717681 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 09M124 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides. |
| AID440641 | Antibacterial activity against multidrug-resistant Streptococcus pneumoniae 1095 harboring ermB gene by NCCLS method | 2009 | Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23 | Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. |
| AID574697 | Enhancement of biofilm formation Staphylococcus epidermidis SW126 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID425400 | Antibacterial activity against Escherichia coli isolate HM605 isolated from colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID508400 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 24 harboring erm(B) gene after 14 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID625288 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID496383 | Antibacterial activity against nontypeable beta-lactamase-negative ampicillin-resistant Haemophilus influenzae 4437 infected in mouse ddY assessed as decrease in viable bacterial count at 40 mg/kg, po bid for 3 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. |
| AID1278502 | Antibacterial activity against Staphylococcus aureus at 15 ug/ml by disc diffusion method | 2016 | Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5 | Metal-based biologically active azoles and β-lactams derived from sulfa drugs. |
| AID576334 | Antimicrobial activity against Chlamydia trachomatis serovar D infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID558612 | Antimicrobial activity against Streptococcus pneumoniae isolate 2617 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID570204 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 205 | 2011 | ACS medicinal chemistry letters, Mar-10, Volume: 2, Issue:3 | Synthesis and antibacterial activity of a novel class of 15-membered macrolide antibiotics, "11a-azalides". |
| AID510850 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae PU-11 expressing erm and mef gene by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activities of 6-O-methylerythromycin A 9-O-(3-aryl-2-propenyl) oxime ketolide, 2,3-enol ether, and alkylide analogues. |
| AID501680 | Antimicrobial activity against macrolide-resistant Streptococcus pneumoniae Ci137 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID311524 | Oral bioavailability in human | 2007 | Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24 | Hologram QSAR model for the prediction of human oral bioavailability. |
| AID155915 | Minimum inhibitory concentration against Pasteurella multocida. | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID283551 | Antimicrobial activity against Streptococcus pneumoniae PC13 transformants | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. |
| AID1867273 | Antibacterial activity against Staphylococcus epidermidis ATCC 12228 assessed as bacterial growth inhibition incubated for 18 hrs by microdilution method | 2022 | Journal of natural products, 05-27, Volume: 85, Issue:5 | Diterpenoids from |
| AID558611 | Antimicrobial activity against Streptococcus pneumoniae isolate 1564 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID206464 | The compound has been evaluated for the antibacterial activity against Staphylococcus aureus EryRi 011GO25i strains | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID285162 | Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. |
| AID475103 | Antibacterial activity against Haemophilus influenzae 1 after 20 hrs by agar dilution method | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4'' positions: Improved antibacterial activities. |
| AID572843 | Antimicrobial activity against Helicobacter pylori | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. |
| AID557664 | Antimicrobial activity against Mycobacterium abscessus isolate MC958 at day 14 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID582683 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 assessed as concentration required to no apparent bacterial growth after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID724504 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID559366 | Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID422673 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 18 passages with levofloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID372561 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in highly mutated locus Ser-385 of ftsI gene assessed as resistance rate by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID416129 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 expressing mef gene by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6 | Synthesis and antibacterial activity of 4'',11-di-O-arylalkylcarbamoyl azithromycin derivatives. |
| AID1210299 | Apparent intrinsic clearance in Sprague-Dawley rat hepatocytes assessed per 10'6 cells at 0.1 to 10 uM up to 90 mins by conventional assay | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Utility of drug depletion-time profiles in isolated hepatocytes for accessing hepatic uptake clearance: identifying rate-limiting steps and role of passive processes. |
| AID425978 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID625290 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID475095 | Antibacterial activity against Streptococcus pneumoniae 7 expressing constitutive ermB methylase after 20 hrs by agar dilution method | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4'' positions: Improved antibacterial activities. |
| AID372554 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in variable mutated locus Asn-526 or Arg-517 of ftsI gene assessed as susceptibility rate by broth microd | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID425968 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 14 passages with gemifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID322971 | Antimicrobial activity against clarithromycin resistant-Mycobacterium avium complex 101 infected C57BL/6 beige mouse spleen assessed as bacterial load at 100 mg/kg once daily 6 days a week for 4 weeks | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium. |
| AID565316 | Antibacterial activity against Mycoplasma genitalium UTMB-10G by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID554555 | Antimicrobial activity against Mycobacterium smegmatis transformed with erm allele Mycobacterium abscessus isolate MC1028 preincubated with 2 ug/ml erythromycin for 20 to 24 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID132631 | The compound was tested in vivo for antibacterial activity against erythromycin susceptible Staphylococcus aureus 011UC4 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID560507 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b2k3421 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID704314 | Cellular uptake in human T NCI-H292 cells at 3 to 20 uM after 3 hrs by by LC-MS/MS analysis relative to azithromycin | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID502782 | Inhibition of Helicobacter pylori-induced inflammation in human AGS cells assessed as reduction of IL-8 production at 10 uM by ELISA | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Identification of 3',4',5'-trimethoxychalcone analogues as potent inhibitors of Helicobacter pylori-induced inflammation in human gastric epithelial cells. |
| AID1439723 | Bactericidal activity against Streptococcus pyogenes 01-968 expressing inducible ermA incubated for 20 to 24 hrs followed by sub-culturing for 24 hrs in absence of compound | 2017 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7 | Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides. |
| AID381665 | Antibacterial activity against ermB-inducible resistant Streptococcus pneumoniae after 20 hrs by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13-hydroxy analogues. |
| AID425401 | Antibacterial activity against Escherichia coli isolate HM615 isolated from colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID381672 | Antibacterial activity against susceptible Haemophilus influenzae after 20 hrs by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13-hydroxy analogues. |
| AID1754227 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. |
| AID496393 | Antiinflammatory activity against nontypeable beta-lactamase-negative ampicillin-resistant Haemophilus influenzae infected in mouse ddY assessed as inflammatory changes in lung at 40 mg/kg, po bid for 3 days relative to control | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. |
| AID735603 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID208613 | The compound was tested in vitro for antibacterial activity against 32 strains of inducibly erythromycin resistant Streptococcus pneumoniae Value is 40/40 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID475094 | Antibacterial activity against Streptococcus pneumoniae 6 expressing constitutive ermB methylase and mefA after 20 hrs by agar dilution method | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4'' positions: Improved antibacterial activities. |
| AID559553 | Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID554653 | Antimicrobial activity against Ureaplasma urealyticum isolate HPA20 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID535358 | Antimicrobial activity against Streptococcus pyogenes clinical isolates assessed as susceptible isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID1550820 | Antimicrobial activity against erythromycin-susceptible Streptococcus pyogenes A3 incubated in CAMHB medium for 20 to 24 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID571650 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by Etest method in presence of 4 ug/ml NAB7075 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID571642 | Antibacterial activity against Enterobacter cloacae CCUG52947 by Etest method in presence of 4 ug/ml NAB7067 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID528975 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient wound assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID372560 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in variable mutated locus Asn-526 or Arg-517 of ftsI gene assessed as resistance rate by broth microdilut | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID209868 | In vivo antibacterial activity of ATCC 6303 strain of Gram positive bacteria Streptococcus pneumoniae (95% confidence interval) | 1998 | Journal of medicinal chemistry, May-07, Volume: 41, Issue:10 | Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues. |
| AID775005 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 by broth microdilution method | 2013 | European journal of medicinal chemistry, Nov, Volume: 69 | Synthesis and antibacterial activity of novel modified 5-O-mycaminose 14-membered ketolides. |
| AID571764 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring acrB::rpsLneo mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID528971 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient urine assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID1677793 | Bacteriostatic activity against Staphylococcus aureus clinical isolate assessed as ratio of MBC to MIC | 2020 | Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21 | Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus. |
| AID1498156 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 harboring mefA gene after 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID209924 | The compound was tested in vitro for antibacterial activity against erythromycin susceptible Streptococcus pyogenes 02A1UC1 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID577492 | Half life in Staphylococcus aureus in in vitro pharmacokinetic/pharmacodynamic model at 250 mg every 12 hrs | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. |
| AID1646208 | Maximum serum concentration in human at 500 mg, po | 2020 | Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12 | Differentiating the Pharmacodynamics and Toxicology of Macrolide and Ketolide Antibiotics. |
| AID261466 | Antibacterial activity against Streptococcus pneumoniae Mef S 3427 | 2006 | Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5 | Synthesis and antibacterial activity of novel C12 vinyl ketolides. |
| AID545912 | Antimicrobial activity against Escherichia coli ATCC 25922 in presence of 32 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID558223 | Antimicrobial activity against Mycobacterium abscessus isolate MC879-2 at day 3 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID130356 | In vivo effective dose against erythromycin susceptible Staphylococcus aureus Smith strain by mouse protection test(95% confidence limits) | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Synthesis and antibacterial activity of acylides (3-O-acyl-erythromycin derivatives): a novel class of macrolide antibiotics. |
| AID422675 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 25 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID83640 | The compound has been evaluated for the antibacterial activity against Haemophilus influenzae 351HT3 (beta-lactamase +) | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID557667 | Antimicrobial activity against Mycobacterium abscessus isolate MC723 at day 14 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID637556 | Antibacterial activity against Moraxella catarrhalis 8176 by NCCLS method | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens. |
| AID1245729 | Ratio of MBC to MIC against methicillin-resistant Staphylococcus aureus PU32 expressing inducible ermA | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19 | Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity. |
| AID730384 | Antibacterial activity against macrolides, lincosamides, streptogramin B and methicillin-resistant Staphylococcus aureus 1015-00 assessed as growth inhibition | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6 | Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates. |
| AID558628 | Antimicrobial activity against Streptococcus pneumoniae isolate 3681 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID326066 | Antimicrobial activity against Streptococcus pneumoniae NMU112 | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. |
| AID1536944 | Anti-inflammatory activity in human PMN assessed as inhibition of fMLP/cytochalasin A-induced CD11b/CD18 expression by measuring CD11b/CD18 expression level at 2.5 uM preincubated for 30 mins followed by fMLP/cytochalasin A addition and measured after 30 | 2019 | Journal of natural products, 02-22, Volume: 82, Issue:2 | Eupatoriopicrin Inhibits Pro-inflammatory Functions of Neutrophils via Suppression of IL-8 and TNF-alpha Production and p38 and ERK 1/2 MAP Kinases. |
| AID635183 | Antibacterial activity against inducible macrolide-resistant, constitutive licosamide and streptogramin-resistant Streptococcus pneumoniae 134 GR-Micro by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID114694 | Effective dose when administered orally in mice infected with Streptococcus pneumoniae ATCC 6303 | 1998 | Journal of medicinal chemistry, May-07, Volume: 41, Issue:10 | Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues. |
| AID318663 | Antibacterial activity against Clostridium perfringens GAI 5526 by broth microdilution method | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7 | Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens. |
| AID524550 | Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as bactericidal at 8 times MIC in 24 hrs by time kill study | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | CEM-101 activity against Gram-positive organisms. |
| AID567804 | Antibacterial activity against erythromycin-susceptible Haemophilus influenzae ATCC 49247 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. |
| AID559559 | Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID444055 | Fraction absorbed in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID502375 | Antibacterial activity against methicillin-resistant Staphylococcus aureus BK2464 by the broth microdilution method | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | A new series of macrolide derivatives with 4''-O-saccharide substituents. |
| AID1550842 | Antimicrobial activity against azithromycin-susceptible Haemophilus influenzae ATCC 49247 incubated in HTM broth medium for 20 to 24 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID373143 | Antimycobacterial activity against Mycobacterium avium complex N084 infected C57BL/6J mouse assessed as liver bacterial count at 200 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID554526 | Antimicrobial activity against Mycobacterium abscessus isolate MC879-2 at day 5 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID554528 | Antimicrobial activity against Mycobacterium abscessus isolate MC879-2 at day 7 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID524921 | Antimicrobial activity against Mycobacterium abscessus 390S assessed as inhibition of biofilm formation up to 128 ug/ml treated during mid log-phase | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID519664 | Inhibition of PAR2-mediated IL1-beta and SLIGKV-NH2-induced interleukin-8 production in normal human epidermal keratinocytes at 10 uM by ELISA | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes. |
| AID554542 | Antimicrobial activity against Mycobacterium smegmatis transformed with erm allele Mycobacterium abscessus isolate MC958 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1550836 | Antimicrobial activity against inducibly erythromycin-resistant and methicillin resistant Staphylococcus aureus PU32 expressing i-ermA incubated in CAMHB medium for 20 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID558186 | Antimicrobial activity against Mycobacterium abscessus isolate MC1082 at day 7 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID21658 | Calculated partition coefficient (clogP) | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID440643 | Antibacterial activity against multidrug-resistant Streptococcus pyogenes 1079 harboring ermB gene by NCCLS method | 2009 | Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23 | Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. |
| AID532022 | Antimicrobial activity against Mycobacterium ulcerans 1059 harboring pTY60K containing pMH94 carrying the luxAB gene under the hsp60 promoter after 14 days determined according to CFU count by bioluminescence method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. |
| AID747244 | Antibacterial activity against drug-resistant Staphylococcus aureus by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11 | Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives. |
| AID270428 | Antibacterial activity against Enterococcus faecalis 29212 by broth microdilution method | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and antibacterial activity of C12 des-methyl ketolides. |
| AID571931 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-S623N mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID558200 | Antimicrobial activity against Mycobacterium abscessus isolate MC1028 at day 7 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID1539190 | Bactericidal activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 incubated for 24 hrs followed by re-plating on tryptic soy agar plates for 24 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID426379 | Antimicrobial activity against erythromycin-susceptible Streptococcus pyogenes 07U084 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID559359 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1427907 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID658059 | Antibacterial activity against Haemophilus influenzae ATCC 49247 after 24 hrs at 37 degC by CLSI protocol based microdilution method | 2012 | Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10 | Novel desosamine-modified 14- and 15-membered macrolides without antibacterial activity. |
| AID322982 | Antimicrobial activity against macrolide-susceptible Mycoplasma pneumoniae FH | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. |
| AID569032 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae A22072 expressing the mef gene by broth microdilution method | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains. |
| AID444051 | Total clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID571445 | Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of 4 ug/ml NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID508394 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 1077 after 50 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID557922 | Antimicrobial activity against Mycobacterium abscessus isolate MC723 at day 5 preincubated with 0.1 ug/ml for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID508460 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2094 harboring erm(A) gene after 5 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID635187 | Antibacterial activity against constitutive macrolide, licosamide and streptogramin-resistant Streptococcus pyogenes 166 GR-Micro by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID558629 | Antimicrobial activity against Streptococcus pneumoniae isolate 3791 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1766088 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC25923 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 49 | Design, synthesis and antibacterial evaluation of novel 3-O-substituted 15-membered azalides possessing 1,2,3-triazole side chains. |
| AID559555 | Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID475093 | Antibacterial activity against Streptococcus pneumoniae 5 expressing constitutive ermB methylase after 20 hrs by agar dilution method | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4'' positions: Improved antibacterial activities. |
| AID1550819 | Antimicrobial activity against constitutively erythromycin resistant Streptococcus pyogenes A2 expressing c-erm incubated in CAMHB medium for 20 to 24 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID560517 | Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate 07b63 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID560518 | Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate 15b52 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| AID557668 | Antimicrobial activity against Mycobacterium abscessus isolate MC724 at day 14 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID775001 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis ATCC 12228 by broth microdilution method | 2013 | European journal of medicinal chemistry, Nov, Volume: 69 | Synthesis and antibacterial activity of novel modified 5-O-mycaminose 14-membered ketolides. |
| AID571448 | Antibacterial activity against Enterobacter cloacae ATCC 23355 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1677799 | Bactericidal activity against methicillin-resistant Staphylococcus aureus ATCC43300 assessed as reduction in number of colony forming units incubated for 24 hrs followed by re-plating and reincubation on tryptic soy agar plate for 24 hrs | 2020 | Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21 | Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus. |
| AID557891 | Antimicrobial activity against Mycobacterium abscessus isolate MC720 at day 5 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID496382 | Antibacterial activity against nontypeable beta-lactamase-negative ampicillin-resistant Haemophilus influenzae 4437 | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. |
| AID508466 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2094 harboring erm(A) gene after 34 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID297686 | Antimycobacterial activity against Mycobacterium bovis BCG at 0.5 to 1.0 uM by microplate alamar blue assay | 2007 | Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19 | Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides. |
| AID582685 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 infected in human THP1 cells assessed as decrease of CFU after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID368795 | Free AUC (0 to 8 hrs) in human plasma at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID322964 | Antimicrobial activity against macrolide-resistant Mycobacterium avium radiometric broth nanodilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium. |
| AID557903 | Antimicrobial activity against Mycobacterium abscessus isolate MC720 at day 9 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID558198 | Antimicrobial activity against Mycobacterium abscessus isolate MC1082 at day 5 preincubated with 0.1 ug/ml erythromycin for 3 days by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. |
| AID644448 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 29213 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID1778129 | Antimicrobial activity against Pseudomonas aeruginosa assessed as microbial growth inhibition by CLSI-protocol based broth microdilution assay | 2021 | Journal of natural products, 04-23, Volume: 84, Issue:4 | Opportunities and Limitations for Assigning Relative Configurations of Antibacterial Bislactones using GIAO NMR Shift Calculations. |
| AID79582 | In vitro minimum inhibitory concentration for antibacterial activity against Haemophilus influenzae ATCC 43095 (ampicillin-susceptible strain that does not produce beta-lactamase) | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID625279 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1488450 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes R1 after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID283552 | Antimicrobial activity against Streptococcus pneumoniae PC13 isolate with erm(B) mutation | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. |
| AID724503 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID724497 | Antibacterial activity against Salmonella typhimurium TA102 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID1142218 | Antimicrobial activity against Helicobacter pylori isolated from gastrointestinal disease patient after 72 hrs by Etest method | 2014 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11 | Development of bacterial transglycosylase inhibitors as new antibiotics: moenomycin A treatment for drug-resistant Helicobacter pylori. |
| AID508430 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 7127 harboring S20N mutation in L4 ribosomal protein and A105V mutation in L22 ribosomal protein after 15 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID318659 | Antibacterial activity against Atopobium parvulum GAI 5542 by broth microdilution method | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7 | Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens. |
| AID279265 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3243 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID508443 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2686 harboring mutation in L4 ribosomal protein after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID270431 | Antibacterial activity against Streptococcus pneumoniae 49619 by broth microdilution method | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and antibacterial activity of C12 des-methyl ketolides. |
| AID1417279 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID297683 | Antimycobacterial activity against Mycobacterium avium ATCC 25291 by microplate alamar blue assay | 2007 | Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19 | Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides. |
| AID372979 | Antimycobacterial activity against Mycobacterium intracellular JATA52-01 after 14 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID368987 | Volume of distribution at steady state in human plasma at 500 mg, po, bid for 3 to 5 days | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
| AID1498839 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 by broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains. |
| AID565323 | Antibacterial activity against Mycoplasma genitalium M6285 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID202104 | In vitro minimum inhibitory concentration for antibacterial activity against erythromycin susceptible strain Streptococcus pneumoniae IID553 | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID588211 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID535346 | Antimicrobial activity against Streptococcus pneumoniae clinical isolates assessed as susceptible isolates by PK/PD technique | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID475104 | Antibacterial activity against Haemophilus influenzae 2 after 20 hrs by agar dilution method | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4'' positions: Improved antibacterial activities. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 68 (1.01) | 18.7374 |
| 1990's | 1492 (22.17) | 18.2507 |
| 2000's | 2443 (36.31) | 29.6817 |
| 2010's | 2006 (29.81) | 24.3611 |
| 2020's | 720 (10.70) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (117.80) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1,606 (22.46%) | 5.53% |
| Reviews | 706 (9.88%) | 6.00% |
| Case Studies | 1,115 (15.60%) | 4.05% |
| Observational | 36 (0.50%) | 0.25% |
| Other | 3,686 (51.56%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind Randomized Placebo-controlled Clinical Trial of the Safety and Efficacy of Intravenous Clarithromycin as Immunomodulatory Therapy for the Management of Sepsis [NCT01223690] | Phase 3 | 600 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Helicobacter Pylori Eradication According to Sequencing-based 23S Ribosomal RNA Point Mutation Associated With Clarithromycin Resistance [NCT03884348] | 431 participants (Actual) | Observational | 2017-01-01 | Completed | |||
| Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene [NCT01289756] | Phase 1 | 20 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Efficacy of Clarithromycin or Moxifloxacin Containing Regimen in 6 Months Sputum Conversion of Mycobacterium Xenopi [NCT01298336] | Phase 3 | 92 participants (Actual) | Interventional | 2011-03-02 | Completed | ||
| A Phase 2/3, Multicenter, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobac [NCT04630145] | Phase 2/Phase 3 | 124 participants (Anticipated) | Interventional | 2021-01-08 | Recruiting | ||
| 14-day PCAB-based and Reverse Hybrid Therapy Fro Helicobacter Pylori [NCT05191888] | Phase 4 | 906 participants (Anticipated) | Interventional | 2021-08-06 | Recruiting | ||
| A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection [NCT01219764] | Phase 4 | 200 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Helicobacter Pylori and Gastric Cancer - the Role of Cytokine Polymorphism, Cytokine Expression and Expression of TLR on Persistence of Helicobacter Pylori Infection and Development of Gastric Cancer. [NCT01137942] | 14 participants (Anticipated) | Observational | 2008-11-30 | Recruiting | |||
| An Open-label, Single-center, Study in Healthy Subjects to Investigate the Effect of Oral Clarithromycin on the Pharmacokinetics of Givinostat (PART 2) [NCT05845567] | Phase 1 | 20 participants (Actual) | Interventional | 2022-03-21 | Completed | ||
| GEM-CLARIDEX: Lenalidomide and Dexamethasone (Ld) Versus Clarithromycin / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as Initial Therapy in Multiple Myeloma [NCT02575144] | Phase 3 | 286 participants (Actual) | Interventional | 2015-09-30 | Active, not recruiting | ||
| THE EFFECT OF HELICOBACTER PYLORI ERADICATION THERAPY TO GASTRIC WALL THICKNESS BEFORE THE LAPAROSCOPIC SLEEVE GASTRECTOMY [NCT03757650] | Phase 4 | 3 participants (Actual) | Interventional | 2018-10-01 | Completed | ||
| A Phase 1, Open-label, 2-cohort, Fixed-sequence, Drug-drug Interaction Study to Investigate the Potential Interaction Between ATI-2173 When Coadministered With Midazolam or Clarithromycin in Healthy Subjects [NCT05137600] | Phase 1 | 36 participants (Actual) | Interventional | 2021-10-28 | Completed | ||
| Antibiotic Susceptibility-based Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy: a Prospective Clinical Trial [NCT03708848] | Phase 4 | 112 participants (Actual) | Interventional | 2018-12-05 | Completed | ||
| A Double-blind Randomised Controlled Trial on Flufenamic Acid for Hospitalised Influenza Infection [NCT03238612] | Phase 2 | 200 participants (Anticipated) | Interventional | 2018-01-08 | Recruiting | ||
| Comparison of the Efficacy of 14-day Sequential Therapy and 10-day Bismuth Quadruple Therapy in the Second Line Therapy for Helicobacter Pylori Infection: A Multi-center Randomized Trial [NCT03208426] | Phase 4 | 240 participants (Anticipated) | Interventional | 2017-10-01 | Recruiting | ||
| Is Clarithromycin a Potential Treatment for Cachexia in People With Lung Cancer? [NCT02416570] | Phase 2 | 1 participants (Actual) | Interventional | 2015-04-30 | Terminated(stopped due to At 6 months 1 participant recruited. Study deemed not feasible and discontinued.) | ||
| A Prospective, Single-center, Open-label, Clinical Trial to Compare the 10-day Sequential Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter Pylori [NCT02373280] | 600 participants (Anticipated) | Interventional | 2014-08-31 | Recruiting | |||
| Evaluation of Effects, Safety, Viral Load and Antibody Level of Functional Food Dietary Supplement Containing Grape Products in Controlled, Randomized Study Using SARSCoV-2 RT-PCR Positive Covid-19 Patients. [NCT05417997] | Phase 3 | 71 participants (Actual) | Interventional | 2021-05-29 | Completed | ||
| Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection-A Randomized Clinical Trial [NCT03658746] | Phase 4 | 420 participants (Actual) | Interventional | 2019-01-01 | Completed | ||
| Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan [NCT04853875] | Phase 4 | 104 participants (Actual) | Interventional | 2021-04-19 | Completed | ||
| Comparison of Genotypic Resistance Guided Versus Susceptibility Testing Guided Therapy for the Third-line Eradication of H. Pylori- a Multicenter Randomized Trial [NCT03555526] | Phase 4 | 320 participants (Anticipated) | Interventional | 2017-12-15 | Recruiting | ||
| An Open Label, Randomized, Two Way Cross Over, Two Period, Two Treatment, Two Sequence Bioequivalence Study of Klaribact (Clarithromycin) 125mg/5ml Suspension Compared With Klaricid (Clarithromycin) 125mg/5ml Suspension in 24 Healthy Adult Subjects Under [NCT05340452] | 24 participants (Actual) | Interventional | 2013-06-29 | Completed | |||
| [NCT02090738] | Phase 2 | 0 participants (Actual) | Interventional | 2014-03-31 | Withdrawn | ||
| Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240] | Early Phase 1 | 11 participants (Actual) | Interventional | 2014-03-06 | Terminated(stopped due to Not enough patient enrollment and lack of staffing) | ||
| 10-Day Antimicrobial Susceptibility Testing Guided Triple Therapy Versus 14-Day Empirical Tailored Therapy for the First-line Treatment of Helicobacter Pylori Infection-A Randomized Controlled Trail [NCT03571230] | Phase 4 | 400 participants (Anticipated) | Interventional | 2018-07-01 | Not yet recruiting | ||
| Outcome Study to Evaluate the Role of Klaricid XL (Clarithromycin Modified Release) in the Treatment of Acute Exacerbation of Chronic Bronchitis (AECB) and Its Impact on Quality of Life Measured by St. George's Respiratory Questionnaire (SGRQ) [NCT01354938] | 220 participants (Actual) | Observational | 2011-05-31 | Completed | |||
| An Open-label, Randomized, 6-Sequence, 3-Period Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between CJ-12420 and Clarithromycin in Healthy Male Subjects [NCT02052336] | Phase 1 | 24 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Anti-Helicobacter Pylori Therapy With Dexlansoprazole MR-Based Concomitant Quadruple Therapy- A Prospective Randomized Trial [NCT03829150] | 202 participants (Actual) | Interventional | 2017-03-01 | Completed | |||
| A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy With Oral Vonoprazan 20 mg or Double-Blind Triple Therapy With Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy With Oral Lansoprazole 30 mg [NCT04167670] | Phase 3 | 1,046 participants (Actual) | Interventional | 2019-12-10 | Completed | ||
| A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab [NCT04302324] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-10-28 | Recruiting | ||
| A Phase 3, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of a Triple Therapy With Tegoprazan, Amoxicillin, and Clarithromycin in H. Pylori Positive Patients [NCT03498456] | Phase 3 | 284 participants (Actual) | Interventional | 2018-06-28 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled Clinical Study of the Efficacy of Intravenous Clarithromycin as Adjunctive Treatment in Patients With Sepsis and Respiratory and Multiple Organ Dysfunction Syndrome [NCT03345992] | Phase 3 | 110 participants (Actual) | Interventional | 2017-12-15 | Completed | ||
| An Open-label, Fixed-sequence, Phase 1 Clinical Trial to Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults [NCT05991401] | Phase 1 | 18 participants (Anticipated) | Interventional | 2023-08-18 | Recruiting | ||
| A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Relative Bioavailability of a Test Extended Release Tablet Formulation of Clarithromycin (500 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Pro [NCT00840411] | Phase 1 | 66 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study [NCT03130452] | Phase 4 | 280 participants (Anticipated) | Interventional | 2017-02-01 | Active, not recruiting | ||
| Open-Label Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of ELPIDA® in Co-Administration With Other Drugs in Healthy Volunteers [NCT03709355] | Phase 1 | 56 participants (Actual) | Interventional | 2018-11-14 | Completed | ||
| Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori [NCT02422706] | Phase 3 | 120 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura [NCT03172676] | Phase 4 | 75 participants (Anticipated) | Interventional | 2020-01-01 | Recruiting | ||
| Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan [NCT03516669] | Phase 4 | 20 participants (Actual) | Interventional | 2018-05-07 | Completed | ||
| Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication [NCT03650543] | Phase 4 | 133 participants (Actual) | Interventional | 2012-09-10 | Completed | ||
| Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital [NCT02068170] | 178 participants (Actual) | Observational | 2014-02-28 | Completed | |||
| The Evaluation of Saccharomyces Boulardii Sachets Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori: a Prospective, Multi-Center Trial [NCT03688828] | 360 participants (Actual) | Interventional | 2018-11-11 | Completed | |||
| A Randomized Controlled Trial of Triple Therapy Versus Sequential Therapy Versus Concomitant Therapy as First Line Treatment for Helicobacter Pylori Infection [NCT02092506] | Phase 4 | 462 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Efficacy of Clarithromycin and Flouroquinolones Based Regimens in H.Pylori Eradication in Covid-19 Era: a Randomized Controlled Trial [NCT05035186] | 233 participants (Actual) | Interventional | 2021-03-21 | Completed | |||
| High-Dose Dual Therapy vs Standard Triple Therapy for Treatment-Naïve H. Pylori: A Prospective Randomized Control Trial in a Diverse Urban New York City Population [NCT05342532] | Phase 4 | 112 participants (Actual) | Interventional | 2019-06-12 | Completed | ||
| Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial [NCT03134378] | Phase 4 | 73 participants (Anticipated) | Interventional | 2016-10-03 | Recruiting | ||
| Helicobacter Pylori Resistance. A Study of Morbidity, Immunological and Clinical Phenotypes [NCT05019586] | 185 participants (Actual) | Observational | 2010-04-15 | Completed | |||
| A Randomized, Open-label, Multiple Dose, Two-part Phase I Clinical Trial to Compare the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of DWP14012 After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxici [NCT03487562] | Phase 1 | 48 participants (Actual) | Interventional | 2018-04-08 | Completed | ||
| An Open-Label, Fixed-Sequence Study to Assess Effects of Clarithromycin on the Single-Dose Pharmacokinetics of JNJ-54861911 in Healthy Male Subjects [NCT02197884] | Phase 1 | 13 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| A Phase 1, Open-label, Drug Interaction Study to Investigate the Effect of Multiple Doses of Clarithromycin on the Pharmacokinetics of LY3502970 in Healthy Participants [NCT05469126] | Phase 1 | 26 participants (Actual) | Interventional | 2022-08-01 | Completed | ||
| A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Relative Bioavailability of a Test Extended Release Tablet Formulation of Clarithromycin (500 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Pro [NCT00840216] | Phase 1 | 22 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| A Relative Bioavailability Study of 500 mg Clarithromycin Tablets Under Non-Fasting Conditions [NCT00836706] | Phase 1 | 24 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| A Relative Bioavailability Study of 500 mg Clarithromycin Tablets Under Fasting COnditions [NCT00835692] | Phase 1 | 60 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| Study the Efficacy of Lactoferrin in Helicobacter Pylori Eradication Either With Standard Triple Therapy or Sequential Therapy in Egyptian Patients [NCT04445948] | Phase 4 | 400 participants (Actual) | Interventional | 2019-11-30 | Completed | ||
| Local Effect of Periodontal Debridement Associated With Different Systemic Antibiotic Protocols and Single or Repeated Application of Photodynamic Therapy to Treat Generalized Aggressive Periodontitis: Randomized Controlled Clinical Trial [NCT03132714] | Phase 2/Phase 3 | 46 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Helicobacter Pylori and Chronic Dyspepsia in Eastern Uganda [NCT04525664] | Early Phase 1 | 376 participants (Actual) | Interventional | 2018-10-01 | Completed | ||
| Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) [NCT04310930] | Phase 2/Phase 3 | 300 participants (Anticipated) | Interventional | 2020-03-02 | Recruiting | ||
| A Randomized, Open-label, Multiple-dose, 3-way Crossover Phase 1 Clinical Trial to Evaluate Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers [NCT05194046] | Phase 1 | 29 participants (Actual) | Interventional | 2020-11-18 | Completed | ||
| A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication [NCT03716622] | Phase 4 | 350 participants (Actual) | Interventional | 2018-07-31 | Completed | ||
| Medico-economic Evaluation of a Therapeutic Strategy Based on Molecular Detection of Antibiotic Resistance in the Management of H Pylori Infection [NCT01168063] | 1,386 participants (Actual) | Interventional | 2010-02-28 | Completed | |||
| Persistent Lyme Empiric Antibiotic Study Europe. A Prospective, Randomised Study Comparing Two Prolonged Oral Antibiotic Strategies After Initial Intravenous Ceftriaxone Therapy for Patients With Symptoms of Proven or Possible Persistent Lyme Disease [NCT01207739] | Phase 4 | 280 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Efficacy of Tailored for Helicobacter Pylori Rescue Treatment Based on Antimicrobial-susceptibility Testing [NCT03413020] | Phase 4 | 200 participants (Actual) | Interventional | 2018-01-03 | Completed | ||
| Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication - A Prospective, Comparative Study [NCT01163435] | Phase 4 | 618 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| "Drug Use Surveillance of Takecab Tablets Supplement to Helicobacter Pylori Eradication" [NCT03219723] | 560 participants (Actual) | Observational | 2015-09-01 | Completed | |||
| Intraluminal Therapy for Helicobacter Pylori Infection [NCT03124420] | Phase 4 | 100 participants (Actual) | Interventional | 2017-04-28 | Completed | ||
| A Phase 1, Double-Blind, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Quadruple Therapy (Bismuth, Clarithromycin, and Amoxicillin) With TAK-438 Versus Quadruple Therapy With Lansoprazole [NCT02892409] | Phase 1 | 30 participants (Actual) | Interventional | 2016-09-05 | Completed | ||
| Study on The Efficacy and Safety of Berberine,Amoxicillin and Vonoprazan Containing Triple Therapy in Helicobacter Pylori First-Line Eradication [NCT05014334] | Phase 4 | 300 participants (Actual) | Interventional | 2021-12-01 | Completed | ||
| Efficacy and Safety of Berberine Hydrochloride, Amoxicillin and Rabeprazole Triple Therapy in the First Eradication of Helicobacter Pylori [NCT04697186] | Phase 4 | 524 participants (Actual) | Interventional | 2021-01-07 | Completed | ||
| [NCT02873065] | Phase 4 | 0 participants | Interventional | 2014-09-30 | Completed | ||
| A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection [NCT06050824] | Phase 4 | 200 participants (Actual) | Interventional | 2022-07-21 | Completed | ||
| Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice [NCT01273441] | Phase 4 | 338 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Randomized Placebo-controlled Phase II Study of Clarithromycin or Placebo Combined With VCD Induction Therapy Prior to High-dose Melphalan With Stem Cell Support in Patients With Newly Diagnosed Multiple Myeloma [NCT02573935] | Phase 2 | 58 participants (Actual) | Interventional | 2015-01-31 | Terminated(stopped due to Suspected side effects to the combination of clarithromycin and VCD (bortezomib, cyclophosphamide and dexamethasone)) | ||
| Comparative Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control on the Gastric Lesions Induced by the Aspirin With the Low Dose Among Patients Treated With the Long Course [NCT00713947] | Phase 4 | 0 participants (Actual) | Interventional | 2008-04-30 | Withdrawn(stopped due to no inclusion) | ||
| A Prospective, Multicenter, Single Arm, Phase II Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone (BiRd Regimen) in the Treatment of the First Relapsed Multiple Myeloma [NCT04063189] | Phase 2 | 100 participants (Anticipated) | Interventional | 2017-03-21 | Recruiting | ||
| A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of 500 mg Clarithromycin Tablets Under Fed Conditions [NCT00602498] | 28 participants (Actual) | Interventional | 2003-03-31 | Completed | |||
| An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover, Bioavailability Study on Clarithromycin Formulations Comparing Clarithromycin 250 mg/5 mL Powder for Oral Suspension of Ranbaxy Laboratories With Biaxin® [NCT00775255] | 40 participants (Actual) | Interventional | 2005-09-30 | Completed | |||
| Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given X 10 Days With Omeprazole in Eradication of Helicobacter Pylori: A Comparison to Omeprazole, Amoxicillin and Clarithromycin Given X 7 Days [NCT00669955] | Phase 3 | 440 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Effect of Eradication of Helicobacter Pylori on the Dyspeptic Symptoms. [NCT00772837] | 370 participants (Actual) | Interventional | 2006-08-31 | Completed | |||
| Tailored Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Randomized Trial [NCT02635191] | Phase 4 | 200 participants (Anticipated) | Interventional | 2014-03-31 | Recruiting | ||
| A Randomized Clinical Trial of Oral Clarithromycin in Community-acquired Pneumonia to Attenuate Inflammatory Responses and Improve Outcomes: the ACCESS Clinical Trial [NCT04724044] | Phase 3 | 278 participants (Actual) | Interventional | 2021-01-25 | Completed | ||
| Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane, Phase III Study. [NCT01503606] | Phase 3 | 151 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions [NCT00881179] | Phase 1 | 24 participants (Actual) | Interventional | 2002-05-31 | Completed | ||
| Study of RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease in Adults With Nodular Bronchiectasis (CleaR-MAC Trial) [NCT04616924] | Phase 3 | 125 participants (Anticipated) | Interventional | 2020-12-01 | Active, not recruiting | ||
| An Open-label, Single-center, Three-part Study in Healthy Subjects to Investigate the Effect of Givinostat on the Pharmacokinetics of Midazolam and Dabigatran, the Effect of Clarithromycin on the Pharmacokinetics of Givinostat and the Pharmacokinetics of [NCT05492318] | Phase 1 | 54 participants (Actual) | Interventional | 2022-03-21 | Completed | ||
| Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication [NCT02547038] | 352 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Relative Bioavailability of Dabigatran After Single Oral Administration of 150 mg Dabigatran Etexilate (Capsule) With or Without Multiple Oral Administration of 500 mg Clarithromycin (Tablet) Bid in Healthy Male and Female Volunteers (an Open Label, Fixed [NCT02171585] | Phase 1 | 20 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| A Single-center, Randomized, Open-label, Crossover Study to Evaluate the Pharmacokinetic Drug-drug Interaction of the Quadruple Therapy With Anaprazole/Amoxicilin/Clarithromycin/Bismuth in Healthy Chinese Male Subjects [NCT04444011] | Phase 1 | 32 participants (Anticipated) | Interventional | 2020-07-01 | Not yet recruiting | ||
| Helicobacter Eradication to Prevent Ulcer Bleeding in Aspirin Users: a Large Simple Randomised Controlled Trial [NCT01506986] | Phase 4 | 30,024 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Comparing the Efficacy and Impact on Gastrointestinal Microbiota of Reverse Hybrid Therapy and Concomitant Therapy in Helicobacter Pylori Eradication [NCT02646332] | 248 participants (Actual) | Interventional | 2015-12-31 | Completed | |||
| Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology [NCT05742568] | Phase 4 | 120 participants (Anticipated) | Interventional | 2022-12-01 | Recruiting | ||
| An Open-Label, Randomized Trial of Four Treatment Regimens for Patients With Disseminated Mycobacterium Avium Complex Disease and Acquired Immunodeficiency Syndrome (AIDS) [NCT00001047] | Phase 3 | 400 participants | Interventional | Completed | |||
| A Phase 2, Open-Label, Single-Arm Study of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma [NCT04843579] | Phase 2 | 4 participants (Actual) | Interventional | 2021-12-29 | Terminated(stopped due to low enrollment) | ||
| A Single-centre Open-label Study in Healthy Adult Volunteers to Determine the Effects of Single-dose and Steady-state TPV/r (500 mg/200 mg) on the Steady-state Pharmacokinetics of Clarithromycin (BIAXIN®) 500 mg Bid and a Preliminary Assessment of the Eff [NCT02251769] | Phase 1 | 24 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| Vonoprazan-based Therapy Versus Standard Regimen for Helicobacter Pylori Infection Management [NCT05614934] | Phase 4 | 81 participants (Anticipated) | Interventional | 2022-06-11 | Recruiting | ||
| Prospective, Randomized Controlled Trial Comparing Amoxicillin and Metronidazole Based Bismuth-containing Quadruple Therapy With Amoxicillin and Clarithromycin Based Quadruple Therapy for First-line Helicobacter Pylori Eradication [NCT02175901] | Phase 4 | 215 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Effectiveness of Rifabutin Triple Therapy for First-line and Rescue Treatment of Helicobacter Pylori Infection [NCT04652284] | Phase 3 | 300 participants (Anticipated) | Interventional | 2021-05-01 | Not yet recruiting | ||
| A Randomized Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral TAK-438 20 mg Compared to Esomeprazole 20 mg Twice Daily in Subjects With Helicobacter Pylori Infection [NCT04198363] | Phase 3 | 510 participants (Actual) | Interventional | 2020-04-30 | Completed | ||
| A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin (A Drug Interaction Study With a CYP3A4/5 Inhibitor or Inducer) [NCT04070495] | Phase 1 | 20 participants (Actual) | Interventional | 2019-08-27 | Completed | ||
| Tailored Antibiotic Susceptibility-guided Therapy Via Gastric Juice PCR for First-line H Pylori Eradication, a Prospective Randomized Controlled Trial [NCT04061447] | 182 participants (Actual) | Interventional | 2016-02-05 | Completed | |||
| Prospective Study of the Effects of Helicobacter Pylori Eradication on Renal Functions and Proteinuria in Patients With Membranous Nephropathy [NCT00983034] | 70 participants (Actual) | Interventional | 2006-03-31 | Completed | |||
| Lenalidomide and Dexamethasone (Rd) Versus Clarithromycin [Biaxin®] / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as Initial Therapy in Multiple Myeloma [NCT02516696] | Phase 3 | 12 participants (Actual) | Interventional | 2016-02-29 | Terminated(stopped due to low enrollment) | ||
| Helicobacter Pylori Eradication Therapy on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection of Gastric Neoplastic Lesions: a Multicenter, Randomized, Double Blind, and Placebo Controlled Trial [NCT00926809] | Phase 4 | 232 participants (Anticipated) | Interventional | 2008-09-30 | Recruiting | ||
| Effect of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects [NCT06005714] | Phase 1 | 36 participants (Actual) | Interventional | 2023-08-15 | Active, not recruiting | ||
| The Observation on the Efficacy of Dual Therapy Based on Vonoprazan in Eradicating Helicobacter Pylori [NCT06004401] | 400 participants (Anticipated) | Interventional | 2023-08-20 | Not yet recruiting | |||
| Comparison Efficacy of 14-day Triple Therapy Between Clarithromycin and Levofloxacin on the Eradication of Helicobacter Pylori in Syrian Population [NCT02693574] | Phase 4 | 74 participants (Actual) | Interventional | 2015-12-01 | Active, not recruiting | ||
| A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Clarithromycin Extended Release for the Treatment of Mild to Moderate Community-Acquired Pneumonia in Adults [NCT00643227] | Phase 3 | 504 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| A Phase IIIB/IV Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets vs. Amoxicillin-Clavulanate for the Treatment of Subjects With Acute Bacterial Sinusitis [NCT00644553] | Phase 3 | 437 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Construction and Application of the Treatment of Refractory Helicobacter Pylori Infection Based on the High-throughput Sequencing Technologies [NCT02741414] | 4,428 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | |||
| Single Dose Crossover Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Healthy Male and Female Volunteers / Fasting State [NCT00648960] | Phase 1 | 64 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| A Phase 1, Open-Label, Drug-Interaction Study to Evaluate the Effect of Clarithromycin, a Potent CYP3A4 Inhibitor, on the Systemic Exposure of Pacritinib in Healthy Subjects [NCT02807051] | Phase 1 | 20 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| A Phase III Comparative Efficacy Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Subjects With Acute Bacterial Exacerbation of Chronic Bronchitis. [NCT00645086] | Phase 3 | 465 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Single Dose Crossover Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Healthy Male and Female Volunteers / Fed State [NCT00648128] | Phase 1 | 44 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Randomized Single Dose Crossover Replicate Comparative Bioavailability Study of Clarithromycin 250 mg Tablets in Healthy Male and Female Volunteers Under Fasted Conditions [NCT00648830] | Phase 1 | 32 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Sequential Helicobacter Pylori Eradication Therapy in Myanmar; a Randomized Clinical Trial of Efficacy and Tolerability [NCT04132479] | Phase 4 | 313 participants (Actual) | Interventional | 2018-01-01 | Completed | ||
| A Randomized Clinical Trial of Clarithromycin/Bismuth Containing Quadruple Therapy for Helicobacter Pylori First-line Treatment [NCT02732249] | Phase 4 | 66 participants (Actual) | Interventional | 2016-04-01 | Completed | ||
| A Double-Blinded, Randomized, Parallel Group, Multi-Center, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300 mg QD to Clarithromycin 250 mg BID for the Treatment of Community-Acquired Pneumonia in Adults [NCT00336544] | Phase 3 | 522 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Maintenance Therapy With Lenalidomide, Dexamethasone and Clarithromycin (Biaxin) Following Autologous/Syngeneic Transplant for Multiple Myeloma [NCT00445692] | Phase 2 | 32 participants (Actual) | Interventional | 2007-01-10 | Completed | ||
| A Phase II Study of Thalidomide (THALOMID®), Clarithromycin (BIAXIN®), Lenalidomide(REVLIMID®), and Dexamethasone (DECADRON®) for Subjects With Newly Diagnosed Multiple Myeloma [NCT00538733] | Phase 2 | 26 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [NCT01326611] | Phase 4 | 273 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections. Can Measurement of Procalcitonin Reduce the Use of Antibiotics? [NCT02171338] | Phase 4 | 55 participants (Anticipated) | Interventional | 2013-10-31 | Active, not recruiting | ||
| A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients [NCT04101708] | Phase 4 | 100 participants (Anticipated) | Interventional | 2019-09-20 | Not yet recruiting | ||
| "Comparison of Treatment Satisfaction and Treatment Adherence of a Novel Application Form Dose Sipping Technology (DST) of Oral Clarithromycin vs. Clarithromycin Syrup in Children Suffering From Acute Otitis Media, Tonsillitis, Pharyngitis, or Acute Bacte [NCT04016051] | Phase 3 | 265 participants (Actual) | Interventional | 2004-09-22 | Completed | ||
| Comparative Recurrence Rate Investigation of Esomeprazole Versus Lansoprazole in Triple-Combination Therapy to Eradicate Helicobacter Pylori Infection Among Pediatrics: Multicentre, Randomized, and Controlled Trials [NCT05861687] | Phase 2/Phase 3 | 51 participants (Actual) | Interventional | 2021-08-01 | Completed | ||
| Efficacy and Safety of Black Seed Oil With Vonoprazan Based Triple Therapy in Treatment of Helicobacter Pylori [NCT05957432] | Phase 2 | 90 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| Multicenter, Randomized, And Double-Blind Study To Evaluate The Safety Of Tigecycline Versus A Ceftriaxone Regimen In The Treatment Of Complicated Intra-Abdominal Infections And Community-Acquired Pneumonia In Subjects Of 8-17 Years [NCT00914888] | Phase 3 | 0 participants (Actual) | Interventional | 2011-01-31 | Withdrawn | ||
| An Open Label, Balanced, Randomised, Two-Treatment, Four-Period, Two- Sequence, Single-Dose, Crossover Fully Replicated, Bioavailability Study on Clarithromycin Formulations Comparing Clarithromycin 250 mg/5 mL Powder for Oral Suspension of Ranbaxy Labora [NCT00775372] | 40 participants | Interventional | 2005-09-30 | Completed | |||
| Comparison Between Tailored Therapy Guided by a Non-invasive Antibiotic Susceptibility Test and Empiric Treatment for First-line Helicobacter Pylori Eradication in Patients With Dyspepsia: a Randomized Controlled Trial. [NCT04107194] | Phase 3 | 362 participants (Anticipated) | Interventional | 2020-01-14 | Recruiting | ||
| A Randomized, Single Blinded, Open-Label Crossover-Study of the Possible Induction of Oxidative Stress by Clarithromycin in Healthy Subjects [NCT00707330] | Phase 1 | 26 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A National, Prospective, Randomized, Open Label Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin vs IV Ceftriaxone + IV Azithromycin Followed by PO Amoxicilline/Clavulanate and PO Clarithromycin in Subjects With Community-acquired Pneumonia [NCT00717561] | Phase 3 | 60 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Clarithromycin Formulations, Comparing Clarithromycin 250 mg Tablets of Ranbaxy Laboratories With Biaxin 250 mg Tablets of Abbott [NCT00774189] | Phase 1 | 32 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination Therapy vs. Oseltamivir Alone for Hospitalised Paediatric Influenza Patients [NCT04315194] | 54 participants (Actual) | Observational [Patient Registry] | 2017-12-18 | Completed | |||
| Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection - A Prospective Randomized, Comparative Study [NCT05332444] | Phase 4 | 450 participants (Anticipated) | Interventional | 2022-04-11 | Recruiting | ||
| The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in Helicobacter Pylori Patients [NCT02648659] | Phase 4 | 50 participants (Actual) | Interventional | 2016-03-02 | Completed | ||
| A Randomized Clinical Trial to Examine the Efficacy of a Clarithromycin-, Amoxicillin-, and Metronidazole-Based Regimen to Eradicate Helicobacter Pylori Infections in Pasto, Colombia [NCT00719420] | Phase 3 | 151 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| A Drug-Drug Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Patients With B-Cell Malignancies [NCT04551963] | Phase 1 | 26 participants (Actual) | Interventional | 2020-11-15 | Completed | ||
| Comparison of Dual Amoxicillin/Vonoprazan Therapy and Triple Vonoprazan/Amoxicillin/Clarithromycin or Metronidazole Therapy for H. Pylori Eradication [NCT02827942] | Phase 3 | 112 participants (Actual) | Interventional | 2016-07-01 | Completed | ||
| Traditional Chinese Medicine Combined With Standard Triple Region for Eradication of Helicobacter Pylori: a Prospective, Double-blinded, Randomized Trial [NCT02803216] | Phase 1/Phase 2 | 576 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| A Multi-center, Post-Marketing Observational Study to Identify the Recovery Time in Children With Lower Respiratory Tract Infections Treated With Klacid Granules for Oral Suspension. [NCT01076166] | 337 participants (Actual) | Observational | 2009-04-30 | Completed | |||
| Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection [NCT02711176] | Phase 4 | 212 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| A Phase II Study of Dexamethasone (DECADRON®), Clarithromycin (BIAXIN®), and Pomalidomide (CC-4047®) for Subjects With Relapsed or Refractory Multiple Myeloma [NCT01159574] | Phase 2 | 121 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Investigation Drug-drug Interaction Between Dabigatran and Clarithromycin [NCT01385683] | Phase 1 | 10 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Randomized Phase III Trial of Cefazolin or Combination of Cefazolin and Erythromycin or Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of the Membranes [NCT01401179] | Phase 3 | 101 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| A Double-Blinded, Randomized, Parallel Group, Multi-Center, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300 mg QD to Clarithromycin (BIAXIN® Filmtab®) 250 mg BID for the Treatment of Community-Acquired Pneumonia in Adults [NCT00336505] | Phase 3 | 584 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Relative Bioavailability of Clarithromycin 250 mg Tablets Under Fasting Conditions [NCT00881738] | Phase 1 | 32 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| A Randomized, Open-label Phase III Study of Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Combination With Standard Therapy in Patients With Newly Diagnosed Multiple Myeloma [NCT02624440] | Phase 2 | 300 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| The Objective of This Study is to Compare the Relative Bioavailability of Clarithromycin 500 mg Tablets (Ranbaxy Laboratories Limited) With That of BIAXIN® 500 mg Tablets in Healthy, Adult Subjects Under Non-Fasting Conditions. [NCT00774696] | 24 participants | Interventional | 2002-12-31 | Completed | |||
| The Objective of This Study is to Compare the Relative Bioavailability of Clarithromycin 500 mg Tablets (Ranbaxy Laboratories Limited) With That of BIAXIN® 500 mg Tablets in Healthy, Adult Subjects Under Fasting Conditions. [NCT00774644] | 33 participants (Actual) | Interventional | 2002-12-31 | Completed | |||
| Beta-lactam Monotherapy Versus Beta-lactam - Macrolide Association as Empiric Antibiotherapy Strategies in Non-severe Hospitalized Community-acquired Pneumonia: a Randomized, Non-inferiority, Open Trial. [NCT00818610] | Phase 4 | 601 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Phase II Study of Clarithromycin (Biaxin), Lenalidomide (Revlimid), and Dexamethasone (Decadron) for Newly Diagnosed Subjects With Multiple Myeloma [NCT00151203] | Phase 2 | 50 participants (Anticipated) | Interventional | 2004-12-31 | Completed | ||
| A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone, With Adjunctive Clarithromycin, in the Treatment of Adult Subjects With Community-Acquired Pneumonia [NCT00621504] | Phase 3 | 606 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| A Phase II Clinical Trial of Dehydroepiandrosterone and Biaxin in Monoclonal Gammopathy of Undetermined and Borderline Significance [NCT00006219] | Phase 2 | 0 participants | Interventional | 2000-08-31 | Completed | ||
| A Prospective, Randomized, Comparative Study of the Safety and Efficacy of Clarithromycin Versus Rifabutin Versus the Combination of Clarithromycin Plus Rifabutin for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia or Disseminated MAC Disea [NCT00001030] | Phase 3 | 1,100 participants | Interventional | Completed | |||
| Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori [NCT00149084] | Phase 3 | 296 participants | Interventional | 2003-04-30 | Recruiting | ||
| Comparative Study of the Levofloxacin-Based and Clarithromycin-Based Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication and Change of Gut Flora and Drug Susceptibility Before and After Treatment [NCT00816140] | Phase 4 | 432 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Randomized Clinical Trial: the Comparison of 15-day Sequential and 10-day Sequential Therapy to PPI-based Triple Therapy for Helicobacter Pylori Infection in Korea [NCT01887249] | Phase 4 | 287 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis [NCT00205634] | Phase 2 | 50 participants | Interventional | 2000-12-31 | Completed | ||
| Comparing Different Regimens for Eradication of Helicobacter Pylori in Kuwait [NCT04617613] | Phase 4 | 603 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| "A Screen and Treat Helicobacter Pylori Eradication Trial in 14-18 Years Old Adolescents Residing in Three Regions of Chile: Effectiveness and Microbiological-host Implications" [NCT05926804] | 500 participants (Anticipated) | Interventional | 2022-08-02 | Recruiting | |||
| A Prospective Phase II, Randomized Multi-center Trial of a Combined Modularized Treatment With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Nivolumab in Patients With Squamous Cell Lung Cancer and Non- Squamous Cell Lung Cancer, [NCT02852083] | Phase 2 | 86 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole and Dapsone and Their Hydroxylamine Metabolites [NCT00000826] | Phase 1 | 48 participants | Interventional | Completed | |||
| Vonoprazan-based Triple Therapy vs. Standard Triple Therapy for Helicobacter Pylori Eradication in Adolescents: A Randomized, Double-blinded Controlled Trial [NCT06162949] | Phase 3 | 240 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
| Efficacy of Clarithromycin in Comparison to Azithromycin in Treatment of Mild COVID-19 Infection, Randomized Controlled Trial [NCT04622891] | 300 participants (Actual) | Interventional | 2020-04-01 | Completed | |||
| A Randomized Controlled Trial: Quadruple vs Tailored Therapy in the Treatment of Helicobacter Pylori Infection [NCT04621487] | 80 participants (Actual) | Interventional | 2019-01-15 | Completed | |||
| Ten-day Amoxicillin-containing Dual Therapy as First-line Helicobacter Pylori Treatment in Elderly Patients: a Randomized Trial [NCT05419674] | Phase 4 | 393 participants (Anticipated) | Interventional | 2022-08-01 | Recruiting | ||
| Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori: A Pilot Study [NCT05126121] | 60 participants (Anticipated) | Interventional | 2021-11-20 | Not yet recruiting | |||
| Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy: Comparison of 8 Weeks Standard Therapy (Rifampicin Plus Clarithromycin) vs. 4 Weeks Standard Plus Amoxicillin/Clavulanate Therapy [RC8 vs. RCA4] [NCT05169554] | Phase 2 | 140 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
| Comparison of the Efficacy of Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy for 10 Days in the First Line Therapy for Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial [NCT01607918] | Phase 4 | 1,300 participants (Anticipated) | Interventional | 2012-02-29 | Recruiting | ||
| Phase 4 Study of Helicobacter Pylori Eradication Therapy [NCT00990405] | Phase 4 | 400 participants (Anticipated) | Interventional | 2009-10-31 | Active, not recruiting | ||
| Helicobacter Pylori Eradication With Berberine Hydrochloride, Lansoprazole, Amoxicillin and Bismuth Versus Clarithromycin Bismuth, Lansoprazole and Amoxicillin: A Randomized, Open-label, Non-inferiority, Phase Ⅳ Trial [NCT02633930] | Phase 4 | 566 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Double-blind, Placebo-controlled, Randomized Study for Assesment of the Efficiency and Safety Quadruple Therapy for Helicobacter Pylori Infection With or Without the Addition of Saccharomyces Boulardi Probiotic [NCT03997279] | Phase 4 | 200 participants (Anticipated) | Interventional | 2019-06-30 | Not yet recruiting | ||
| Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy: A Randomized Controlled Trial in Taiwan [NCT06156085] | Phase 4 | 318 participants (Anticipated) | Interventional | 2023-11-14 | Recruiting | ||
| A Study on the Efficacy and Safety of Egg Yolk Antibody in Adjuvant Treatment of Helicobacter Pylori Infection [NCT05410223] | 100 participants (Anticipated) | Interventional | 2021-04-06 | Recruiting | |||
| Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in Ukraine [NCT01095978] | 2,822 participants (Actual) | Observational | 2009-08-31 | Completed | |||
| A Phase 1, Open-Label, Sequential Design Study to Evaluate the Effect of Multiple Oral Doses of Clarithromycin on the Pharmacokinetics of a Single Oral Dose of TAK-438 [NCT02774902] | Phase 1 | 16 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Pharmacokinetic Drug-Drug Interaction Study of Voriconazole With Clarithromycin. [NCT05380245] | Phase 4 | 12 participants (Actual) | Interventional | 2018-11-01 | Completed | ||
| A Multi-center, Post-Marketing Observational Study to Identify the Recovery Time in Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR [NCT01076153] | 760 participants (Actual) | Observational | 2008-12-31 | Completed | |||
| CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections [NCT03236987] | Phase 3 | 424 participants (Anticipated) | Interventional | 2018-02-05 | Recruiting | ||
| Clinical Trial to Define the Effect of Perioperative H. Pylori Eradication With Antibiotic Treatment on Long Term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemothe [NCT02387203] | Phase 2 | 80 participants (Anticipated) | Interventional | 2015-01-31 | Active, not recruiting | ||
| Effects of Clopidogrel and Clarithromycin on the Disposition of Sibutramine and Its Active Metabolites M1 and M2 in Relation to CYP2B6*6 Polymorphism [NCT01421706] | Phase 1 | 20 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Susceptibility-Guided Sequential Therapy Versus Empirical Therapy for Helicobacter Pylori Infection: a Randomised Controlled Trial [NCT05549115] | 500 participants (Anticipated) | Interventional | 2022-09-20 | Recruiting | |||
| Genotypic Resistance-guided Triple Therapy Versus Empirical Concomitant Therapy for First-line H. Pylori Eradication. [NCT04090021] | Phase 4 | 304 participants (Anticipated) | Interventional | 2019-09-01 | Recruiting | ||
| Maintenance Therapy With Thalidomide, Dexamethasone and Clarithromycin (Biaxin) Following Autologous/Syngeneic Transplant for Multiple Myeloma [NCT00182663] | Phase 2 | 30 participants (Anticipated) | Interventional | 2003-06-30 | Completed | ||
| Pharmacokinetic Study of Clarithromycin in Premature Infants With Safety Evaluation [NCT01851954] | Phase 2 | 6 participants (Actual) | Interventional | 2013-02-28 | Terminated(stopped due to declined enrollment) | ||
| A Phase 2 Study of Pomalidomide as a Replacement for Lenalidomide for Multiple Myeloma Patients Relapsed or Refractory to a Lenalidomide-Containing Combination Regimen [NCT02188368] | Phase 2 | 45 participants (Actual) | Interventional | 2014-07-07 | Terminated(stopped due to Lack of enrollment) | ||
| Phase I/II Study of Ixazomib in Combination With Pomalidomide, Clarithromycin and Dexamethasone (PiC-D) in Patients With Double Refractory Multiple Myeloma [NCT02542657] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2015-10-31 | Active, not recruiting | ||
| Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants [NCT02912234] | Phase 1 | 20 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Helicobacter Pylori Eradication Clostridium Butyricum Capsule and Bacillus Coagulans Tablets With Hydrochloride,Esomeprazole,Amoxicillin and Bismuth-containing Quadruple Therapy: a Randomized,Single-center，Open-label,Phase Ⅳ Trail [NCT05237115] | Phase 4 | 600 participants (Actual) | Interventional | 2020-05-05 | Completed | ||
| An Open Label Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects With Active Crohn's Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study [NCT03009396] | Phase 3 | 54 participants (Actual) | Interventional | 2017-03-18 | Completed | ||
| Clarithromycin Plus CTd (Cyclophosphamide,Thalidomide and Dexamethasone)Regimen for Patients With Newly Diagnosed Multiple Myeloma:a Phase 3 , Multicenter,Randomized, Open-Label Trial. [NCT02248428] | Phase 3 | 130 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | ||
| [NCT01481844] | Phase 3 | 101 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura [NCT00467571] | Phase 4 | 26 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| [NCT00475527] | Phase 4 | 0 participants (Actual) | Interventional | Withdrawn(stopped due to problem of accrual) | |||
| Biaxin(Clarithromycin)Based Antibiotic Therapy In Previously Untreated, Advanced Stage Indolent Lymphoma [NCT00461084] | 36 participants (Actual) | Observational | 2007-04-30 | Completed | |||
| Increased Second-line Eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Conventional Triple Therapy. [NCT01572597] | Phase 4 | 120 participants (Anticipated) | Interventional | 2011-06-30 | Recruiting | ||
| A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of 250 mg Clarithromycin Tablets Under Fasting Conditions [NCT00601315] | 40 participants (Actual) | Interventional | 2003-04-30 | Completed | |||
| Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis [NCT00513552] | Phase 4 | 0 participants (Actual) | Interventional | 2007-07-31 | Withdrawn(stopped due to No patient) | ||
| Efficacy of Antibiotic Susceptibility-based Tailored Versus Empiric Therapy for Helicobacter Pylori First-line Treatment：a Randomized Clinical Trial [NCT02935010] | Phase 4 | 382 participants (Actual) | Interventional | 2017-02-05 | Completed | ||
| Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication [NCT02934152] | Phase 4 | 400 participants (Anticipated) | Interventional | 2016-10-31 | Not yet recruiting | ||
| A Multi-center Study for Eradication of Helicobacter Pylori With Triple Therapy Based on Accurate Susceptibility Testing of Clarithromycin [NCT02923856] | 672 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | |||
| Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment - a Randomized Trial [NCT05152004] | 240 participants (Actual) | Interventional | 2018-09-01 | Completed | |||
| Effect of Repeated Dosing of Clarithromycin on PK of Linaprazan Glurate/Linaprazan, Effect of Single Dose of Linaprazan Glurate on PK of Clarithromycin, Single/Repeated Dosing of Linaprazan Glurate on PK of Midazolam to Healthy Subjects [NCT05633147] | Phase 1 | 35 participants (Actual) | Interventional | 2022-11-27 | Completed | ||
| A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma [NCT02343042] | Phase 1/Phase 2 | 518 participants (Actual) | Interventional | 2015-10-31 | Active, not recruiting | ||
| Conventional Therapy vs Sequential Therapy for the Treatment of Helicobacter Pylori Infection [NCT01723059] | 184 participants (Anticipated) | Interventional | 2012-02-29 | Recruiting | |||
| Helicobacter Pylori Eradication and Follow-up in Zhongshan Hospital [NCT05061732] | Phase 4 | 4,447 participants (Anticipated) | Interventional | 2021-09-30 | Recruiting | ||
| A Pharmacokinetic Study to Evaluate the Effect of Clarithromycin on the Pharmacokinetic Profile of Colchicine in Healthy Adults [NCT00984061] | Phase 1 | 24 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp (Randomized Controlled Study) [NCT03065868] | Phase 4 | 32 participants (Actual) | Interventional | 2015-12-09 | Completed | ||
| CURRENT PRACTICE STUDY OF ANTIBIOTIC TREATMENT OF GASTRIC MALT LYMPHOMA [NCT00002682] | Phase 2 | 5 participants (Actual) | Interventional | 1995-08-10 | Completed | ||
| Use of Antibiotics to Eradicate Bacterial Pathogens Colonising the Colonic Mucosa in Ulcerative Colitis Patients [NCT00355602] | 40 participants (Anticipated) | Interventional | 2006-07-31 | Completed | |||
| A Phase 1, Open-label, Randomized, Crossover Study to Assess the Drug-Drug Interaction Between Bedaquiline and Clarithromycin in Healthy Adult Volunteers [NCT03800550] | Phase 1 | 16 participants (Actual) | Interventional | 2019-02-13 | Completed | ||
| Usefulness of Antimicrobial Susceptibility in the Eradication of Helicobacter Pylori [NCT01486082] | 1 participants (Anticipated) | Observational | 2011-02-28 | Recruiting | |||
| Comparison of Efficacy and Safety of Triple Regimen Based on Clarithromycin VS Metronidazole in Pediatric Population in Pakistan [NCT04721704] | 36 participants (Anticipated) | Interventional | 2020-09-14 | Recruiting | |||
| Randomised Controlled Trial of Clarithromycin in Active Crohn's Disease [NCT00269386] | Phase 3 | 44 participants (Actual) | Interventional | 2000-04-30 | Completed | ||
| A Phase II Trial Addressing Feasibility and Activity of Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma [NCT03031483] | Phase 2 | 44 participants (Actual) | Interventional | 2017-04-03 | Active, not recruiting | ||
| Randomised Trial for Early Lesions Caused by M. Ulcerans - Comparison Between 8 Weeks Streptomycin and Rifampicin (SR), or 4 Weeks SR Followed by 4 Weeks R Plus Clarithromycin [NCT00321178] | Phase 2/Phase 3 | 151 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Multicenter Randomized Clinical Trial of 10 and 14 Days [NCT05049902] | Phase 4 | 1,300 participants (Actual) | Interventional | 2021-09-21 | Completed | ||
| Phase III, Randomized, Double Blind Study of Low Dose Long Term Clarithromycin Versus Placebo in Treatment of Chronic Pulmonary Lesions Due to Sulfur Mustard [NCT00381147] | Phase 3 | 0 participants | Interventional | Completed | |||
| The Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease - a Randomized, Placebo Controlled, Double Blinded, Multicentre, Clinical Trial [NCT00121550] | Phase 3 | 4,372 participants (Actual) | Interventional | 1999-10-31 | Completed | ||
| Sequential Therapy Versus Triple Therapy for Helicobacter Pylori Eradication: a Placebo-controlled Trial [NCT00403364] | Phase 2/Phase 3 | 300 participants | Interventional | 2003-07-31 | Completed | ||
| Treatment of Low-Grade Gastric Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type Stages IE & II1E (HELYX-Study) [NCT00154440] | Phase 3 | 200 participants | Interventional | 2001-11-30 | Recruiting | ||
| Dyspeptic Symptoms Evolution After Eradication of Helicobacter Pylori in Patients With Different Endoscopic Findings: a Randomized Double-blind Placebo-controlled Clinical Trial With 12 Months of Follow-up [NCT00404534] | Phase 3 | 407 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Efficacy of Helicobacter Pylori Eradication on Symptoms of Functional Dyspepsia - A Randomised Controlled Trial [NCT04697641] | 202 participants (Actual) | Interventional | 2017-09-01 | Completed | |||
| Prospective Randomised Trial of First and Second Line Treatments of Helicobacter Pylori Infection in Slovenia [NCT04359966] | 560 participants (Anticipated) | Interventional | 2020-05-10 | Not yet recruiting | |||
| Clarithromycin for the Treatment of Hypersomnia [NCT01146600] | Phase 2 | 26 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Dual Therapy With High-Dose of Rabeprazole and Amoxicilline Versus Triple Therapy With Rabeprazole, Amoxicilline and Metronidazole as the Second Line Therapy for the Cure of H. Pylori Infection [NCT00197418] | Phase 2/Phase 3 | 0 participants | Interventional | 2003-08-31 | Recruiting | ||
| Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate Consortiu [NCT01745588] | Phase 2 | 23 participants (Actual) | Interventional | 2012-12-31 | Active, not recruiting | ||
| Open, Noncomparative Trial of Multidrug Regimens Containing Clarithromycin and Rifabutin Administered Three Times Per Week for the Treatment of M. Avium Complex (MAC) Lung Disease [NCT00598897] | Phase 4 | 89 participants (Actual) | Interventional | 1995-08-31 | Completed | ||
| Open Study of Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM) [NCT00600769] | Phase 4 | 210 participants (Actual) | Interventional | 1991-01-31 | Completed | ||
| [NCT02275988] | Phase 1 | 20 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia. [NCT00002192] | Phase 2 | 0 participants | Interventional | Completed | |||
| A Prospective, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of the Safety and Efficacy of Clarithromycin for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients With CD4 Counts <= 100 Cell [NCT00002336] | 0 participants | Interventional | 1992-11-30 | Completed | |||
| A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS [NCT00000644] | Phase 2 | 100 participants | Interventional | Completed | |||
| Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis [NCT00000794] | Phase 2 | 100 participants | Interventional | Completed | |||
| A Phase I/II Dose-Ranging, Pharmacokinetic, Drug Interaction, Safety and Preliminary Efficacy Study of Oral Clarithromycin Granules for Suspension, in Combination With Zidovudine or Dideoxyinosine, in the Treatment of Disseminated Mycobacterium Avium Comp [NCT00000971] | Phase 1 | 24 participants | Interventional | Completed | |||
| Immunomodulatory Effect of Macrolides in Naturally Occurring Influenza Virus Infections in the Community [NCT03824847] | Phase 4 | 100 participants (Anticipated) | Interventional | 2023-06-01 | Suspended(stopped due to Community recruitment suspended due to COVID-19) | ||
| Comparison Efficacy of 14-day Concomitant Therapy:Clarithromycin vs.Levofloxacin in Eradication of H.Pylori [NCT03021590] | Phase 4 | 0 participants (Actual) | Interventional | 2017-06-01 | Withdrawn(stopped due to No Participants Enrolled) | ||
| Efficacy of Quadruple Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests as First-line Treatment for Helicobacter Pylori Infection [NCT05718609] | Phase 4 | 855 participants (Anticipated) | Interventional | 2023-03-01 | Recruiting | ||
| A Randomized, Open-label, Parallel-design Study to Evaluate Pharmacokinetic Drug Interactions and Safety After Coadministration of Clarithromycin, Amoxicillin and Ilaprazole [NCT02998437] | Phase 1 | 28 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| A Phase 1, Double-Blind, Parallel Group Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Quadruple Therapy (Bismuth, Clarithromycin, and Amoxicillin) With Vonoprazan Versus Quadruple Therapy With Esomeprazole [NCT04753437] | Phase 1 | 44 participants (Actual) | Interventional | 2021-04-06 | Completed | ||
| A Prospective, Multi-center, Randomized, Open-label, Parallel Design Clinical Trial to Compare 10-day Sequential Therapy and 14-day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea [NCT02159976] | 390 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial [NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of Mucosa-associated Lymphoid Tissue Type of The Stomach [NCT00201422] | 70 participants (Actual) | Interventional | 1996-06-30 | Completed | |||
| Comparing 10-day Reverse Hybrid Therapy and 10-day Triple Therapy Plus Bismuth Therapy on Helicobacter Pylori Eradication [NCT04566211] | 440 participants (Anticipated) | Interventional | 2020-01-01 | Recruiting | |||
| Antibiotic-mediated Improvements in Vigilance: Mechanisms of Action of Clarithromycin in Hypersomnia Syndromes [NCT04026958] | Phase 2 | 92 participants (Anticipated) | Interventional | 2019-09-04 | Recruiting | ||
| Randomized Aseptic Pharmacokinetic Pharmacodynamic Outpatient Registry Trial of Respiratory Tract Infections in Adults (RAPPORT) [NCT00245453] | Phase 4 | 0 participants (Actual) | Interventional | 2005-10-31 | Withdrawn(stopped due to Terminated by sponsor) | ||
| Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER) [NCT01075204] | 335 participants (Actual) | Observational | 2011-01-31 | Completed | |||
| Multicentre,Prospective Study of First-line Antibiotic Therapy for Early-stage Low-grade and High-grade Gastric Mucosa-associated Lymphoid Tissue-type Lymphoma and Potential Predicting Factor for Treatment Outcome [NCT00327132] | 47 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4. [NCT00002194] | Phase 1 | 36 participants | Interventional | Completed | |||
| Clarithromycin as Immunomodulatory Therapy for the Management of Septic Syndrome by Ventilator-Associated Pneumonia [NCT00297674] | Phase 4 | 200 participants | Interventional | 2004-06-30 | Completed | ||
| A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Subjects [NCT05965570] | Phase 1 | 22 participants (Actual) | Interventional | 2023-07-28 | Completed | ||
| A Phase 3, Randomized, Double-Blind, Double Dummy, Multicenter, Parallel Group Comparison Study to Evaluate Efficacy and Safety of a Triple Therapy With TAK-438, Amoxicillin and Clarithromycin by Comparison With a Triple Therapy With AG-1749 (Lansoprazole [NCT01505127] | Phase 3 | 650 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Prophylaxis of Bronchopulmonary Dysplasia With Clarithromycin [NCT01652118] | Phase 3 | 250 participants (Anticipated) | Interventional | 2011-10-31 | Recruiting | ||
| Efficacies of Hybrid, High-dose Dual and Bismuth Quadruple Therapies for the First-line Anti-H Pylori Treatment and Tetracycline-levofloxacin Quadruple Therapy for the Second-line Anti-H Pylori Treatment - a Multicentre Randomized Trial [NCT03779074] | Phase 3 | 918 participants (Actual) | Interventional | 2018-09-03 | Completed | ||
| Randomized Controlled Trial Comparing Efficacy of 8 Weeks Treatment With Clarithromycin and Rifampicin Versus Streptomycin and Rifampicin for Buruli Ulcer (M. Ulcerans Infection) [NCT01659437] | Phase 2/Phase 3 | 310 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Phase 1, Open-label, Drug-drug Interaction Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects [NCT02080780] | Phase 1 | 24 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Clinical Efficacy and Health Economic Evaluation of Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment：Multicenter Randomized Controlled Study [NCT05250050] | Phase 4 | 388 participants (Anticipated) | Interventional | 2022-03-25 | Recruiting | ||
| [NCT01667575] | Phase 4 | 180 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Assessment of Change in CYP3A Activity by Route of Administration Using Metabolic Markers in Healthy Male Volunteers [NCT03366974] | Phase 1 | 16 participants (Actual) | Interventional | 2017-12-28 | Completed | ||
| Evaluation and Validation of Metabolic Markers for the Prediction of Drug-drug Interaction of Various CYP3A4 Substrates and Inhibitors in Healthy Male Subjects [NCT02975037] | Phase 1 | 32 participants (Actual) | Interventional | 2017-02-06 | Completed | ||
| The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori: a Prospective, Multi-Center, Randomized Controlled Trial [NCT05189444] | 672 participants (Anticipated) | Interventional | 2022-03-25 | Not yet recruiting | |||
| Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication: A Single-center, Randomised, Controlled Trial. [NCT06168214] | Phase 4 | 1,404 participants (Anticipated) | Interventional | 2023-09-04 | Recruiting | ||
| Ten Days Quadruple Versus Sequential Therapy as Empirical First and Second Line Treatment for Helicobacter Pylori Eradication: a Randomized Crossover Trial [NCT01760824] | 391 participants (Actual) | Interventional | 2011-05-31 | Completed | |||
| A Phase 1, Open-Label, 2-Arm, Fixed-Sequence Study to Evaluate the Potential Effects of Multiple Doses of Rifampin (CYP3A4 Inducer) and Clarithromycin (CYP3A4 Inhibitor) on the Single Dose Pharmacokinetics of Deflazacort in Healthy Subjects [NCT02286635] | Phase 1 | 58 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| The Effect of Propolis and Nutritional Education in Patients With H. Pylori on Gastrointestinal Symptoms [NCT05259007] | Phase 4 | 96 participants (Anticipated) | Interventional | 2022-02-22 | Not yet recruiting | ||
| An Open-label, Randomized Study to Evaluate Pharmacokinetic Interaction, Pharmacodynamics and Safety After Multiple Oral Dosing of CJ-12420 and Amoxicillin/Clarithromycin in Healthy Subjects [NCT03011996] | Phase 1 | 60 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment [NCT02988089] | Phase 4 | 480 participants (Anticipated) | Interventional | 2017-04-20 | Recruiting | ||
| Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial [NCT02249546] | Phase 4 | 654 participants (Anticipated) | Interventional | 2014-09-30 | Recruiting | ||
| Effects of Potent Inhibition of CYP2C8, CYP2J2, and CYP3A4, Using Gemfibrozil, Ketoconazole, and Clarithromycin as Probes, on the Pharmacokinetics of LY2409021 in Healthy Subjects [NCT01836198] | Phase 1 | 30 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Efficacy and Safety Study of BiRD (Biaxin [Clarithromycin]/Revlimid [Lenalidomide]/Dexamethasone) Combination Therapy in Relapsed/Refractory Myeloma [NCT02986451] | Phase 2 | 0 participants (Actual) | Interventional | 2016-12-31 | Withdrawn | ||
| Evaluation of the Safety, Tolerance and Pharmacokinetics of Rifabutin/Clarithromycin Combination and Rifabutin/Azithromycin Combination in HIV-Infected Patients [NCT00001023] | 91 participants | Interventional | Completed | ||||
| A Randomized Open-Label Study of the Tolerability and Efficacy of Clarithromycin and Ethambutol in Combination With or Without Clofazimine for the Treatment of Disseminated MAC (dMAC) in Patients With AIDS [NCT00002331] | 0 participants | Interventional | 1994-01-31 | Completed | |||
| Effects of CYP3A Inhibition by Clarithromycin on the Pharmacokinetics of LY2835219 and Its Metabolites in Cancer Patients [NCT02117648] | Phase 1 | 26 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Risk of Acute Liver Injury in Users of Antimicrobials in the HealthCore Integrated Research Database Population [NCT01434173] | 1,299,056 participants (Actual) | Observational | 2001-07-31 | Completed | |||
| "Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple Hybrid and Concomitant Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance" [NCT01464060] | Phase 4 | 400 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy as First-Line Regimen for Helicobacter Pylori Eradication [NCT04558502] | Phase 4 | 339 participants (Anticipated) | Interventional | 2022-01-05 | Not yet recruiting | ||
| A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients [NCT00002140] | Phase 3 | 0 participants | Interventional | Completed | |||
| Pharmacokinetic Interaction Between Trospium Chloride After Intravenous (2 mg) and Oral Administration (30 mg) With Ranitidine (300 mg p.o.) as an Inhibitor of OCT1 and With Clarithromycin (500 mg p.o.) as an Inhibitor of P-glycoprotein in 24 Healthy Subj [NCT03011463] | Phase 1 | 24 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori [NCT01922765] | Phase 4 | 540 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole [NCT02552641] | Phase 4 | 0 participants (Actual) | Interventional | 2015-09-30 | Withdrawn | ||
| Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Rifasutenizol (TNP 2198) in Combination With Rabeprazole and Amoxicillin in the Primary Treatment of Participants With H. Pylori Infection [NCT05857163] | Phase 3 | 700 participants (Anticipated) | Interventional | 2023-05-18 | Recruiting | ||
| Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson [NCT03440112] | Phase 1/Phase 2 | 34 participants (Actual) | Interventional | 2018-01-29 | Completed | ||
| Comparison Between Ten Days Sequential Treatment (With Metronidazole or Tetracycline) and Ten Days Standard Triple Therapy of Helicobacter Pylori [NCT01573975] | Phase 4 | 345 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Multicenter, Randomized, And Double-Blind Study To Evaluate The Safety Of Tigecycline Versus A Ceftriaxone Regimen In The Treatment Of Complicated Intra-Abdominal Infections And Community-Acquired Pneumonia In Subjects Of 8-17 Years [NCT01602874] | Phase 3 | 0 participants (Actual) | Interventional | 2011-01-31 | Withdrawn | ||
| Comparison of Different Efficacy of Macrolide and Glucocorticoid in the Treatment of Chronic Rhinosinusitis Patients After Endoscopic Sinus Surgery [NCT02182492] | 187 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA) [NCT00318708] | Phase 3 | 92 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Open Label, Randomized, Single Site Clinical Trial To Compare The Safety Of Herbal Melanin Extracted From Nigella Sativa Seeds Vs Standard Of Care Treatment In Treating Gastritis Patients [NCT03428568] | Phase 2 | 132 participants (Anticipated) | Interventional | 2018-03-31 | Not yet recruiting | ||
| Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA): A Study Of Personalized Diagnosis of Primary Aldosteronism With Implications For Treatment [NCT03414918] | 342 participants (Anticipated) | Interventional | 2018-03-31 | Not yet recruiting | |||
| A Phase II/III Prospective, Multicenter, Randomized, Controlled Trial Comparing the Safety and Efficacy of Three Clarithromycin-Containing Combination Drug Regimens for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Disease in Persons Wit [NCT00001058] | Phase 2 | 246 participants | Interventional | Completed | |||
| A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo [NCT00002101] | Phase 3 | 450 participants | Interventional | Completed | |||
| A Phase II Clinical Trial of Anti-Helicobacter Pylori Treatment in Endoscopically Diagnosed Low-Grade Localized Gastric Lymphoma [NCT00003151] | Phase 2 | 96 participants (Anticipated) | Interventional | 1997-09-30 | Completed | ||
| The Exploration for Pharmacodynamics and Pharmacokinetic Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy Subjects [NCT01921647] | Phase 1 | 95 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| Comparison of 7-day Triple, 10-day Sequential, and 7-day Concomitant Therapies for Helicobacter Pylori Infection in Taiwan [NCT01769365] | Phase 4 | 307 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Treatment of Pulmonary Disease Caused by MAIS, M.Xenopi or M.Malmoense: A Comparison of Two Triple Drug Regimens and an Assessment of the Value of Immunotherapy With M.Vaccae [NCT00367913] | Phase 4 | 400 participants | Interventional | 1995-03-31 | Completed | ||
| Clarithromycin as Adjuvant to Periodontal Debridement in the Treatment of Generalized Aggressive Periodontitis: Randomized Clinical Trial [NCT02829983] | 40 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| [NCT00004689] | Phase 2 | 50 participants | Interventional | 1991-01-31 | Completed | ||
| Efficacy and Safety of Helicobacter Pylori Eradication Dual or Triple Regimes Using Vonoprazan as the Antacid [NCT05345210] | Phase 4 | 500 participants (Anticipated) | Interventional | 2022-04-25 | Recruiting | ||
| [NCT00368342] | Phase 4 | 0 participants | Interventional | Completed | |||
| Efficacy of Potassium Competitive Acid Blockers (P-CABs) Versus Proton Pump Inhibitors (PPIs) in the First and the Second Lines Eradication Regimens for H. Pylori in Egyptian Patients [NCT06101420] | Phase 3 | 232 participants (Actual) | Interventional | 2022-01-01 | Completed | ||
| Personalized Treatment for Refractory H Pylori Infection [NCT02547025] | 126 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
| Delineation of Therapeutic Potential and the Causal Relationship Between Vitamin D and Helicobacter Pylori (HP) Infection and Gastritis [NCT03142620] | Phase 3 | 96 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| Effect of Clarithromycin on the Pharmacokinetics of LY2216684 in Healthy Subjects [NCT01460407] | Phase 1 | 14 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Compare 14-day Reverse Hybrid Therapy and 14-day Triple Therapy Plus Bismuth on Helicobacter Pylori Eradication [NCT03321773] | 440 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | |||
| Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori [NCT03108287] | Phase 4 | 162 participants (Actual) | Interventional | 2013-04-01 | Completed | ||
| A Single-center, Open-label, Drug-drug Interaction Study of XZP-3287 Tablets in Healthy Subjects [NCT04951713] | Phase 1 | 60 participants (Anticipated) | Interventional | 2021-07-31 | Recruiting | ||
| Two Independent Phase 1b Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin [NCT03043989] | Phase 1 | 4 participants (Actual) | Interventional | 2017-03-21 | Terminated(stopped due to Low accrual) | ||
| The Effect of Therapy on the Tissue Burden of Disseminated MAC Infection as Measured by Quantitative Bone Marrow Culture and Correlation With Quantitative Blood Culture in HIV-Infected Patients [NCT00001039] | Phase 2 | 24 participants | Interventional | Completed | |||
| Multicentre, Prospective Study of First-line Antibiotic Therapy for Early-stage H. Pylori-Positive Gastric Pure (de Novo) Diffuse Large B-cell Lymphoma and Potential Predicting Factor for Treatment Outcome [NCT02388581] | Phase 2 | 30 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
| Efficacy of Clarithromycin is an Adjunct to Scaling and Root Planing .A Clinical Microbiological and Immunological Study. [NCT02359721] | Phase 4 | 30 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment [NCT03139253] | Phase 4 | 120 participants (Anticipated) | Interventional | 2017-05-30 | Not yet recruiting | ||
| "The Effects of the Synbiotic Bifidobacterium Lactis B94 Plus Inulin Addition on Standard Triple Therapy of Helicobacter Pylori Eradication in Children" [NCT03165253] | 69 participants (Actual) | Interventional | 2011-06-30 | Completed | |||
| Administration of an Oral PDE5 Inhibitor, Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma [NCT01374217] | Phase 2 | 14 participants (Actual) | Interventional | 2012-04-30 | Terminated(stopped due to early stopping rule) | ||
| An Open-label Crossover Trial Assessing the Value of Dabigatran in a Drug Interaction Cocktail in Healthy Young Volunteers [NCT02361619] | Phase 1 | 16 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Clarithromycin-, Metronidazole-, or Levofloxacin-containing Therapy for Helicobacter Pylori-infected Penicillin-allergic Patients: A Randomized Controlled Trial [NCT05023577] | Phase 4 | 504 participants (Anticipated) | Interventional | 2021-08-26 | Recruiting | ||
| An Open-Label Study to Evaluate the Absolute Bioavailability of Intranasal and Oral Esketamine and the Effects of Clarithromycin on the Pharmacokinetics of Intranasal Esketamine in Healthy Subjects [NCT02343289] | Phase 1 | 18 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| An Open-label, Fixed-sequence Study to Evaluate the Drug-drug Interactions Between Tegoprazan Tablets and Bismuth Potassium Citrate Capsules, Amoxicillin Capsules, and Clarithromycin Tablets in Healthy Subjects [NCT05915871] | Phase 1 | 22 participants (Actual) | Interventional | 2023-03-23 | Completed | ||
| Clinical ECG Study to Evaluate Electrophysiological Effects of Potential QT Prolonging Drugs With Novel ECG Biomarkers With Exposure-Response Analysis [NCT05716854] | Phase 1 | 44 participants (Actual) | Interventional | 2023-03-21 | Completed | ||
| Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori. [NCT01575899] | Phase 4 | 208 participants (Actual) | Interventional | 2007-12-31 | Terminated(stopped due to Early termination due to efficacy) | ||
| Evaluation of the Local Effect of Nonsurgical Periodontal Treatment of Generalized Aggressive Periodontitis Associated or Not With Systemic Antibiotics and Photodynamic Therapy.: a Randomized Clinical Trial [NCT03142776] | 60 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| A Phase 3, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of Clarithromycin(Biaxin)-Lenalidomide-Low-Dose-Dexamethasone (BiRd) Combined With B-cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-cell Therapy in Pati [NCT04287660] | Phase 3 | 20 participants (Anticipated) | Interventional | 2017-10-19 | Recruiting | ||
| Comparison of 14-day Sequential and Hybrid Therapies for H Pylori Infection [NCT01085786] | Phase 4 | 240 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Anti-inflammatory Clarithromycin to Improve SARS-CoV-2 (COVID-19) Infection Early: The ACHIEVE Open-label Non-randomized Clinical Trial [NCT04398004] | Phase 2 | 90 participants (Actual) | Interventional | 2020-05-06 | Completed | ||
| Phase II Clinical Trial on the Activity of Salvage Therapy With High Dose Oral Clarithromycin in Patients With Relapsed or Refractory Extranodal Marginal Zone Lymphoma [NCT01516606] | Phase 2 | 23 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study) [NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Effect of Modulating CYP3A4 Activity on Mineral Homeostasis [NCT02019875] | Early Phase 1 | 92 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Study of Novel Triple Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori in Children [NCT04415983] | Phase 3 | 100 participants (Anticipated) | Interventional | 2020-06-01 | Recruiting | ||
| A Phase II Trial of Broad Spectrum Antibiotic Therapy for Early Stage, Non-progressive Chronic Lymphocytic Leukaemia Without Adverse Prognostic Factors [NCT01279252] | Phase 2 | 71 participants (Anticipated) | Interventional | 2011-07-31 | Completed | ||
| Effect of Helicobacter Pylori Eradication on Glandular Atrophy and Metachronous Cancer in Patients Undergoing Endoscopic Mucosal Resection for Gastric Cancer [NCT02407119] | Phase 3 | 470 participants (Actual) | Interventional | 2003-06-30 | Active, not recruiting | ||
| Helicobacter Pylori Eradication to Prevent Gastric Cancer in Subjects With Family History of Gastric Cancer: A Randomized Controlled Study [NCT01678027] | Phase 3 | 1,838 participants (Actual) | Interventional | 2004-11-30 | Active, not recruiting | ||
| Comparison of Vonoprazan and Amoxicillin Dual Therapy With Standard Triple Therapy With Proton Pump Inhibitor for Helicobacter Pylori Eradication; a Randomized Control Trial [NCT04901663] | Phase 4 | 179 participants (Actual) | Interventional | 2021-06-21 | Completed | ||
| Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Multicenter Randomized Clinical Trial of 10 and 14 Days [NCT04901117] | Phase 4 | 1,300 participants (Anticipated) | Interventional | 2021-06-30 | Not yet recruiting | ||
| Protocol for a Randomised Trial of Observation Versus Chlorambucil After Anti-Helicobacter Therapy in Low Grade Gastric Lymphoma [NCT00003617] | Phase 3 | 200 participants (Anticipated) | Interventional | 1995-03-31 | Active, not recruiting | ||
| Full-mouth Periodontal Debridement Associated With Two Different Antibiotic Agents to Treat Generalized Aggressive Periodontitis: Randomized Controlled Clinical Trial [NCT02969928] | Phase 2/Phase 3 | 46 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients: a Double Blind Placebo Controlled Randomized Clinical Trial [NCT01593592] | 70 participants (Actual) | Interventional | 2012-06-30 | Completed | |||
| Long-term StaphyloCoccus Aureus decolonizAtion in Patients on Home parenteRal nutRition: a randomIzed multicEnter tRial. [NCT03173053] | 63 participants (Actual) | Interventional | 2018-02-08 | Terminated(stopped due to Results interim-analysis) | |||
| A Phase 1 Study of Oral IXAZOMIB (MLN9708) to Assess Relative Bioavailability, Food Effect, Drug-Drug Interaction With Ketoconazole, Clarithromycin or Rifampin; and Safety and Tolerability in Patients With Advanced Nonhematologic Malignancies or Lymphoma [NCT01454076] | Phase 1 | 112 participants (Actual) | Interventional | 2011-11-10 | Completed | ||
| The Impact of Antibiotics MIC Value on the Efficacy of Treatment Regimens for Helicobacter Pylori Infection. [NCT03583476] | 1,821 participants (Anticipated) | Observational | 2018-04-01 | Recruiting | |||
| Helicobacter Pylori Eradication With Berberine Hydrochloride,Esomeprazole,Amoxicillin and Clarithromycin Versus Bismuth,Esomeprazole,Amoxicillin,and Clarithromycin: a Randomized,Open-label, Non-inferiority, Phase Ⅳ Trail [NCT02296021] | Phase 4 | 612 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| A Phase 3, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of a Triple Therapy With CJ-12420, Amoxicillin and Clarithromycin in H. Pylori Positive Patients [NCT03317223] | Phase 3 | 350 participants (Actual) | Interventional | 2017-10-17 | Completed | ||
| Effect of Long Term Clarithromycin for Prevention of Exacerbations in Non-cystic Fibrosis Bronchiectasis in Asian Populations [NCT04658277] | 40 participants (Anticipated) | Interventional | 2020-10-01 | Recruiting | |||
| Change of Gut Microbiome and Symptom After H.Pylori Eradication Therapy in Patients With Functional Dyspepsia [NCT04449185] | Phase 4 | 60 participants (Anticipated) | Interventional | 2020-06-30 | Not yet recruiting | ||
| Comparison of Two Novel First-line Anti-Helicobacter Pylori Therapy: A Prospective Randomized Trial [NCT03383003] | 240 participants (Actual) | Interventional | 2016-03-01 | Completed | |||
| Efficacy and Safety of Intravenous IIaprazole for Peptic Ulcer Bleeding: A Randomized, Double-Blind, Omeprazole-Controlled, Multicenter, and Phase 3 Trail in China [NCT03362281] | Phase 3 | 540 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| 10 Day Concomitant Versus 14 Day Hybrid Regimen as First Line H. Pylori Eradication Treatment in a High Clarithromycin Resistance Area. A Multicenter Randomized Equivalence Trial [NCT03592069] | Phase 4 | 345 participants (Actual) | Interventional | 2018-02-21 | Completed | ||
| The Pharmacokinetic Effect of Clarithromycin on the AUC0-12h of Linezolid in Multidrug-resistant and Extensively Drug-resistant Tuberculosis (MDR/XDR-TB) Patients [NCT01521364] | Phase 4 | 7 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Efficacy on Helicobacter Pylori Eradication With Sequential Antibiotic Compared to Triple Therapy for 14 Days [NCT02395458] | Phase 4 | 142 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Vonoprazan Fumarate in Combination With Amoxicillin for the First-line Eradication - a Multicenter, Randomized, Parallel Controlled Study [NCT05196945] | Phase 4 | 316 participants (Anticipated) | Interventional | 2022-03-31 | Not yet recruiting | ||
| Strategy on the Increment of H. Pylori Eradication Rate and Investigating the Gastric Pathology and Antimicrobial Resistance in Diabetic Patients [NCT02466919] | Phase 4 | 114 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| The Effect of Broccoli Sprout Extract and Probiotics on Proton Pump Inhibitor-based Triple Therapy for Eradication of Helicobacter Pylori: a Prospective Randomized Trial [NCT03220542] | Phase 4 | 360 participants (Anticipated) | Interventional | 2016-01-31 | Active, not recruiting | ||
| Impact of Azithromycin and Clarithromycin Therapy on Pharyngeal Carriage of Macrolide-Resistant Streptococci Among Healthy Volunteers: A Randomised, Double-Blind, Placebo-Controlled Trial [NCT00354952] | 203 participants | Interventional | 2002-07-31 | Completed | |||
| An Open Label, Randomized, Single Dose, Two-way Crossover , Two-Period, Two-Treatment, Two-Sequence Bioequivalence Study of Klaribact Tablet (Clarithromycin 500 mg), Compared With Reference Product, Klaricid Tablet (Clarithromycin 500 mg) in Healthy Adult [NCT05436769] | Phase 1 | 24 participants (Actual) | Interventional | 2012-10-23 | Completed | ||
| A Phase II Study of Sequential Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Newly Diagnosed Multiple Myeloma [NCT01559935] | Phase 2 | 74 participants (Actual) | Interventional | 2012-03-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||